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Chapter 1
 | Physiology in harmony with nature
 The day/night cycle is the consequence of the rotation of the earth around its own axis on 
its path around the sun. This daily cycle has a period of 24 hours. As a result of the earth 
movement, living organisms are exposed to environmental changes, such as daily cycles of 
light and darkness and diurnal changes in temperature, that are associated with the day and 
night. Almost all the species have developed an internal timing system or “biological clock” 
to adapt to such external changes (Pittendrigh 1996). The biological clock generates a circa-
dian rhythm that regulates physiological processes in order to optimize them to a particular 
time of the day. Harmony of an organism with itself, internally, and with the environmental 
changes is crucial for both survival and well-being of an organism. For example, at an early 
evolutionary stage various species developed the clock system to limit sunlight-sensitive 
processes, such as DNA replication, to the night (Khapre et al., 2010). Lack of internal syn-
chrony, which is caused by shift work, and jet lag, may have long or short term health con-
sequences for the body. For instance, shift work is considered as a carcinogenic factor, and 
the risk of cancer is enhanced by the number of the years an individual spends working at 
night (Schernhammer et al.,2003; Lee et al., 2010). Other complications that are related to 
circadian dysfunction have been reported by different studies (e.g., de-regulated hormonal 
function, fatigue, gastrointestinal disturbance, diabetes) (Takahashi et al.,2008; Preuss et al., 
2008; Arble et al., 2010). 
 | Circadian rhythms  
 The endogenous circadian oscillation was first reported by the French scientist “Jean-
Jacques d’Ortous de Mairan” in 1729. He first noticed the daily movements of “Mimosa pu-
dica” or “sensitive plant” leaves in response to the day and night. Interestingly, he discovered 
that these daily movements persist when the plant is kept in constant darkness (Kuhlman et 
al., 2007). The leaves were open during the day and closed at a certain time in the evening. 
Although de Mairan related these rhythms to passive reactions, his observation was the hall-
mark of the circadian rhythm discovery. The term circadian derives from the latin words of 
circa (around) and diem (day). 
 A circadian rhythm is a selfsustained biological event with a period of approximately 24 
hours (Pittendrigh, 1960). One of the main characteristics of a circadian rhythm is its endoge-
nous property (Wever et al., 1986). In the absence of synchronizing signals, the clock system 
will “free-fun” and oscillate with a period that is close to 24 hours but not exactly 24 hours. 
These endogenous rhythms are entrained to the exact 24 hour period of earth rotation by ex-
ternal environmental cues, notably light (Sharma et al., 2003; Ko et al., 2006). The external 
cues that are able to reset or synchronize the circadian rhythms are called “time givers” or 
by its original German name “Zeitgebers”. In circadian biology, timing under entrained con-
ditions is expressed in Zeitgeber Time (ZT), where ZT0 corresponds to lights on. Circadian 
time (CT) is a term used to refer to the internal physiological time in free-running conditions, 
i.e. in the absence of Zeitgebers, and, the start of a subjective day is called CT0.  Living 
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organisms respond differently to the light pulses depending on when they were exposed to 
the light (Boulos et al., 2002). Responses to light pulses throughout the day can be plotted in 
order to generate a phase response curve (PRC). For example, if the light pulse is given at the 
beginning of the subjective night, a phase delay is seen in the circadian rhythm. In contrast, 
if the light stimuli are given at the end of the subjective night, a phase advance is observed 
(Pittendrigh et al.,1988). Light pulses during the subjective day have no effect on the rhythm. 
 | The mammalian circadian clock
The SCN master clock
The circadian clock system is conserved among all the species from prokaryotes, such as 
cyanobacteria (Iwasaka et al., 2000; Mori et al., 2000), to eukaryotes such as mammals (Rep-
pert et al., 2001).  Circadian systems are characterized by three basic features: 1. An envi-
ronmental input (such as light), 2. An internal and self-sustained oscillator (circadian clock), 
and 3. An output (rhythmic oscillation in physiology or behavior). In animals, the circadian 
system is organized in a hierarchical manner, with a central brain clock at the top of hierarchy 
and peripheral clocks all over the body (Ku et al., 2006). 
 In mammals, the master clock is centrally located in the superchiasmatic nucleus of the 
hypothalamus (SCN). Damaging the SCN in rats disrupts both the activity/rest cycle and 
drinking behavior rhythms (Stephan et al.,1972). The role of the SCN in the circadian system 
has been further studied by the tau mutant golden hamsters. These mutant animals display a 
dramatic short circadian period of about 20 hours, compared to the wild type animals with a 
24 hour circadian period (Ralph et al., 1990). Researchers could restore some of the circadian 
behavior by transplanting the SCN from the wild type hamsters in to the mutant hamsters 
(Ralph et al., 1990). In contrast, transplantation of the SCN from tau mutant hamsters in to 
the wild type animals results in a short circadian period in the wild type hamsters. These ex-
periments indicated the importance of the SCN as the master circadian clock. 
 The SCN is composed of approximately 20,000 neurons. Each individual SCN neuron has 
a self-sustained and cell autonomous circadian oscillator with a broad range in circadian 
periodicity varying between 22 to 30 hours (Welsh et al., 1995; Mohawk et al., 2012). SCN 
clocks are constantly entrained (synchronized) to the day-night cycle of 24 hours. The pho-
tic information is received by photoreceptors located in the retina. Subsequently, the light 
information is transmitted to the SCN via the retinohypothalamic tract (RHT) (Meijer et al., 
2007). A subset of ganglion cells in the inner layer of the retina that express the melanopsin 
photopigment are considered as the main circadian photoreceptors (Berson et al., 2002). The 
other photoreceptors, rods and cones, play an accessory role in maintaining circadian entrain-
ment (Hattar et al., 2003).  The SCN neurons keep synchrony and stay coupled to each other 
through synaptic connections (Aton et al., 2005). This intracellular coupling between the 
SCN neurons is critical for robust circadian rhythmicity, that leads to robust circadian out-
puts. Accordingly, synchronizing signals are transmitted to the peripheral clocks to achieve 
coherent rhythm in the entire organism. 
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Peripheral clocks 
 Rhythmic clock gene expression and protein expression has been identified in the peripheral 
tissues or non-SCN cells throughout the body (Yamazaki et al., 2000). Importantly, circadian 
rhythmicity persists in isolated tissues in vitro, where no control of the SCN exists, indicating 
the endogenous nature of the circadian oscillation at the periphery (Yamazaki et al., 2000). 
In vivo, these cellular clocks receive entraining signals via neural and hormonal stimuli from 
the SCN to maintain synchrony (Welsh et al., 2004). However, the circadian oscillation in 
isolated tissues or cell cultures dampens in time due to desynchronization between the cells 
in the absence of SCN signals. On the other hand, clock synchronizers such as as forskolin 
or dexamethasone can be used to temporarily resynchronize the cellular clocks in cell cul-
tures (Yagita et al., 2001; Yamazaki et al., 2000). Upon treatment with clock synchronizers, 
several signal transduction pathways are activated, such as Mitogen-Activated Protein Ki-
nase (MAPK) cascade and cAMP pathway, that lead to re-setting and synchronizing of the 
circadian oscillator (Balsalobre et., 2000). The peripheral and SCN clocks share the same 
molecular mechanisms to drive their circadian oscillation. However, there are differences 
in the manner in which these two clock systems get synchronized (Mohawk et al., 2012). 
For instance, while the prominent synchronizing signal for the SCN is the light signal, the 
peripheral clocks are sensitive to the feeding rhythm (Stokkan et al., 2001; Damiola et al., 
2000). The hormones secreted upon feeding or fasting are the main phase entraining factors 
for the peripheral clocks. Circadian oscillation in the peripheral cells gives rhythmicity to 
mRNA expression of  about 10% of  the whole genome in each specific tissue (Panda et al., 
2002; Miller et al., 2007). 
 | Molecular mechanism of the mammalian circadian clock 
The core molecular oscillator
 The molecular mechanism of the circadian clock is based on auto-regulatoy  transcrip-
tional-translational feedback loops (TTFL) composed of positive (activating) and negative 
(inhibitory) elements (Reppert et al., 2002).  The TTFL drives cyclic gene expression and 
protein expression of the clock genes with a period of approximately 24 hours (Lowery et 
al., 2004). 
 The activator (positive) elements of the circadian system are Brain Muscle Arnt-Like pro-
tein-1 (Bmal1) and Circadian Locomotor receptor Cycles Output Kaput (Clock) (Lowery et 
al., 2004). (Fig. 1).  Clock mutant mice showed lengthened circadian period with gradual loss 
of circadian rhythmicity (Vitaterna et al., 1994). Mice lacking Bmal1 were unable to gener-
ate endogenous circadian rhythms (Bunger et al., 2000), indicating a key role of BMAL1 
and CLOCK proteins in circadian rhythm generation. CLOCK and BMAL1 belong to he-
lix-loop-helix, Per Arntl Sim (bHLH-PAS) domain containing proteins (Bunger et al., 2000) 
and heterodimerize to form an active transcription factor that binds to the Enhancer-box 
(E-box) elements (5’-CACGTG-3’) of their target genes (Takahashi et al., 2008). Period 
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(Per 1,2) and Cryptocrome (Cry 1,2) comprise the negative feedback loop of the circadian 
machinery (Takahashi et al., 2008). Homozygous Per1 mutant mice show a shorter circadian 
period (Zheng et al., 2001; Cermakian et al., 2001).  Per2 mutant mice also exhibit a shorter 
circadian period, but gradually lose the circadian rhythmicity in constant darkness (Zheng et 
al.,1999). On the other hand, Cry1 and Cry2 deficient mice display a shortened and length-
ened circadian period, respectively (Van der Horst et al., 1999). In the absence of both cryp-
tochromes (Cry1-/-, Cry2-/-) a complete and immediate loss of rhythmicity is reported (van 
der Horst et al., 1999). These studies show that PER and CRY proteins are core circadian 
elements. Transcription of Per and Cry genes is induced by the CLOCK/BMAL1 complex. 
CRY/PER proteins are synthesized, accumulate in the cytoplasm, and after heterodimeriztion 
shuttle between the cytoplasm and the nucleus (Yagita et al., 2002). Once nuclear levels of 
PER/CRY complexes are sufficiently high, they inhibit transcription of E-box genes (includ-
ing their own genes) by blocking CLOCK/BMAL1-mediated transcription (Shearman et al., 
2000; Sato et al., 2006) (Fig. 1). 
 Posttranslational modifications, such as phosphorylation, acetylation, and ubiquitination, 
are equally important for stabilization or degradation and cellular translocation of the clock 
proteins. Phosphorylation of PER and CRY proteins regulates the circadian period (tau) in 
mammals (Lee et al.,2001). PER/CRY complexes are phosphorylated mainly by casein ki-
nase 1 delta (CK1 δ) and epsilon (CK1 ε), and are degraded by 26S proteasome complexes, 
which allows reactivation of CLOCK/BMAL1-driven transcription (Takahashi et al., 2008). 
It has been shown that CRY proteins are crucial for the stabilization of phosphorylated PER2, 
but are not required for stabilization of phosphorylated PER1, suggesting fine tuning in the 
interaction between clock proteins. PER1 phosphorylation appears instead to be mainly im-
portant for nuclear translocation rather than stabilization of the protein (Lee et al.,2001). In 
addition, BMAL1 undergoes extensive post translational modifications, such as phosphory-
lation (Tamaru et al., 2009), acetylation (Hirayama et al., 2007), and ubiquitination (Kwon et 
al.,2006). These post translational modifications define activity and stability of the BMAL1 
protein which is crucial for circadian function. For instance, it has been shown that the 
CLOCK protein possesses histone acetyl transferase activity (HAT) and acetylates its own 
partner, BMAL1 protein (Doi et al., 2006; Hirayama et al., 2007). Acetylation of BMAL1 in 
turn facilitates recruitment of CRY1 protein to nucleus facilitating transcription repression of 
CLOCK/BMAL1 heterodimer. Therefore, posttranslational modifications of the core clock 
proteins define the period of the circadian system and contribute to the stability and activity 
of these proteins. 
 There are additional feedback loops that reinforce the strength of the CLOCK/BMAL1 
and PER/CRY loop (Lowery et al., 2004). CLOCK/BMAL1 heterodimers also drive the 
transcription of two nuclear receptors: Rev-Erbα, and RORα. REV-ERBα inhibits gene ex-
pression of Bmal1, and to a lesser extent of Clock, by binding to ROR responsive elements 
(ROREs) that are located in the promoters of these genes (Preitner et al. 2002; Lowrey et al., 
2004). While REV-ERBα inhibits transcription of Bmal1, RORα activates it.
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Figure 1. Transcriptional-translational network of the mammalian circadian 
oscillator. Diagram showing the molecular mechanism of the mammalian circadian system 
composed of a primary negative feedback loop, and a secondary auto-regulatory feedback 
loop. The primary negative feedback loop of the circadian oscillator involves Clock, 
Bmal1, Per1, Per2, Cry1, Cry2 genes. CLOCK/BMAL1 heterodimer activates E-box 
transcription of Per and Cry genes. Subsequently, PER and CRY proteins heterodimerize 
and translocate to the nucleus to inhibit CLOCK/BMAL1-driven transcription. The 
secondary auto-regulatory feedback loop composed of Rev-erbα and Rorα elements that 
are the direct target of CLOCK/BMAL1 transcription factor. REV-ERBα competes with 
RORα to the bind retinoic acid-related orphan receptor response elements (RRE) located 
in the promoter of the Bmal1 gene. REV-ERBα feedback to repress Bmal1 transcription 
and RORα inhibit expression of Bmal1. PER and CRY proteins are mainly phosphorylated 
by Casein Kinase 1 Delta (CK1 δ) and Casein Kinase 1 Epsilon, (CK1 ε)  an important 
regulatory mechanism to  define the circadian periodicity.
 This results in a high amplitude oscillation of Bmal1 mRNA during a circadian cycle.  A 
number of other clock components can be noted such as Timeless (Tim), Dec1, Dec2 and 
E4BP4 but their roles have not been clearly specified. (Lowrey et al., 2004; Takahashi et al 
2008).
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Clock-controlled outputs
 Circadian transcription of the core clock genes gives rhythmicity to the expression of numer-
ous genes that are involved in various biological processes. These so-called Clock Controlled 
Genes (CCG) comprise over 10% of a tissue’s transcriptome (Panda et al., 2002; Miller et 
al., 2007). Importantly, CCGs that are under circadian transcription differ in each specific 
tissue, which means that the cellular physiology and metabolism is tissue specific (Mohawk 
et al., 2012). These oscillating genes bring rhythmicity to many of the physiological process-
es, including hormone secretion, drug and xenobiotic metabolism, glucose homeostasis and 
cell proliferation (Takahashi et al., 2008). Considering the importance of the circadian clock 
and the wide range of physiological events that are regulated in a circadian manner, it is no 
surprise that environmental disturbance (such as jet lag) or genetic disruption of circadian 
rhythmicity predispose to a range of diseases including metabolic syndrome, cardiovascular 
disease and cancer (Arble et al., 2010; Fu et al., 2013). 
 | Cell cycle control
 The cell cycle represents another oscillatory system that co-exists with the circadian clock 
in dividing cells. The circadian clock and the cell cycle share many common features to 
drive their oscillatory events. Sequential rounds of transcription, translation, post translation-
al modification, and degradation govern their cyclic events. The cell cycle follows a sequence 
of events in which cells copy their genome during S phase, and divide the genome into two 
daughter cells during mitosis (M phase). The S phase and Mitosis are separated by two gap 
phases (G1 and G2). During the G1 and G2 phases cells are prepared for the next step by 
cell growth, protein synthesis, and DNA repair (Norbury et al., 1992). The molecular events 
controlling the cell cycle are ordered and unidirectional. Cell cycle check points ensure the 
successful completion of each step, and allow transition to the next step (Noijma et al., 1997). 
 Progression through the cell cycle relies on the rhythmic activity of cyclin-CDK kinase 
complexes. Within these complexes, cyclins form the regulatory subunits and CDKs the cat-
alytic subunits. (Tyson & Novak, 2008). Specific combination of cyclin-CDK complexes 
triggers various cell cycle events, such as DNA replication and mitosis, at a particular time 
during the cell cycle. Cyclin D is synthesized in response to growth stimuli in early G1 phase. 
It associates with the CDK4 and CDK6 kinases (Guillemot et al., 2001). The active cyclin D 
and CDK4 complex phosphorylates tumor suppressor RB protein in G1. The RB molecule is 
required to inhibit transcription of the genes required for G1 to S transition (Giacinti et al., 
2006; Henley et al.,2012). Hyperphosphorylated Rb dissociates from the Rb/E2F complex 
resulting in activation of E2F complex. The E2F complex is a positive regulator of the cell 
cycle (Magnaghi-Jaulin et al., 1998). Activation of E2F as a transcriptional factor induces 
transcription of the genes regulating G1/S transition, such as cyclin E (Geng et al., 1996). In 
mid-G1, cyclin E is transcribed, along with CDK2, facilitating G1/S transition (Koff et al., 
1992). Cyclin A2 transcription rises at the beginning of S phase and, in complex with its cat-
alytic subunit CDK2, is essential for DNA replication and S phase progression (Erlandsson 
18
Chapter 1
et al., 2000; Coverley et al., 2002; Kalaszczynska et al., 2009). Cyclin B1 levels rise from the 
late S phase till late G2 phase allowing the protein to form complexes with CDK1 (Pines et 
al.,1989) (Fig. 2). 
CyclinB1-CDK1 initially should be kept in an inactive state to avoid premature mitosis. 
WEE1 and MYT1 kinases are responsible for the inhibitory phosphorylation of the CDK1 
subunit, consequently CyclinB1-CDK1 complex is kept in a low or inactive state as a result 
of this phosphorylation (Mueller et al., 1995; Parker et al.,1992). A high level of Cyclin B1, 
and high level of Cyclin B1-CDK1 complex, generate sufficient activity for this protein com-
plex to set off the double feedback loop in which Cyclin B1-CDK1 can inhibit its inhibitor 
(Wee1) and activate its activator (Cdc25), resulting in a rapid activation of Cyclin B1-Cdk1 
and mitotic entry (Boutros et al., 2006; Lindqvist et al., 2009) (Fig. 2)
Cyclic expression of the cyclins is highly timed and scheduled, and their disappearance is 
regulated through induced proteolysis by the 26S proteasome. Timed degradation of the Cy-
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Figure 2. Schematic representation of the cell division cycle. Cyclin-CDK complexes 
regulating progression of the cells through different cell cycle phases. Phosphorylation 
of RB molecule by Cyclin D/CDK4-6 complexes in early or mid G1 phase results in 
dissociation of RB and E2F. E2F molecule triggers transition of the cells from G1 to S. 
Mitosis is initiated by Cyclin B1-CDK1 complex. Inhibitory phosphorylation of CDK1 by 
Wee1 kinase avoids premature mitosis. Cyclin B1-CDK1 complex is activated by CDC25 
phosphatase. DNA damage check point molecules act mainly on CDC25 to prevent the 
activation of Cyclin B1-CDK1 complex. 
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clins is equally important for cell cycle progression as their timed expression. For instance, 
Cyclin B1 destruction is essential for mitotic exit (Pines et al., 2006;). Activity of Cyclin 
B1-CDK1 complex stops the segregation of chromosomes and stalls the cells at the end of 
anaphase (Holloway et al., 1993; Pines et al.,2006). Moreover, destruction of Cyclin A2 
starts right after nuclear envelope break down, being almost completely degraded before 
metaphase (Den-Elzen et al., 2001; Geley et al., 2001). Overexpression of Cyclin A2 in late 
G2 phase cells delays chromosome alignment, subsequently delaying mitosis (Den Elzen et 
al., 2001).
 Transition of the cells from one phase to another is tightly regulated by cell cycle check-
points. Restriction point R in the late G1 phase is an important check point in the mammalian 
cell cycle. Before this restriction point, the cell cycle depends on external stimuli (growth 
factors) to proceed through G1. After the restriction point, the cell becomes independent of 
external mitogenic stimuli and can complete the cell division cycle autonomously (Pardee 
et al., 1974; Johnson et al., 2013). One other important cell cycle checkpoint is the G2/M 
checkpoint. This checkpoint ensures genome stability before cells enter M phase, avoiding 
that a defective genome passes to the next generation of the cells. When cells are exposed 
to genotoxic agents, or in case of defective replication in S phase, DNA damage response 
pathways are activated (Kastan et al., 2004). As it is mentioned before, the main driver of 
mitotic entry is the activity of Cyclin B1-Cdk1. Therefore, DNA damage response pathways 
modulate regulators of Cyclin B1-CDK1 complex to pause the cells in G2 (Stark et al., 
2004). The DNA damage response is mainly triggered by two signaling cascades: Ataxia-Tel-
angiectasia Mutated and Check Point Kinase 2 (ATM/CHK2), and ATM-Rad3-related and 
CheckPoint Kinase 1 (ATR/CHK1) (Sancar et al., 2010). The G2/M check point is regulated 
by CHK1-dependent phosphorylation of CDC25 phosphatase which is an important activator 
of CyclinB-CDK2 complex (Figure 2). Phosphorylation of CDC25 prevents activation of 
Cyclin B-CDK2 complex and stalls the cells in G2 phase (Boutros., 2007). 
 | The interaction between the circadian oscillator and the cell 
cycle machinery  
 Initial studies suggest a cross-talk between the circadian clock and the cell cycle. For in-
stance, it has been shown that a light-induced phase shift in mouse behavior leads to a corre-
sponding shift in the proliferation timing of cells in the intestine (Scheving et al., 1983). On 
the other hand, DNA damage phase advanced circadian rhythms in a dose and time depen-
dent manner (Oklejewicz et al., 2008). These studies indicate mutual influences of these two 
systems on each other. Research on human oral mucosa and skin has provided a first clue to 
on association between clock gene expression and cell cycle phase (Bjarnason et al., 1999 
and 2001). This was achieved through the analysis of rhythmic expression of clock genes and 
cell cycle proteins in human oral mucosa and skin biopsies over 24 hours. Expression of Per1 
mRNA was shown to peak in the morning, and to coincide with the peak of p53 expression 
as a G1 marker. In contrast, Bmal1 transcripts reached their highest level at night, showing 
synchrony with the peak expression of CyclinB1, a marker of G2 and M phase. Rhythmicity 
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in DNA synthesis and mitosis has also been demonstrated in hematopoietic, immune system, 
gastro-intestinal tract, liver, and skin cells of rodents (Lévi et al., 2007).
In a study by Matsuo and colleagues it has been shown that, in critical situations such as 
partial hepatectomy, the circadian rhythm affects the timing of cell division in vivo (Matsuo 
et al., 2003). This was shown by a partial hepatectomy in wild type mice, which caused the 
hepatocytes to enter M phase at a specific time of the day. This M phase gating was not seen 
in Cry deficient mice that displayed loss of circadian rhythmicity. (Matsuo et al., 2003). 
Circadian gating of cell division has been also proposed in other studies. For instance, it has 
been reported that approximately 16% of human epidermal cells undergo mitosis mainly at 
night (Scheving et al.,1959). 
 The dynamics of the circadian clock and cell cycle machineries and the interaction between 
these oscillators has also been addressed at the level of the individual cell by the use of a 
fluorescent circadian reporter (Rev-Erbα-VNP) which is under the direct control of CLOCK/
BMAL1 complex. Using the Rev-Erbα reporter in a mouse fibroblast cell line (NIH3T3), the 
dynamic interaction between the circadian clock and cell cycle has been determined (Nagoshi 
et al., 2004; Bieler et al., 2014; Feillet et al., 2014). In the study by Nagoshi and coworkers, 
it was shown that there are three specific and non-random circadian time windows in which 
cell division occurs in the NIH3T3 cells. However, at the same time, the period and phase of 
the circadian clock were influenced and altered after each cell division event (Nagoshi et al., 
2004). Later, using the same circadian clock reporter (Rev-Erbα-VNP) (Bieler et al., 2014) 
in combination with two cell cycle markers (FUCCI reporter system: hCDT1-mKOrange 
for G1, and hGeminin-CFP for S/G2/M) (Feillet et al., 2014), a tight synchrony between 
the circadian clock and the cell cycle has been reported at the single cell level. It has been 
shown that the circadian clock and the cell cycle are tightly phase coupled, and are oscillating 
with the same frequencies (1:1 ratio). A remarkable shortening of the circadian period was 
observed in dividing cells compared to non-dividing cells, indicating the influence of the cell 
cycle on the circadian clock (Bieler et al.,2014; Feillet et al., 2014). Bieler and colleagues 
reported a uni-directional link between the circadian clock and the cell cycle, suggesting that 
in the absence of external cues (clock synchronizers), the effect of the cell cycle on circadian 
period is dominant (Bieler et al., 2014).  In contrast, in the study by Feillet and coworkers, 
a bi-directional link between these two oscillatory systems has been uncovered (Feillet et 
al.,2015). They have shown that synchronization of the circadian clock by physiological 
cues, such as dexamethasone, clustered cell division. This indicates that when the circadian 
oscillator is exposed to synchronizing cues, the effect of the circadian system on the cell cy-
cle is dominant. In contrast, in the absence of clock sysnchronizers, the influence of the cell 
cycle on the circadian clock is dominant. 
 Our knowledge regarding the molecular mechanisms underlying the interaction between 
these two oscillatory systems is gradually increasing. Circadian clock genes regulate import-
ant cell cycle check points by either transcriptional control of critical regulatory genes, or by 
direct protein-protein interactions.  For instance, oncogene c-Myc (G0/G1 transition) is neg-
atively regulated by the BMAL1/CLOCK transcription factor (Fu et al., 2002). G1 and G1/S 
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checkpoints are under circadian control through cyclic transcription of the tumor suppressor 
genes p21WAF1/CIP1 and p16-Ink4A (Gréchez-Cassiau et al., 2008; Kowalska et al., 2013). 
p21 is negatively regulated by BMAL1, as suggested by a high level of P21 protein reported 
in Bmal1-/- hepatocytes (Grechez-Cassaiu et al., 2008). The multifunctional nuclear protein 
NONO binds to the p16 promoter and drives its circadian transcription in a PER dependent 
manner (Kowalska et al., 2013). In the absence of PER or NONO, the circadian expression 
of p16 is abolished. Likewise, expression of the Wee1 gene (an important G2/M checkpoint 
kinase) is under circadian control (Matsuo et al., 2003). Oppositely, there is also evidence 
regarding the molecular influence of the cell cycle on the circadian clock. The cell cycle gene 
p53 negatively regulates Per2 expression, therefore affecting circadian period (Miki et al., 
2013). 
 As a consequence of these complex interconnectivities between the circadian clock and the 
cell cycle, it is not surprising that loss of circadian control can be considered as a key factor 
for abnormal cell growth. It has been reported that Per1/Per2 or Cry1/Cry2 deficient mice 
show increased bone mass formation because of an accelerated G1/S transition in osteoblast 
cells (Fu et al., 2005). This result was attributed to high expression levels of G1 cyclins 
such as cyclin D1 in PER deficient mice (Fu et al., 2005). In another study, by Destici and 
co-workers, an accelerated cell cycle progression and high proliferation rate has been report-
ed in primary Cry1-/-, Cry2-/- mouse fibroblasts (Destici et al., 2011). Primary hepatocytes 
from Bmal1 knockout mice showed a decreased proliferation rate, which was related to the 
altered expression of tumor suppressor gene P21 (Grechez-Cassaiu et al.,2008). Taken to-
gether, all the above data suggest a unique effect of clock genes on the cell cycle progression 
that impact different cell cycle phases in a specific manner. 
 | The circadian clock, cell cycle, and cancer 
 Genetic disruption and environmental disturbance of the circadian system have been asso-
ciated with a range of physiological disorders (Lee et al., 2010). For instance, altered insulin 
and glucose levels in the Clock deficient mice lead to a range of metabolic disorders such as 
obesity, hyperlipidemia, and hypoinsulinemia (Turek et al., 2005). 
 Epidemiological studies have shown that human night shift work is linked to increased risk 
of breast, colon, lung, prostate, and non-Hodgkin’s cancer (Stevens et al., 2009; schernham-
mer et al., 2003; Kloog et al., 2009; Lahti et al., 2008). Night shift work is considered as a 
carcinogenic factor, as the risk of cancer development is increased by the number of the years 
an individual spends working at night (Schernhammer et al., 2003; Lee et al., 2010).  Several 
studies have shown that loss of circadian homeostasis in mice leads to accelerated mammary 
tumor growth. For instance, breast cancer prone p53 mutant mice show accelerated tumor 
development under a jetlag protocol (Van Dycke et al., 2015).  In addition, ablation of the 
SCN in mice increases the growth rate of implanted tumors (Filipski et al., 2002; Filipski et 
al., 2009). 
 Many of the genes that are mutated in human cancers are directly involved in the regulation 
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of cell division. Likewise, altered expression of circadian clock genes that are involved in the 
regulation of different cell cycle check points has been reported by various studies (Fu et al., 
2002; Kondratov et al., 2006; Lee et al., 2010). For instance, mutations in the Per1 and Per2 
genes were detected in breast and colon cancer patients (Sjoblom et al., 2006). It has been 
shown that PER1 participates in the ATM-CHK2 DNA damage signaling pathway, which is 
activated upon DNA double strand breaks caused by ionizing radiation (Sancar et al., 2010). 
PER1 interacts with both ATM and CHK2 proteins for an efficient activation of the signaling 
cascade, which results in cell cycle arrest or activation of repairing pathways (Sancar et al., 
2010). Exposure of cancer cell lines over-expressing Per1 to ionizing radiation (IR) revealed 
an increased apoptosis sensitivity. In contrast, suppression of Per1 expression by siRNA in 
IR exposed cancer cell lines results in a reduction of the apoptotic rate (Grey et al.,2006). 
Furthermore, Per2 mutant mice showed increased tumor development upon exposure to ion-
izing radiation (Fu et al.,2002; Lee et al.,2006). Altered expression of cell cycle related genes 
such as p53 and c-Myc is proposed as an underlying mechanism. In addition, down regulation 
of the Per2 gene in breast cancer cells accelerates the proliferation rate by increasing Cyclin 
D and Cyclin E levels in vitro (Yang et al., 2009). All above data suggest that Per1 and Per2 
are tumor-suppressor genes. Therefore, mutations in circadian clock components can pre-
dispose the mice to cancer by increasing the cell growth and cell proliferation rate through 
general cell cycle dis-regulation.
 ATR/CHK1 is another DNA damage signaling cascade that is activated in response to UV 
DNA damage (Sancar et al., 2010).  It has been shown that CRYs are also involved in this 
DNA damage signaling cascade via the Timeless (TIM) circadian clock protein (Unsal-Kac-
maz et al., 2005). TIM simultaneously binds to cryptochromes and ATR/CHK1 proteins, ac-
tivating ATR/CHK1 DNA damage pathway (Unsal-Kacmaz et al., 2005; Kang et al., 2014). 
Downregulation of Tim disrupts both the circadian oscillation and ATR/CHK1 signaling 
pathway (Sancar et al., 2010). 
 | Scope of the thesis
 The circadian system regulates proper synchronization of several processes within an or-
ganism, as well as between an organism and its environment. Importantly, genetic variation 
in clock genes and environmental circadian disturbance have been linked to metabolic dis-
ease, sleep disorders, depression and endocrine imbalance, and abnormal cell growth (Lee 
et al., 2010). Abnormal cell growth is characterized by impaired cell cycle progression. The 
circadian clock and the cell cycle have been considered as two independent oscillators for 
a long time. Increasing evidence has challenged this speculation by showing that there is 
a strong bi-directional link between these two oscillatory systems (Feillet et al., 2014 and 
2015). Importantly, recent molecular studies provided reliable evidence showing the involve-
ment of the clock genes in the regulation of important cell cycle check points, and vice versa. 
Although our knowledge is steadily increasing, still many questions remain to be answered: 
(1) In the context of the bi-directional link between these two oscillatory systems, how do 
alterations in one of the cycles affect the other? 
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(2) What are the candidate molecules playing a key role in the coupling between these two 
systems, and how can use we these newly identified molecules for therapeutic purposes?  
(3) Since a hallmark of cancer is cell cycle dysregulation, and almost all cancer cell lines 
show abnormal cell proliferation and abnormal circadian gene expression, what is the status 
of the coupling between the circadian clock and the cell cycle in cancer cells?
 Here, we investigated the role of positive and negative circadian elements on cell cycle pro-
gression of a mouse fibroblast cell line simultaneously expressing a circadian clock (Rev-Er-
bα) and cell cycle markers (Fucci reporter system: pFucci-G1 and pFucci-S/G2/M) (Feillet 
et al., 2014). We determined the kinetics of the cell cycle phases in the absence of individual 
core circadian clock gene at the single cell level. Furthermore, we elucidated the underlying 
molecular mechanisms. Moreover, we studied the coupling between the circadian clock and 
cell cycle systems in cancer cells at the single cell level, using a p53 mutant mouse breast car-
cinoma cell line. Finally, we took a combined gene knockdown and transcriptomics approach 
to analyze the impact of clock gene inactivation on the cancer properties of H1299 human 
non-small lung carcinoma cells.  
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Chapter 2
|  Abstract
We previously identified a tight bidirectional phase coupling between the 
circadian clock and the cell cycle. To understand the role of the CLOCK/
BMAL1 complex, representing the main positive regulator of the circa-
dian oscillator, we knocked down Bmal1 or Clock in NIH3T33C mouse 
fibroblasts (carrying fluorescent reporters for clock and cell cycle phase) 
and analyzed timing of cell division in individual cells and cell popula-
tions. Inactivation of Bmal1 resulted in a loss of circadian rhythmicity and 
a lengthening of the cell cycle, originating from delayed G2/M transition. 
Subsequent molecular analysis revealed reduced levels of Cyclin B1, an 
important G2/M regulator, upon suppression of Bmal1 gene expression. 
In complete agreement with these experimental observations, simulation 
of Bmal1 knockdown in a computational model for coupled mammalian 
circadian clock and cell cycle oscillators (now incorporating Cyclin B1 in-
duction by BMAL1) revealed a lengthening of the cell cycle. Similar data 
were obtained upon knockdown of Clock gene expression. In conclusion, 
the CLOCK/BMAL1 complex controls cell cycle progression at the level 
of G2/M transition through direct regulation of Cyclin B1 expression.
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 | Introduction
 The circadian clock and the cell cycle are two fundamental, highly dynamic, and evolu-
tionary well conserved biological oscillators that employ cyclic gene expression and protein 
degradation to impose diurnal rhythmicity on behavior, physiology and metabolism, and to 
drive cell division, respectively. 
 The mammalian circadian clock consists of a light-entrainable central clock located in the 
hypothalamic suprachiasmatic nucleus (SCN) of the brain, and peripheral clocks situated in 
the individual cells of almost all other tissues (Takahashi et al., 2008). At the molecular level, 
the circadian clock is based on intertwined positive and negative transcriptional-translational 
feedback loops (Mohawk et al., 2012). In short, the positive elements of the circadian clock, 
encoded by the Brain and Muscle Arnt-like protein-1 (Bmal1) and the Clock genes, form 
a heterodimer that activates transcription of E-box promoter element containing genes, in-
cluding the core clock genes Period (Per1 and Per2), Cryptochrome (Cry1 and Cry2), and 
nuclear hormone receptor Rev-Erbα. Once formed, PER and CRY proteins heterodimerize 
and translocate to the nucleus where they inhibit CLOCK/BMAL1-mediated transcription 
of E-box genes, including their own (Mohawk et al., 2012). Post-translational modification 
events, including phosphorylation and ubiquitination, target the PER and CRY proteins for 
degradation by the 26S proteasome complex, which in turn allows reactivation of CLOCK/
BMAL1-mediated transcription and initiation of a new circadian cycle (Gallego et al., 2007; 
Stojkovic et al., 2014). In addition, CLOCK/BMAL1-driven cyclic expression of the Rev-Er-
bα gene (encoding an inhibitor of ROR-driven Bmal1 expression) causes Bmal1 expression 
to oscillate, which confers robustness to the circadian core oscillator. BMAL1 and CLOCK 
are also responsible for the cyclic transcription of E-box-containing clock-controlled genes 
(CCG) that couple the circadian oscillator to a wide variety of physiological pathways. 
 Similar to the circadian clock, the cell cycle behaves as an oscillator in which cyclic expres-
sion of key cell cycle molecules (i.e. cyclins) regulates cell cycle progression in a sequential 
and unidirectional manner (Tyson & Novak, 2008; Gérard & Goldbeter, 2009). Cyclins are 
produced at specific stages of the cell cycle and associate with their respective constitutively 
expressed Cyclin-Dependent Kinase (CDK) partner. The kinase activity of the cyclin-CDK 
complexes triggers various events at specific times during the cell cycle. In short, mitogenic 
signals prompt the expression of Cyclin D, which binds to CDK4 and CDK6 and irreversibly 
drives the cell through G1 phase and prepares it for replication. The underlying signalling 
cascade includes activation of the Ccne1 and Ccna2 cyclin genes (Henley & Dick, 2012). Cy-
clin E protein levels peak at late G1, resulting in the formation of Cyclin E/CDK2 complexes 
that initiate G1/S transition and subsequent DNA replication (Koff et al., 1992; Jackson et al., 
1995). Cyclin A2 starts to appear during S phase and, along with its catalytic subunit CDK2, 
is essential for DNA replication and S phase progression (Erlandsson et al., 2000; Coverley 
et al., 2002; Kalaszczynska et al., 2009). Ablation of Cyclin A2 in cultured cells blocks DNA 
synthesis and delays S phase progression (Girard et al., 1991; Pagano et al., 1992). Mitotic 
entry is triggered by Cyclin B1/CDK1 (Gavet & Pines, 2010). Transcription of the Cyclin B1 
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gene CcnB1 starts in S phase with Cyclin B1 protein levels and Cyclin B1/CDK1 complex 
formation peaking at late G2 (Lindqvist et al., 2009, Fung et al., 2005). However, Cyclin B1/
CDK1 complexes are initially kept in an inactive state by WEE1 and MYT1 kinase-mediated 
phosphorylation of specific CDK1 residues to avoid premature mitosis (Mueller et al., 1995; 
Parker & Piwnica-Worms, 1992; Fung et al., 2005). Once protein levels are sufficiently high, 
Cyclin B1 triggers the de-phosphorylation of CDK1, thereby activating its own (i.e. Cyclin 
B1/CDK1) complex and promotes entry into mitosis (Lindqvist et al., 2009). In conclusion, 
oscillations in the amount and activity of the various Cyclin/CDK complexes are crucial for 
cell cycle progression. 
 Multiple studies have provided evidence for a strong connection between the circadian 
clock and cell cycle in proliferating cells. Bjarnason and coworkers have shown circadian 
variation in the abundance of cell cycle proteins in human oral mucosa (Bjarnason et al., 
1999). Moreover, expression of clock genes in human oral mucosa and skin was associated 
with specific cell cycle phases. Notably, peak expression of the Cyclin B1 gene Cnnb1 co-
incides with that of the Bmal1 clock gene, while Per1 transcription coincides with the peak 
of p53 mRNA levels in late G1 (Bjarnason et al., 2001). Studies addressing the molecular 
link between the circadian and cell cycle oscillator have shown that the circadian clock can 
affect the cell cycle at different levels. For instance, expression of the G2/M inhibitor WEE1 
is under circadian control via CLOCK/BMAL1 responsive E-box elements in the Wee1 gene 
promoter (Matsuo et al., 2003). Likewise, G1 to S transition has been reported to be under 
circadian control through CLOCK/BMAL1-mediated cyclic transcription of the cell cycle 
inhibitor gene p21WAF1/CIP1 (Gréchez-Cassiau et al., 2008). Furthermore, the multifunc-
tional nuclear protein NONO was found to bind to the promoter of the p16-Ink4A cell cycle 
checkpoint gene and drive circadian expression in a PER-dependent manner (Kowalska et 
al., 2013). Oppositely, the cell cycle regulator protein CDK1 has been suggested to control 
the circadian clock through phosphorylation of REV-ERBα, which targets the latter protein 
for FBXW7α-mediated degradation (Zhao et al., 2016).
 Besides those molecular links, initial studies with NIH3T3 cells containing a fluorescent 
clock reporter that allows time lapse imaging of the circadian clock in individual proliferat-
ing cells revealed that mitosis occurred at specific time windows, suggesting that cell division 
is gated by the circadian clock (Nagoshi et al., 2004). Recently, we and others used afore-
mentioned NIH3T3 cells to address the dynamic coupling between the clock and cell cycle 
in more detail by simultaneous single cell time lapse imaging of circadian clock performance 
and cell cycle progression, the latter visualized through mitotic events (Bieler at al., 2014) or 
fluorescent cell cycle reporters (Feillet et al., 2014). Interestingly, in the absence of external 
resetting cues, the cell cycle and circadian clock were shown to be phase locked in a 1:1 ratio, 
with the clock reporter reproducibly peaking 5 h after mitosis (Feillet et al., 2014; Bieler et 
al., 2014). Notably, the length of the circadian cycle in proliferating cells adjusted to that of 
the cell cycle. On the other hand, synchronization of the circadian clock by physiological 
cues (such as dexamethasone) causes clustering of cell divisions, indicating that the cell cy-
cle is synchronized via the circadian clock and that, accordingly, the coupling between these 
two oscillators is bidirectional (Feillet et al., 2014). The molecular nature of the coupling of 
the circadian clock to the cell cycle nevertheless remains to be determined. Mathematical 
models for the circadian clock (Leloup & Goldbeter, 2003, 2004) and the cell cycle (Gérard 
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& Goldbeter, 2009, 2014) have been integrated into a comprehensive computational model 
(Gérard & Goldbeter 2012) that enables the in silico analysis of the connection between the 
circadian clock and the cell cycle based on the molecular information provided in literature. 
This approach has provided new insight into the interaction of these oscillating systems and 
the conditions under which the cell cycle can be entrained by the circadian clock as a function 
of both the strength of coupling to the circadian clock and the duration of the cell cycle prior 
to such coupling (Gérard & Goldbeter 2012). 
 Although our knowledge on the coupling of the circadian clock and cell cycle is steadily 
increasing, relatively little is known on how genetic clock defects affect the interaction be-
tween these two oscillatory machineries. In the current study, we used our NIH3T33C mouse 
fibroblast line with fluorescent reporter genes for the circadian clock and cell cycle phase 
(Feillet et al., 2014) to investigate the role of the BMAL1 and CLOCK proteins in cell cycle 
progression. We show that cell cycle duration is prolonged after siRNA mediated silencing 
of either Bmal1 or Clock expression, and provide insight into the mechanism underlying this 
effect. Moreover, we used the biological data to probe and reinforce the computational model 
for the coupled mammalian circadian clock and cell cycle oscillators. 
 | Materials & Methods
Cell culture and gene knockdown
 NIH3T3 and NIH3T33C cells, the latter containing Rev-Erbα-VNP clock reporter and FUCCI 
hCdt1-mKOrange and hGeminin-CFP FUCCI cell cycle reporter genes; Feillet et al., 2014) 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)/F10 (Lonza) containing 
10% Fetal Bovine Serum (FBS) (Gibco), 100 U/ml Penicillin and 100 µg/ml Streptomycin in 
a standard humidified incubator at 37°C and 5% CO2 (pH7.7). 
 To knockdown Bmal1 or Clock expression, we used Silencer® Select Pre-designed siRNA 
for Arntl (ThermoFisher Scientific; catalog number 4390771) and Clock (ThermoFisher Sci-
entific; catalog number 4390771). As a negative control, we used Silencer® Select Negative 
Control No. 1 siRNA (ThermoFisher Scientific; catalog number 4390843). Reverse transfec-
tion was performed in 6 well plates (population studies) or in 4 well poly-L-lysine coated 
glass bottom dishes (D141410, Matsunami Glass Ind.), using the Lipofectamine® RNAi-
MAX method (Invitrogen) as described by the manufacturer, except that Opti-MEM was 
replaced by (serum-free) DMEM/F10.  After 24 hours, transfection medium was replaced by 
regular culture medium. Cells were harvested at the indicated time points and processed for 
further analysis.
 In a subset of experiments, the cell cycle of proliferating cells was synchronized by treat-
ment of cell cultures with 2.5 mM thymidine (Sigma), starting 48 hours after RNAi transfec-
tion. After 24 hours, cells were released from thymidine block by washing 3 times with PBS 
and harvested at the indicated time points. 
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Time-lapse fluorescence microscopy 
 For time-lapse recording of circadian clock and cell cycle progression, cells (transfected 
and grown on glass bottom dishes) were placed in the temperature (37°C), CO2 (5%) and 
humidity controlled chamber of a live cell imaging Zeiss LSM510/Axiovert 200M confocal 
microscope, equipped with a 10x Ph objective. Images were recorded every 30 min for 72 
hours or more using a Coolsnap HQ/Andor Neo sCMOS camera. Live cell imaging was con-
ducted using the following parameters (as set up in Zeiss 200 software): Venus (green): 1000 
ms (filter cube: Ex= 475/40 nm, DM= 500 nm, Em= 530/50 nm); mKO2 (red): 300 ms (filter 
cube: Ex= 534/20 nm, DM=552 nm, Em: 572/38 nm); CFP (blue): 300 ms (filter cube: Ex= 
458/17 nm, DM=450 nm, Em: 479/40 nm). Acquired images were concatenated and merged 
into a single file to generate a movie which was used for further analysis as described in detail 
by Feillet and coworkers (Feillet et al., 2014). In short, single cell numerical time series for 
each of the fluorescent markers were generated using the LineageTracker plugin for ImageJ 
(https://github.com/pkrusche/lineagetracker.jsonexport). Time series were analyzed for cir-
cadian cycle length, cell cycle length and G1 and S/G2/M cell cycle phase length. The G1 
phase is defined as the interval between the peaks of hGeminin-CFP and hCDT1-mKOrange 
expression. Oppositely, the S/G2/M phase is defined as the interval between the peaks of 
hCDT1-mKOrange and hGeminin-CFP expression.
mRNA and protein analysis
 Gene expression levels were determined by quantitative RT-PCR. Total RNA was isolated 
from cultured cells in triplicate using TRIzol (Invitrogen) following manufacturer’s instruc-
tions. First-strand cDNA was synthesized from 1 μg of total RNA using oligo (dT) primers 
and SuperScript reverse transcriptase (Invitrogen) according to the manufacturer’s proto-
col. Quantitative PCR amplification was performed using the iCycler iQ™ Real-Time PCR 
Detection System (BioRad), with SYBR-green and primer sets generating intron-spanning 
products of 150-300 bp. The following forward and reverse primers were used: Bmal1: Fwd 
5’-AAG CTT CTG CAC AAT CCA CAG CAC-3’ and Rev 5’-TGT CTG GCT CAT TGT 
CTT CGT CCA-3’; Clock: Fwd 5’-CTT CCT GGT AAC GCG AGA AAG -3’ and Rev 5’-
GTC GAA TCT CAC TAG CAT CTG AC -3’; B2M: Fwd 5’-CCG GCC TGT ATC CAG 
AAA-3’ and Rev 5’-AAT TCA ATG TGA GGC GGG TGG AAC-3’. 
 Protein expression levels were determined by Western blot analysis. Cells were lysed in 
RIPA lysis buffer, composed of 2 mM Tris-HCl PH8.0, 1% TX-100, 0.5% NaDOC, 0.1% 
SDS, 5.15 mM NaCl, 5 mM NaF, 1.25 mM NaVO3, 10 mM EDTA supplemented with a 
PhosSTOP phosphatase inhibitor tablet (Roche) and a Pierce Protease Inhibitor tablet (Ther-
moFisher). Lysates were cleared by centrifugation at 13,000 g for 10 minutes at 4°C. Pro-
tein concentration was determined using the BCA Protein Assay Reagent (Pierce®, Ther-
mo Scientific). Absorbance was measured at 560 nm using a GloMax-Multi+ Microplate 
Multimode Reader (Promega). Proteins were loaded on Bis-Tris Plus 4-12% polyacrylamide 
gel (Novex®, Life technologies), size separated and transferred to a Polyvinylidene fluoride 
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(PVDF) membrane. After blocking with 4% skim milk, membranes were incubated with 
primary antibodies (listed below) overnight at 4°C. After washing, membranes were incu-
bated with the secondary antibodies (1:2000 dilution) for 1 hour at 4°C. Protein bands were 
visualized using Western Lightning™ Chemiluminescence Reagent Plus (PerkinElmer) and 
autoradiography. Bands were quantified by Fiji® software and normalized against to β-actin 
protein levels. 
 Antibodies used: Primary antibodies: Santa Cruze: Actin C-2 (sc8432), BMAL1 (sc48790), 
CLOCK (sc25361), Cyclin B1 (sc245), Cyclin A (sc751), WEE1 (sc325); Abcam: Cyclin 
E (ab7959), Cyclin D (ab134175),. Secondary antibodies: goat anti-rabbit IgG (H+L)-HRP 
conjugate or goat anti-mouse IgG (H+L)-HRP conjugate. 
Flow cytometry
 To analyze cell cycle status by quantification of DNA content, cells were harvested 48 hours 
after siRNA transfection, washed with PBS, and fixed overnight at 4°C with cold 70% etha-
nol. Next, fixed cells were washed with PBS, treated for 15 min at 37°C with PBS containing 
100 μg/ml bovine pancreas RNase (Calbiochem), and left overnight at 4°C in PBS with 40 
μg/ml propidium iodide (PI; Life Technologies). Alternatively, to specifically detect mitot-
ic cells, fixed cells were stained for the presence of the MPM-2 phospho-epitope on DNA 
topoisomerase IIα, using mouse anti-MPM2 primary antibodies (Merck-Millipore; dilution 
1:200; 1 h on ice) and goat-anti mouse FITC secondary antibodies (Jackson ImmunoRe-
search; dilution 1:50; 30 min on ice). Cells were analyzed by a Becton Dickinson LSRFortes-
saTM Cell Analyzer (BD Biosiences). PI and FITC fluorescence intensities were measured 
at 610 nm and 530 nm, respectively. For each condition, at least 20000 cells were counted. 
Frequency histograms were made using BD FACSDivaTM software (BD Biosciences).
DNA synthesis assay
 DNA synthesis was determined using the Click-iT® EdU Alexa Fluor® 594 Imaging Kit 
(Invitrogen). Cells were pulse labelled with 5-ethynyl-2’-deoxyuridine (EdU) for 1 hour, 
fixed with 3.7% formaldehyde, and incubated with Alexa Fluor® 594 according to the man-
ufacturer’s instructions. Images were generated using a Zeiss Axiovert 200M microscope 
and processed using ImageJ software. For each image, total intensity was normalized to the 
number of cells. 
Mathematical modeling
 To study the interaction between the circadian clock and the cell cycle we used two compu-
tational models previously proposed for the mammalian circadian clock and for the mamma-
lian cell cycle, respectively. The model for the mammalian circadian clock incorporates the 
positive and negative regulations involving the PER, CRY, CLOCK, BMAL1 and REV-ER-
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Ba proteins (Leloup & Goldbeter, 2003, 2004). This model (in which, for simplicity, PER1 
and PER2, as well as CRY1 and CRY2 are treated as single entities) accounts for the oc-
currence of spontaneous circadian oscillations of the above-mentioned proteins and their 
mRNAs in a variety of experimental conditions.
 The model for the mammalian cell cycle is based on the regulatory properties of the CDK 
network that drives the transitions between the successive phases of the cell cycle (Gérard 
& Goldbeter, 2009, 2014). The model contains four CDK modules, each of which controls 
the transition to a particular cell cycle phase. Thus, Cyclin D/CDK4-6 and Cyclin E/CDK2 
promote progression in G1 and elicit the G1/S transition; the activation of Cyclin A/CDK2 
ensures progression in S and G2, while the peak of Cyclin B/CDK1 activity brings about pro-
gression into mitosis. Exit from the quiescent state is triggered above a critical level of growth 
factor by the synthesis of Cyclin D, which allows cells to enter the G1 phase. Synthesis of the 
various cyclins is regulated through the balance between the antagonistic effects exerted by 
the transcription factor E2F and the tumor suppressor pRB, which respectively promote and 
inhibit cell cycle progression. Additional regulations in this model for the CDK network bear 
on the control exerted by the proteins SKP2, CDH1, or CDC20 on the degradation of cyclins 
E, A, and B at the G1/S or G2/M transitions, respectively. Moreover, the activity of each cy-
clin/CDK complex can itself be regulated through CDK phosphorylation-dephosphorylation. 
At suprathreshold levels of growth factor sustained oscillations spontaneously occur in the 
CDK network, which may be associated with cellular proliferation since they correspond to 
the repetitive, sequential activation of the various cyclin-CDK complexes responsible for 
the ordered progression along the successive phases of the cell cycle (Gérard & Goldbeter, 
2009, 2014).
 The cell cycle is coupled to the circadian clock through several molecular processes (see 
above), such as the induction of Wee1 expression by CLOCK/BMAL1. Such coupling may 
lead to entrainment of the cell cycle by the circadian clock (Gérard & Goldbeter, 2012). The 
equations governing the models for the coupled circadian clock and cell cycle models are 
given in the Supporting Information section. Here we focus on the case where the cell cycle 
is coupled to the circadian control via the induction of Wee1 gene expression by CLOCK/
BMAL1. We also introduce coupling via the induction of Cnnb1 (Cyclin B1) gene expression 
by CLOCK/BMAL1, as suggested by the experiments reported in the present study. To mod-
el the impact of knockdown of Bmal1 gene expression, we reduce the rate of Bmal1 mRNA 
synthesis (measured by parameter vsB) in the model for the circadian clock. 
Statistical analysis 
 All statistical analyses were carried out with GraphPad software. For single cell studies, 
after performing the normality test, the two-tailed Mann-Whitney U-test was used to analyze 
the period of the circadian and cell cycle clocks (including G1, S/G2/M phase length). For 
Western blot, flow cytometry, and immunofluorescence experiments, the two-tailed Student’s 
t-test was applied. 
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 | Results 
Suppression of Bmal1 expression lengthens the cell cycle 
 To study the role of BMAL1 in cell cycle progression, we used NIH3T33C cells, expressing 
fluorescent markers for the circadian clock (Rev-Erbα-VNP fusion protein; yellow), as well 
as G1 phase (hCdt1-mKOrange fusion protein; red) and combined S, G2, and M (hereafter 
referred to as S/G2/M) phase (hGeminin-CFP fusion protein; blue) of the cell cycle (Feillet et 
al., 2014). NIH3T33C cells were transiently transfected with a siRNA targeting Bmal1 mRNA 
or with a non-targeting siRNA (used as a negative control) and are hereafter referred to as 
siBmal1 and siCtrl cells, respectively. Analysis of Bmal1 mRNA and BMAL1 protein levels 
in proliferating siBmal1 cells 72 hours after transfection, revealed 74% down regulation of 
Bmal1 gene expression in siBmal1 cell cultures (Fig S1A), resulting in a 71% reduction in 
BMAL1 protein (Fig S1B) levels.
 We first analysed clock performance and cell cycle progression in siBmal1 and siCtrl cells 
(n=50 individual cells per condition) over a period of 72 hours using live cell imaging con-
focal microscopy (see Fig 1A for a representative example of time lapse images of a siCtrl 
cell, spanning a complete G1/S/G2/M cycle). In line with our previous data (Feillet et al., 
2014), proliferating siCtrl cells show robust rhythmic expression of the clock marker and a 
tight phase coupling of the circadian clock and cell cycle (Fig 1B; upper panel). The period 
of the cell cycle, as calculated from the interval between two peaks of hCdt1-mKOrange 
expression, is 17.1 ± 0.3 h (mean ± SE; Fig 1C). In marked contrast, we observed a complete 
suppression of circadian oscillations and robust down regulation of Rev-Erbα-VNP protein 
levels in proliferating siBmal1 cells, indicative for efficient knockdown of Bmal1 expression 
(Fig 1B, lower panel). Moreover, knockdown of Bmal1 expression significantly (p<0.001) 
increased cell cycle length from 17.1 ± 0.3 h to 21.4 ± 0.5 h (mean ± SE; Fig 1C).
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Figure 1. Cell cycle dynamics in siCtrl and siBmal1 cells. (A) Representative example 
of time series images of the nucleus of a proliferating siCtrl (NIH3T33C) cell, stably 
expressing circadian clock (Rev-Erbα-VNP; yellow), as well as G1 (hCdt1-mKOrange; 
red) and S/G2/M (hGeminin-CFP; blue) cell cycle markers. Shown are pictures at 1.5 hour 
time intervals over a 18 h period, spanning one cell cycle. (B) Circadian clock performance 
and cell cycle progression in a siCtrl (left panel) and a siBmal1 cell (right panel). Plotted 
are fluorescence intensities of each of the markers over a 48 hour period. The G1 phase 
is defined as the interval between the peaks of hGeminin-CFP and hCDT1-mKOrange 
expression. Oppositely, the S/G2/M phase is defined as the interval between the peaks of 
hCDT1-mKOrange and hGeminin-CFP expression. (C) Box plot showing the cell cycle 
period and G1 and S/G2/M cell cycle phase length in siCtrl and siBmal1 cells (n=50 
cells per condition). Lowest and highest boundaries of the box indicate the 25th and 75th 
percentiles, respectively. The whiskers above and below the box designate the 95th and 5th 
percentiles, respectively. The solid line and cross within the box represent the median and 
mean value, respectively. *** p<0.001 (Mann Whitney test).
Next, we quantified the length of G1 and S/G2/M phase in siCtrl and siBmal1 cells. For 
simplicity, as the FUCCI markers are indicators for either G1 or S/G2/M phase rather than 
exact predictors of the start and end of these cell cycle phases, we defined the G1 phase as 
the interval between the peaks of hGeminin-CFP and hCDT1-mKOrange expression, and the 
S/G2/M phase as the interval between the peaks of hCDT1-mKOrange and hGeminin-CFP 
expression. As shown in Fig 1C, the mean length of the G1 phase in siCtrl cells (8.2 ± 0.2 
h) does not significantly differ (p=0.2) from that in siBmal1 cells (8.7 ± 0.3 h). Interestingly, 
the average length of the S/G2/M phase significantly (p<0.001) increased from 9.0 ± 0.8 h in 
siCtrl cells to 13.0 ± 0.3 h in siBmal1 cells (Fig 1C). 
 Taken together, these results show that the BMAL1 protein acts as a cell cycle period mod-
ulator. 
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Suppression of Bmal1 expression specifically affects the G2 phase 
The single cell experiments show that silencing Bmal1 expression lengthens the S/G2/M 
phase of the cell cycle, but do not allow to discriminate between the three phases. To inves-
tigate which specific cell cycle phase is prolonged, we compared the cell cycle distribution 
of proliferating siCtrl and siBmal1 cells by flow cytometry of propidium iodide stained cells 
(Fig 2A) and quantified the cell cycle phase distribution (Fig 2B). In line with the single cell 
experiments, we did not observe significant changes in the percentage of G1 and S phase cells 
after knockdown of Bmal1 expression (G1 phase: 53.5 ± 1.2 % and 52.7 ± 0.5 % ; S phase: 
31.4 ± 1.0% and 28.5 ± 0.3 for siCtrl and siBmal1 cells respectively; mean ± SEM). On the 
other hand, the percentage of G2/M cells significantly (p=0.01) increased from 13.4 ± 0.5 
% in siCtrl cells to 17.1 ± 0.3 % in siBmal1 cells (Fig 2B). In order to discriminate between 
G2 and M phase, we also stained the cells with an antibody against the mitosis-specific 
MPM-2 phosphoepitope on DNA topoisomerase IIα. As shown in Fig 2C, the percentage of 
MPM2-positive cells is comparable for proliferating siCtrl and siBmal1 cell cultures.  From 
these data, we conclude that the observed lengthening of the S/G2/M phase after knockdown 
of Bmal1 is solely due to an increased duration of the G2 phase. 
Suppression of Bmal1 expression specifically affects Cyclin B1 expres-
sion
 The observed lengthening of the combined S/G2/M phase in siBmal1 cells (single cell anal-
ysis) and increased number of siBmal1 cells in the G2 phase (flow-cytometry analysis) clear-
ly point to a regulatory role of BMAL1 in the kinetics of the cell cycle. We therefore next 
examined the expression levels of the various cyclins in proliferating siCtrl and siBmal1 cells 
by western blot analysis (Fig 2D). Following quantification (Fig 2E), the expression levels 
of Cyclin D1, Cyclin E, and Cyclin A (important regulators of G1 phase, G1/S transition and 
S phase, respectively) in siBmal1 cells did not significantly differ from those in siCtrl cells. 
However, the Cyclin B1 (a driver of G2/M transition) protein level is significantly (p=0.03) 
reduced in siBmal1 cells. This suggests that the accumulation of siBmal1 cells in G2 phase, 
and the delay in G2/M transition, are caused by low levels of Cyclin B1.
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Figure 2. Cell cycle phase distribution of siCtrl and siBmal1 cells. (A) Flow cytometric 
analysis of cell cycle phases in siCtrl and siBmal1 cells. Shown are representative examples 
of propidium iodide (PI) stained siCtrl and siBmal1 cells, analysed for DNA content. The 
vertical axis indicates the relative number of cells and the horizontal axis indicates the 
relative PI fluorescence. The 2N and 4N peaks and intermediate region correspond to 
G1, G2/M and S phase, respectively. (B) Quantification of cell cycle phase distribution 
of proliferating siCtrl and siBmal1 cells. Shown are the average cell numbers of the 3 
independent experiments (each performed in triplicate; 20000 cell counts per triplicate). 
The data were compared using the two-tailed unpaired Student’s t-test. Error bars indicate 
SE. * p=0.01. (C) Flow cytometry analysis of the number of mitotic cells. The bivariate dot 
plots show DNA content (PI) and mitotic phosphoproteins content (MPM2 stain) on the 
X and Y axis, respectively. The box marks cells stained positive for MPM2. (D) Western 
blot analysis of whole cell extracts from proliferating siCtrl and siBmal1 cells for Cyclin 
D, Cyclin E, Cyclin A2, and Cyclin B1 proteins. Shown are representative examples of 
n=3 biological replicates. Actin was used as a loading control. (E) Average cyclin protein 
levels in proliferating siCtrl and siBmal1 cells. Cyclin expression levels were normalized 
against actin. Cyclin expression levels in control cells were set as 1. Error bars indicate SD 
(n=3 experiments). 
45
2
Suppression of Bmal1 expression causes an overall reduction of Cyclin 
B1 expression
 Obviously, aforementioned experiments with asynchronously proliferating cells do not dis-
criminate between the various cell cycle phases. We therefore set out to further investigate 
the expression and kinetics of accumulation of the various cyclins in cell cycle synchronized 
siCtrl and siBmal1 cells. To this end, we used a single 24 hour thymidine block, which 
causes cells to accumulate at G1/S boundary. Pulse-labeling of siCtrl and siBmal1 cells with 
5-ethynyl-2′-deoxyuridine (EdU) for one hour at 1 h intervals after release from the thymidine 
block (Fig 3A) revealed that DNA synthesis (as detected by immunofluorescent labeling) in 
siCtrl and siBmal1 cells follows similar kinetics, peaking 3 hours after thymidine block re-
lease (Fig 3B). Assuming that the peak in DNA synthesis represents mid-S phase, S phase in 
siCtrl and siBmal1 cells is estimated to span 5 to 6 hours, which is in good agreement with 
the flow cytometry data (30% S-phase cells at a cell cycle length of 18 hours = 5.4 h). Next, 
we determined Cyclin E (G1/S marker) and Cyclin A2 (S phase marker) protein levels by 
western blot analysis in siCtrl and siBmal1 cells harvested 0, 2, 4, 6, 8, and 10 hours after 
release from thymidine (Fig 3C). Quantification of the cyclin levels (Fig 3D and E) revealed 
that kinetics of Cyclin E and Cyclin A2 were comparable to siCtrl cells, which is in complete 
agreement with our observation that siBmal1 cells show normal G1 and S phase progression. 
 Next, we determined Cyclin B1 protein levels in siCtrl and siBmal1 cells after release from 
the thymidine block. As shown in Fig 3F and G, Cyclin B1 protein levels gradually increased 
in siCtrl cells, reaching a maximum 6 h after thymidine release at the moment when cells are 
in G2 phase. In line with our earlier observation in asynchronously dividing cells (Fig 2D 
and F), siBmal1 cells express the Cyclin B1 protein at lower levels. Moreover, siBmal1 cells 
display impaired induction of Cyclin B1 during G2 phase, which may explain the delay in 
G2/M transition.  
 Last but not least, as WEE1 is an inhibitor of Cyclin B/CDK1 activity and Wee1 expression 
is under circadian control (Matsuo et al., 2003), we also analyzed aforementioned protein 
samples for WEE1 expression (Fig 3H). As expected, in the absence of the CLOCK/BMAL1 
transcription activator, siBmal1 cells express WEE1 protein at markedly reduced level (Fig 
3I). However, as reduced expression of this negative regulator is expected to accelerate, 
rather than delay G2 to M transition, the lower WEE1 protein levels in siBmal1 cells do not 
explain the delayed G2/M transition. Instead, our data demonstrate that the circadian clock 
protein BMAL1 is a modulator of cell cycle period that promotes G2 to M transition through 
induction of Cyclin B1 expression. 
Suppression of Clock expression lengthens the cell cycle and dampens 
Cyclin B1 expression
 The question arises to what extent the observed modulation of G2/M transition is a spe-
cific function of the individual BMAL1 protein, or whether this requires CLOCK/BMAL1 
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Figure 3. Cell cycle protein expression in siCtrl and siBmal1 cells. (A) Cytochemical 
analysis of DNA synthesis in cell cycle synchronized siCtrl and siBmal1 cells after release 
from a 24 h thymidine block. Cells were harvested at 1 h intervals. Prior to harvesting, 
cells were exposed to a 1 h pulse labelling with EdU. (B) S phase kinetics. Quantification 
of Edu incorporation by siCtrl and Bmal1 cells during the 1 h pulse labelling interval, 
preceding cell harvesting. The Y axis indicates the mean fluorescence intensity, corrected 
for the number of cells. The X axis indicates time of harvesting after thymidine release. 
Error bars indicate SE (n=3 experiments). The grey bar indicates the estimated time of S/
G2 transition. (C, F and H) Western blot analysis of Cyclin E and Cyclin A2 (C), Cyclin B1 
(F) and WEE1 (H) protein levels in siCtrl and siBmal1 cells after release from a thymidine 
block. Shown are representative examples of n=3 independent experiments. Actin was 
used as a loading control. (D, E, G and I) Kinetics of Cyclin E (D), Cyclin A2 (E), Cyclin 
B1 (G) and WEE1 (I) expression after release from a thymidine block. Expression levels 
were normalized against actin. Expression levels in siCtrl cells at t=0 were set as 1. Error 
bars indicate SE. 
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heterodimerization. We therefore transiently transfected NIH3T33c cells with a siRNA tar-
geting the Clock gene or with a non-targeting control siRNA to obtain siClock cells. Analysis 
of Clock mRNA and CLOCK protein levels in proliferating siClock and siCtrl cells 72 hours 
after transfection, revealed 63% down regulation of Clock gene expression in siClock cell 
cultures (Fig S1C), resulting in a 88% reduction in CLOCK protein levels (Fig S1D). We 
next analysed clock performance and cell cycle progression in siClock and siCtrl cells (n=40 
individual cells per condition) over a period of 72 hours using time laps confocal microscopy 
(for a representative example, see Fig 4A). Like siBmal1 cells, siClock cells are arrhythmic, 
as evident from the loss of cyclic expression of the REV-ERBα clock reporter, and proliferate 
significantly slower (p=0.03) than siCtrl cells (19.7 ± 0.3 h vs 18.7 ± 0.3 h per cycle; mean ± 
SEM). As shown in Fig 4B, the G1 phase was not significantly affected in Clock knock down 
cells, as compared to siCtrl cells (9.2 ± 0.2 h vs 8.5 ± 0.3 h; mean ± SEM p=0.07). Instead, 
the increased cell cycle period in siClock cells originates from a lengthened S/G2/M phase 
(9.4 ± 0.1 h in siCtrl and 11.0 ± 0.2 h in siClock cells; p<0.001). Subsequent analysis of the 
cell cycle distribution of proliferating siCtrl and siClock cells by flow cytometry revealed a 
significant increase in the percentage of G2/M cells (14.3 ± 0.1 in siCtrl and 20.1 ± 1.2 in 
siClock cells; mean ± SEM; p=0.03), and relatively less S phase cells in proliferating siClock 
cell cultures (27.1 ± 0.6 in siCtrl and 21.3 ± 1.0 in siClock cells; p=0.01) (Fig.4D). These 
findings indicate that proliferating siClock cells markedly resemble siBmal1 cells in that the 
cell cycle period is increased due to slower G2/M cell cycle progression. 
 We therefore next analyzed the kinetics of Cyclin B1 accumulation in siClock and siCtrl 
cells after release from a 24 hour thymidine block (Fig 4D). As expected, Cyclin B1 protein 
levels gradually increased in siCtrl cells peaking 6 hours after thymidine release (Fig 4E, 
see also Fig 3G). In contrast, siClock cells show markedly reduced Cyclin B1 protein levels 
peaking some 7 hours after thymidine release (Fig 4E). Taken together, these data indicate 
that modulation of G2/M transition through induction of Cyclin B1 is a characteristic of the 
CLOCK/BMAL1 heterodimer, rather than the BMAL1 protein alone. 
Mathematical modeling of CLOCK/BMAL1-controlled cell cycle pro-
gression 
 The biological data on the modulating effect of CLOCK/BMAL1 on cell cycle progression 
serve as an ideal tool to probe and reinforce the computational model for coupled mammalian 
circadian clock and cell cycle oscillators, as defined by Goldbeter and coworkers (Leloup & 
Goldbeter, 2003, 2004; Gérard & Goldbeter, 2009, 2012). We therefore set out to test whether 
the computational model would also respond with a delay in G2/M transition after simulating 
a reduction in Bmal1 or Clock expression levels. The coupling between the circadian clock 
and the cell cycle is mediated by several cell cycle proteins such as WEE1 (Matsuo et al, 
2003), p21 (Gréchez-Cassiau et al., 2008), NONO (Kowalska et al., 2013), and, as shown 
here, Cyclin B1. Oppositely, there are indications that the cell cycle may have an effect on 
the circadian clock, but the mechanism of such a coupling remains unclear (Traynard et al, 
2016; Paijmans et al, 2016), although a recent study points to the enhancement of REV-ERBα 
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Figure 4. Cell cycle dynamics and Cyclin B1 protein expression in siCtrl and siClock 
cells. (A) Circadian clock performance and cell cycle progression in a siCtrl (left panel) 
and a siClock cell (right panel). Plotted are fluorescence intensities of each of the markers 
over a 60 hour period. (B) Box plot showing the total cell cycle period and G1 and S/
G2/M cell cycle phase length in siCtrl and siClock cells (n=40 cells per condition). Lowest 
and highest boundaries of the box indicate the 25th and 75th percentiles, respectively. The 
whiskers above and below the box designate the 95th and 5th percentiles, respectively. The 
solid line and cross within the box represent the median and mean value, respectively. *** 
p<0.001 (Mann Whitney test). (C) Flow cytometric analysis of cell cycle phases in siCtrl 
and siClock cells. Shown are representative examples of propidium iodide (PI) stained 
siCtrl and siBmal1 cells, analysed for DNA content. The vertical axis indicates the relative 
number of cells and the horizontal axis indicates the relative PI fluorescence. The 2N and 
4N peaks and intermediate region correspond to G1, G2/M and S phase, respectively. (D) 
Quantification of cell cycle phase distribution of proliferating siCtrl and siClock cells. 
Shown are the average cell numbers of the 3 independent experiments (each performed 
in triplicate; 20000 cell counts per triplicate). The data were compared using the two-
tailed unpaired Student’s t-test. Error bars indicate SE. * p=0.01 and  p=0.3. (E) Western 
blot analysis of Cyclin B1 protein levels in siCtrl and siClock cells after release from a 
thymidine block. Shown are representative examples of n=3 independent experiments. 
Actin was used as a loading control. (F) Kinetics of Cyclin B1 expression after release 
from a thymidine block. Cyclin B1 expression levels were normalized against actin. The 
Cyclin B expression level in siCtrl cells at t=0 was set as 1. Error bars indicate SE (n=3 
independent experiments).
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degradation through phosphorylation by CDK1 (Zhao et al., 2016). Therefore, despite recent 
evidence for bidirectional coupling between the cell cycle and the circadian clock (Feillet 
et al., 2015; Bieler et al, 2014), we decided to focus on the situation where the cell cycle is 
unidirectionally coupled to the circadian clock via CLOCK/BMAL1-mediated induction of 
Wee1 and Cnnb1 expression. Below, we first model the impact of Bmal1 inactivation on cell 
cycle progression, and subsequently address the effect of in silico knockdown of Clock gene 
expression.
 We consider that in proliferating cells the circadian clock has an overall length of 18 hours 
(close to the value of 17.1 h observed experimentally in proliferating siCtrl cells; Fig 1B and 
1C). We select an autonomous period of the cell cycle of 21.1 h, which is close to the cell 
cycle length observed in siBmal1 cells in the absence of the circadian clock (Fig 1B). In line 
with the experimental data (Fig 1B), the time evolution of Bmal1 and Rev-Erbα mRNA levels 
in our computational model shows that under control conditions the circadian clock oscillates 
with a cycle length of 18h (Fig 5A), while all four Cyclin/CDK protein complexes (Fig 5C), 
as well as the WEE1 protein (Fig 5E) display sustained oscillations with the same period. 
These results represent entrainment of the cell cycle by the circadian clock via BMAL1-me-
diated induction of Wee1 and CcnB1 (Cyclin B1) gene expression. This circadian control 
comes on top of a basal expression of the two genes, as suggested by the observation of low 
levels of Cyclin B1 and WEE1 protein in siBmal1 cells (Fig 3G and 3I).
 When Bmal1 gene expression is suppressed in silico by reducing the Bmal1 mRNA synthe-
sis rate (vsB) by 70%, computational time series analysis reveals that Bmal1 mRNA levels are 
no longer oscillating and that BMAL1 protein levels are constitutively low (Fig 5B). As a 
consequence, Rev-Erbα mRNA levels are also constitutively low (Fig 5B). These data are in 
full agreement with the experimental data obtained with siBmal1 cells (Fig 1B; Figs S1A and 
S1B) and show that the circadian clock is arrested when Bmal1 expression is knocked down. 
Interestingly, and also in full agreement with the experimental data, the cell cycle length is 
prolonged from 18h to 21.1 h after in silico reduction of Bmal1 expression levels (compare 
Fig 5C and 5D). Notably, the width of the activity peak of Cyclin B/CDK1 is significantly 
increased upon suppression of Bmal1 expression, while that of other Cyclins appears unaf-
fected (Fig 5C and 5D). In addition, the WEE1 protein concentration decreases in the model 
after in silico Bmal1 knockdown due to the lack of CLOCK/BMAL1-mediated induction of 
Wee1 gene expression (Fig 5Eand 5F).
 Next, we examined in more detail how suppression of Bmal1 expression in our mathe-
matical model affects the duration of the G1 and S/G2/M cell cycle phases. To this end, we 
defined the G1 phase as the time from mid-decrease of Cyclin B/CDK1 to 30%-decrease of 
Cyclin D/CDK4-6 levels and the S/G2/M phase as the time from 30%-decrease of Cyclin 
D/CDK4-6 to mid-decrease of Cyclin B/CDK1 levels (see Fig  6A and 6B). Analysis of the 
computed time series reveals that under normal conditions, the G1 and S/G2/M phases span 
5.84 h and 12.19h, respectively (Fig 6A), while in silico reduction of Bmal1 mRNA synthesis 
by 70% results in G1 and S/G2/M cell cycle phase lengths of 6.41 h and 14.74 h, respectively 
(Fig 6B). Thus, in line with the experimental data (Figs 1B and 1C), elongation of the cell 
50
Chapter 2
cycle period upon suppression of Bmal1 expression is predominantly caused by lengthening 
of the S/G2/M phase. 
Figure 5. Computational modeling of the impact of Bmal1 knockdown on Cyclin/
CDK levels. Analysis of the effect of silencing of Bmal1 expression in the computational 
model for coupled mammalian circadian clock and cell cycle oscillators. The time series 
in the upper panels show the evolutions of Bmal1 mRNA (dark cyan, solid line), total 
BMAL1 protein (dark cyan, dashed line) and Rev-Erbα mRNA (orange) under normal 
conditions (A) or when the synthesis rate of Bmal1 mRNA is reduced by 70% (B). The 
period of the circadian clock is 18h in control conditions. However, the oscillations in (B) 
disappear upon decreasing Bmal1 mRNA synthesis. The time series in the middle panels 
show the time evolutions of Cyclin A/CDK2 (light green), Cyclin E/CDK2 (mustard 
green), Cyclin B/CDK1 (blue) and CyclinD/CDK4-6 (red) in control conditions, when the 
cell cycle is synchronized to the circadian clock (C), or when Bmal1 is knocked down (D). 
The period of the cell cycle increases from 18h in (C) to 21.1 h in (D). Also, the width of 
the activity peak of Cyclin B/CDK1 (blue) is significantly increased. The time series in the 
bottom panels show the evolutions of Cyclin B/CDK1 (blue) and WEE1 (black) when cells 
are in control conditions (C) or when Bmal1 gene expression is knocked down (D). The 
concentration of WEE1 decreases in (D) due to the lack of induction Wee1 transcription 
by BMAL1. Parameter values used for numerical simulations are listed in the SI appendix. 
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 The mathematical simulations, as shown above, reveal a normal amplitude oscillation of 
Cyclin B1/CDK1 levels after 70% reduction of the Bmal1 mRNA synthesis, which appears 
to contrast somewhat with the experimental data, showing a 20-25% reduction in Cyclin B1 
protein levels. We therefore also determined the time evolution of the total Cyclin B1 protein 
level (free and complexed with CDK1) under control conditions (Fig 6C) and upon reduced 
Bmal1 gene expression (Fig 6D). The results indicate that, as in the experimental observa-
tions (see Fig 2D), total Cyclin B1 levels decrease upon knocking down Bmal1, which holds 
with the view that BMAL1 induces CcnB1 gene expression, as reported above. 
 Similar results were obtained upon knocking down Clock instead of Bmal1 in the compu-
tational model for coupled mammalian circadian clock and cell cycle oscillators (data not 
shown), which may not come as a surprise as CLOCK and BMAL1 act as a heterodimeric 
complex. 
 In conclusion, the performance of the computational model for coupled mammalian circa-
dian clock and cell cycle oscillators after simulation of Bmal1 or Clock silencing is in full 
agreement with the experimental observations in proliferating siCtrl, siBmal1 and siClock 
cells.
Figure 6. Computational 
modeling of the impact of 
Bmal1 knockdown on cell 
cycle phase length. The 
time series in the upper 
panels show the evolutions 
of Cylin D/CDK4-6 (red) 
and Cyclin B/CDK1 (blue) 
when the circadian clock 
is in control conditions (A) 
or when Bmal1 expression 
is reduced by 70% (B). 
As in the corresponding 
Figure 4, the period of the 
cell cycle increases from 
18 h in (A) up to 21.1 h 
when Bmal1 expression is 
supressed (B). The black bars indicate the G1 phase (from mid-decrease of Cyclin B/CDK1 
to 30%-decrease in Cyclin D/CDK4-6) and S/G2/M phase (from 30%-decrease in Cyclin 
D/CDK4-6 to mid-decrease of cyclin B/CDK1). The durations of G1 and S/G2/M in (A) 
are 5.84 h and 12.19 h, respectively. The durations of G1 and S/G2/M in (B) are 6.41 h and 
14.74 h, respectively. Thus, the S/G2/M phase contributes most to the prolongation of cell 
cycle duration upon knocking down BMAL1. The time series in the lower panels show the 
evolutions of total Cyclin B (dashed blue line) in control conditions (C) or upon suppression 
of Bmal1 RNA synthesis (D). The total amount of Cyclin B (free + complexed with the 
kinase CDK1 and its inhibitor p21) decreases when Bmal1 expression is reduced.
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 | Discussion
 Previously, we have reported the existence of a bi-directional link between the circadian 
clock and the cell cycle (Feillet et al., 2014). Indeed, synchronization and resetting of the 
circadian clock by external cues (such as dexamethasone) can synchronize cell cycle pro-
gression. Oppositely, a clear shortening of the circadian cycle occurred in dividing cells as 
compared to non-dividing cells, suggesting that the cell cycle can reset the circadian clock. In 
the present study, we have taken a combined cell and molecular biological approach to inves-
tigate the impact of the circadian clock on cell cycle progression by genetic disruption of the 
molecular circadian oscillator. We show that disruption of the positive limb of the circadian 
transcription-translation feedback loop-based molecular oscillator through knock-down of 
the circadian clock genes Bmal1 or Clock prolonged the cell cycle of cultured fibroblasts. Our 
results show that this slowdown in cell cycle progression results from a delay in the G2/M 
transition.  Since inactivation of Bmal1 or Clock triggers a highly comparable cell cycle phe-
notype, G2/M checkpoint control appears a function of the CLOCK/BMAL1 heterodimer, 
rather than the individual proteins.
 To investigate the molecular mechanism underlying the observed delay in cell cycle pro-
gression in the absence of BMAL1 or CLOCK, we zoomed in on cell cycle protein ex-
pression during G2 phase and G2/M transition using cell cycle synchronized siBmal1 and 
siClock cells. Interestingly, whereas the kinetics of S phase progression remained unaffected, 
knockdown of Bmal1 or Clock expression resulted in overall lower Cyclin B1 protein levels, 
as well as a reduction of the Cyclin B1 peak at G2 phase. Since a high Cyclin B1 protein level 
is essential for G2 progression and mitotic entry, the impaired induction of Cyclin B1 protein 
levels well explains the delayed cell cycle progression in G2 phase. This view is consistent 
with the study by Matsuo and coworkers (2003) focussing on cell cycle re-entry of remaining 
mouse hepatocytes after partial hepatectomy at ZT0 or ZT8 (ZT, Zeitgeber time in a 12 hour 
light–12 hour dark cycle; ZT0 represents lights on and ZT12, lights off). Whereas S phase 
kinetics was independent of the time of surgery, CcnB1 mRNA and Cyclin B1 protein levels, 
as well as Cyclin B1/CDK1 peak activity, were delayed by about 8 to 12 hours when partial 
hepatectomy was performed at ZT0 as compared to ZT8 (Matsuo et al., 2003), demonstrat-
ing that clock-controlled timing of Cyclin B1 expression and activity is determining G2/M 
transition. 
 It has been well established that expression of the Wee1 gene, encoding an important kinase 
regulating the G2/M checkpoint, is under direct control of the CLOCK/BMAL1 complex 
(Matsuo et al., 2003). As WEE1 acts as an inhibitor of CDK1 to prevent premature mitotic 
entry, one would expect inhibition of Bmal1 expression to accelerate cell cycle progression 
due to a reduction of WEE1 protein level and kinase activity. On the contrary, however, we 
observed a delay in G2/M transition of proliferating siBmal1 and siClock cells, accompanied 
by a reduction in Cyclin B1 protein levels. It appears, therefore, that the CLOCK/BMAL1 
complex regulates at the same time the expression of an inhibitor (WEE1) and an activator 
(Cyclin B1) of G2/M transition. Regardless of this dual role of the CLOCK/BMAL1 complex 
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in controlling the G2/M checkpoint, the increased cell cycle length of siBmal1 and siClock 
cells suggests that the dominant effect of CLOCK/BMAL1 is to induce expression of the 
Cyclin B1 encoding gene Cnnb1. The induction of Wee1 by CLOCK/BMAL1 could never-
theless contribute to further extending the duration of the G2/M phase by enlarging the width 
of the peak in CyclinB1/CDK1 in the absence of its inhibitor WEE1 in siBmal1 cells. Such 
a counter-intuitive effect is suggested by numerical simulations of the mathemathical model 
for coupled clock - cell cycle oscillators, which showed that induction of Wee1 by CLOCK/
BMAL1 can shorten the duration of the cell cycle by reducing the half-width of the peaks in 
Cyclin B1/CDK1 (Gérard & Goldbeter, 2012).
 Understanding how transcription of the Cyclin B1 gene CcnB1 is regulated during the cell 
cycle would help us to understand how BMAL1 can modulate cell cycle progression. Pro-
moter analysis of the CcnB1 gene uncovered four E-box elements (CANNTG), one of which 
showing consensus for the Upstream Stimulatory Factor (USF) and acting as a G2-specific 
regulator of Cyclin B1 expression (Cogswell et al., 1995). Since the USF E-box sequence 
CACGTG matches that of the E-box elements recognized by CLOCK/BMAL1, our results 
suggest a direct role for BMAL1 in the G2-specific induction of CyclinB1. We do not exclude 
the possibility that BMAL1 may also indirectly influence Cyclin B1 protein levels through 
(cyclic) expression of other clock genes or clock-controlled genes. For instance, BMAL has 
been shown to control expression of the tumor suppressor gene p53 (Mullenders et al., 2009; 
Jiang et al., 2016). The p53 protein, in turn,  has been suggested to prevent G2/M transition 
by attenuating CcnB1 promoter activity and reducing Cyclin B1 protein levels (Innocente 
et al., 1999). Adding to the level of complexity of circadian control of G2/M transition, the 
circadian clock protein PER2 (expression of which is under control of CLOCK/BMAL1) can 
stabilize the p53 protein and influence its subcellular localization, i.e. cytoplasmic vs nuclear 
(Gotoh et al., 2016). The latter scenario, however, appears less likely as, in contrast with our 
experimental data, suppression of BMAL1 should result in enhanced Cyclin B1 levels and 
accelerated mitotic entry. To discriminate between direct and indirect control of CLOCK and 
BMAL1 over G2/M transition, it will be of prime importance to generate a NIH3T33C cell 
line with (endogenous) fluorescent protein tagged CcnB1 genes to study the kinetics of Cy-
clin B1 expression in the presence/absence of proteins like WEE1, p53, and PER2. 
 The availability of a model for the coupling of the cell cycle to the circadian clock in mam-
malian cells allows us to probe, by means of computer simulations, the effect of knocking 
down Bmal1 or Clock on the dynamics of the cell cycle. Previous theoretical investigations of 
this coupling (Gérard & Goldbeter, 2012) were based on the circadian control of several com-
ponents of the cell cycle machinery, such as the kinase WEE1, the CDK inhibitor p21, and 
Cyclin E. Here, the experimental study confirmed that WEE1, a kinase that inhibits CDK1, 
is under control of the circadian clock via the induction of Wee1 expression by CLOCK/
BMAL1. The experiments uncovered an additional mode of coupling due to the induction 
of CcnB1 expression by CLOCK/BMAL1. We therefore incorporated these two modes of 
coupling into the combined model for the cell cycle and circadian clock in mammalian cells.
 The model indicates that the induction of Ccnb1 and Wee1 expression by CLOCK/BMAL1 
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allows the cell cycle to synchronize with to the circadian clock at a period in the order of 18h. 
Upon suppression of BMAL1 expression by reducing the Bmal1 mRNA synthesis rate by 
70%, the circadian clock stops ticking and the cell cycle recovers its autonomous period of 
oscillation, close to 21h. The lengthening of the period in our mathematical model is largely 
due to an increase of a few hours in the duration of the S/G2/M phase, which is in good agree-
ment with the experimental data. The simulations suggest that this increase can be related to 
an increase in the half-width of the peak in CDK1. The larger duration of the peak in CDK1 is 
due to the decreased inhibition of the enzymatic activity by WEE1, given that the level of this 
inhibitory kinase drops when knocking down its inducer BMAL1. In this respect, it is inter-
esting to note that inactivation of BMAL1 in hippocampal neurons both experimentally and 
in silico causes a cell cycle effect, i.e. delayed cell cycle exit (Bouchard-Cannon et al., 2013).
 Disruption of the circadian clock (genetically or environmentally) results in altered cell 
proliferation, and in some cases cancer predisposition. However, only few studies have been 
performed to detect the intracellular pathways or the key molecules responsible for the al-
tered proliferation capacity. Our study addressed the role of BMAL1 and CLOCK in the 
expression of Cyclin B1, one of the key molecules for G2 phase and G2/M transition. The 
question arises whether the reduced Cyclin B1 protein levels in the absence of CLOCK/
BMAL1 are the result of (i) the inactivation of the positive limb of the circadian transcription 
translation feedback loop, or (ii) a complete/overall loss of the clock. Future experiments 
with circadian clock deficient Cry1/Cry2 knockdown NIH3T33C cells should provide an an-
swer to this question. 
  Finally, stable gene silencing of Cyclin B1 has been reported to inhibit proliferation, and 
sensitizes breast cancer cells to taxol treatment (Androic et al., 2008). Downregulation of 
Cyclin B1 via knock-down of Bmal1 could be an attractive strategy for anti-proliferative 
therapy. This might ultimately delay tumor progression. However, the state of circadian clock 
and cell cycle coupling in cancer cells still remains to be studied.
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Figure S1. Bmal1 and Clock mRNA and BMAL1 and CLOCK protein levels in 
siBmal1 and siClock cells. NIH3T33C cells were transiently transfected with Silencer® 
Select Pre-designed control, Bmal1 or Clock siRNA to generate siCtrl, siBmal1 cells and 
siClock cells, respectively. (A) Quantitative RT-PCR analysis of Bmal1 mRNA level in 
proliferating siCtrl and siBmal1 cells 72 hours after transient siRNA transfection (n=3). 
mRNA levels were normalized to that of the B2M housekeeping gene and expressed 
relative to the mRNA level in siCtrl cells, which was set as 1.  Error bars indicate SE. 
** p<0.01. (B) Western blot analysis of BMAL1 protein levels in siCtrl and siBmal1 cell 
lysates 72 hours after transient siRNA transfection (n=3). Protein levels were normalized to 
β-actin protein levels. Error bars indicate SE.* p=0.02. (C) Quantitative RT-PCR analysis 
of Clock mRNA level in proliferating siCtrl and siClock cells 72 hours after transient 
siRNA transfection (n=3). mRNA levels were normalized to that of the B2M housekeeping 
gene and expressed relative to the mRNA level in siCtrl cells, which was set as 1.  Error 
bars indicate SE. ** p<0.01. (D) Western blot analysis of CLOCK protein levels in siCtrl 
and siClock cell lysates 72 hours after transient siRNA transfection (n=3). Protein levels 
were normalized to β-actin protein levels. Error bars indicate SE.  * p=0.03.
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Detailed description of the mathematical modeling of the cicadian 
clock-cell cycle connection
 To study the interaction between the circadian clock and the cell cycle we used two compu-
tational models previously proposed for the mammalian circadian clock and for the mamma-
lian cell cycle, respectively. The model for the mammalian circadian clock incorporates the 
positive and negative regulations involving the PER, CRY, CLOCK, BMAL1 and REV-ER-
Ba proteins (Leloup & Goldbeter, 2003, 2004). For simplicity, the PER1 and PER2 proteins, 
on one hand, and the CRY1 and CRY2 proteins on the other hand, are considered as a single 
entity referred to as PER and CRY, respectively; moreover, the CLOCK protein is assumed 
to be expressed constitutively and to instantaneously form a complex with BMAL1. This 
model accounts for the occurrence of circadian oscillations of the above-mentioned proteins 
and their mRNAs in a variety of experimental conditions (Leloup & Goldbeter, 2003, 2004). 
 The model for the mammalian cell cycle is based on the regulatory properties of the CDK 
network that drives the transitions between the successive phases of the cell cycle (Gérard & 
Goldbeter, 2009, 2014). The model contains four CDK modules, each of which controls tran-
sition to a particular cell cycle phase. Thus, Cyclin D/CDK4-6 and Cyclin E/CDK2 promote 
progression in G1 and elicit the G1/S transition; the activation of Cyclin A/CDK2 ensures 
progression in S and G2, while the peak of Cyclin B/CDK1 activity brings about progression 
into mitosis. Exit from the quiescent state is triggered above a critical level of growth fac-
tor by the synthesis of Cyclin D, which allows cells to enter the G1 phase. Synthesis of the 
various cyclins is regulated through the balance between the antagonistic effects exerted by 
the transcription factor E2F and the tumor suppressor pRB, which respectively promote and 
inhibit cell cycle progression. Additional regulations in this model for the CDK network bear 
on the control exerted by the proteins SKP2, CDH1, or CDC20 on the degradation of cyclins 
E, A, and B at the G1/S or G2/M transitions, respectively. Moreover, the activity of each cy-
clin/CDK complex can itself be regulated through CDK phosphorylation-dephosphorylation. 
At suprathreshold levels of growth factor sustained oscillations spontaneously occur in the 
CDK network, which may be associated with cellular proliferation since they correspond to 
the repetitive, sequential activation of the various cyclin-CDK complexes responsible for 
the ordered progression along the successive phases of the cell cycle (Gérard & Goldbeter, 
2009, 2014).
 The circadian clock model is governed by 19 kinetic equations (Leloup & Goldbeter, 2003) 
while the model for the mammalian cell cycle is described by 39 differential equations (Gé-
rard & Goldbeter, 2012). In a previous study the cell cycle was coupled to the circadian 
clock via the circadian control of WEE1, p21 or Cyclin E; any one of these three modes of 
coupling can lead to entrainment of the cell cycle by the circadian clock over a range of cell 
cycle durations prior to coupling (see Gérard & Goldbeter, 2012 for a computational study 
of circadian entrainment of the cell cycle resulting from these various modes of coupling, 
and for a list of kinetic equations for the coupled cell cycle-circadian clock system). Here we 
focus on the case where the cell cycle is coupled to the circadian control via the induction of 
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Wee1 gene expression by BMAL1, and also introduce coupling via the induction of Cyclin B1 
gene expression by BMAL1, as suggested by the experiments reported in the present study.  
 To describe the coupling of the cell cycle to the circadian clock via the kinase WEE1 we 
incorporate in the CDK network model an additional kinetic equation for the mRNA of the 
Wee1 gene, which includes the induction of Wee1 expression by CLOCK/BMAL1. The equa-
tions (1) and (2) describing the coupling of the cell cycle to the circadian clock through acti-
vation of the transcription of the Wee1 gene by CLOCK/BMAL1 are:
 
 These equations replace equation [38] in our previous model (Gérard & Goldbeter; 2012). 
Here, equation (1) describes the time evolution of the Wee1 mRNA positively regulated by 
the circadian clock complex, CLOCK/BMAL1 (Bn), with an activation constant Kaw, while 
equation (2) shows the time evolution of the kinase WEE1. The synthesis of this protein 
kinase combines two terms: the basal rate of WEE1 synthesis (νswee1) is independent from 
the circadian clock, while the second term, (Ksw. Mw), reflects WEE1 synthesis at a rate 
proportional to the Wee1 mRNA controlled by CLOCK/BMAL1 in a circadian manner. The 
total amount of Wee1 mRNA can therefore be viewed as the sum of two terms, (νswee1/Ksw) 
+ Mw which are respectively independent from, and dependent on the circadian clock. The 
coupling strength is expressed by parameter νsw, which measures the magnitude of the Wee1 
mRNA synthesized under control by the circadian clock. An alternative measure of coupling 
strength is provided by the parameter Kaw, which characterizes the activation of Wee1 expres-
sion by CLOCK/BMAL1; the strength of the coupling to the circadian clock increases Kaw as 
progressively decreases.
A similar approach was used to describe the coupling of the cell cycle to the circadian clock 
via Cyclin B1. Thus, we incorporated in the model for the CDK network an additional ki-
netic equation for the Cyclin B1 (CcnB1) mRNA, which includes the induction of Cyclin B1 
expression by CLOCK/BMAL1. The equations (3)and (4) describing the coupling of the cell 
cycle to the circadian clock through the activation of the transcription of the Cyclin B1 gene 
by CLOCK/BMAL1 are:
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Equations (3) and (4) replace equation [30] in (Gérard & Goldbeter, 2009).
 The synthesis of the Cyclin B mRNA, Mcb, is described by two terms: the first term is the 
basal synthesis rate (vcb), which is independent of CLOCK/BMAL1, and the second term 
( ) reflects the induction by CLOCK/BMAL1. The parameter (vscb) represents 
the coupling strength, which measures the magnitude of the Cyclin B mRNA synthesized 
under the control by the circadian clock.
 To model the impact of knockdown of Bmal1 gene expression, we reduce the rate of Bmal1 
mRNA synthesis, vsB in the model for the circadian clock. In this model, we consider that the 
level of Clock gene expression is constant and that BMAL1 instantaneously forms a complex 
with CLOCK. Parameter values used for numerical simulations in Figs 4 and 5 are listed in 
SI Appendix Table S1. The autonomous period of the cell cycle is 21.1 h, which value is ob-
tained by setting the scaling parameter eps = 20.45. The period of the circadian clock is 18 h 
which is obtained by setting the scaling parameter delta = 1.336. Knocking down BMAL1 is 
achieved in the model by reducing by 70% the rate of Bmal1 mRNA synthesis, vsB, from 1.55 
nM/h in (A) and (C) to 0.465 nM/h in (B) and (D).
The initial values for the 19 concentration variables in the circadian clock model are all equal 
to 0.1 nM. The initial values for the 41 concentration variables in the cell cycle part of the 
model are (in μM): AP1=0.01; pRB=1; pRBc1=0.25; pRBp=0.1; pRBc2=0.01; pRBpp=0.01; 
E2F=0.1; E2Fp=0.05; Cd=0.01; Mdi=0.01; Md=0.01; Mdp27=0.01; Ce=0.01; Mei=0.01; 
Me=0.01; Skp2=0.01; Mep27=0.01; Pei=0.01; Pe=0.01; Ca=0.01; Mai=0.01; Ma=0.01; 
Map27=0.01; p27=0.25; p27p=0.01; Cdh1i=0.01; Cdh1a=0.01; Pai=0.01; Pa=0.01; 
Mcb=0.01; Cb=0.01; Mbi=0.01; Mb=0.01; Mbp27=0.01; Cdc20i=0.01; Cdc20a=0.01; 
Pbi=0.01; Pb=0.01; Mw=0.01; WEE1=0.1; WEE1p=0.01.
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Table S1: Parameters of the model
 Parameter values used for the numerical simulations as presented in Figures 4 and 5. Indi-
cated are the parameter values for the circadian clock, the cell cycle, and the coupling of the 
circadian clock and cell cycle through Wee1 (Gérard and Goldbeter, 2009, 2012). The last 
section of the table lists the parameter values used to extend the aforementioned coupling 
model to circadian control of Cyclin B1 (see equations 3 and 4 in the detailed description of 
the mathematical modeling of the circadian clock - cell cycle connection).
Symbol           Definition Value in model
Circadian clock
Parameters are (with some modifications) based on those provided in Supporting Figure 8 in Leloup 
and Goldbeter  (2003; see http://www.pnas.org/content/100/12/7051/suppl/DC1) and on Table 1 in 
Leloup and Goldbeter (2004).
delta Scaling factor used to modify the time scale of circadian clock 1.336
k1 Rate constant for entry of the PER/CRY complex into the nucleus 0.8 h–1
k2 Rate constant for exit of the PER/CRY complex from the nucleus 0.4 h–1
k3 Rate constant for the formation of the PER/CRY complex 0.8 nM–1 h–1
k4 Rate constant for dissociation of the PER/CRY complex 0.4 h
–1
k5 Rate constant for entry of the BMAL1 protein into the nucleus 0.8 h
–1
k6 Rate constant for exit of the BMAL1 protein from the nucleus 0.4 h
–1
k7 Rate constant for the formation of the inactive PER/CRY/CLOCK/BMAL1 complex 1 nM–1 h–1
k8 Rate constant for the dissociation of the PER/CRY/CLOCK/BMAL1 complex 0.2 h
–1
k9 Rate constant for entry of the REV-ERBα protein into the nucleus 0.8 h
–1
k10 Rate constant for exit of the REV-ERBα protein from the nucleus 0.4 h
–1
KAP Constant for activation by CLOCK-BMAL1 (Bn) of Per mRNA synthesis 0.6 nM
KAC Constant for activation by CLOCK-BMAL1 (Bn) of Cry mRNA synthesis 0.6 nM
KAR Constant for activation by CLOCK-BMAL1 (Bn) of Rev-erbα mRNA synthesis 0.6 nM
KIB Constant of inhibition by Rev-ERBα protein of Bmal1 mRNA synthesis 1 nM
kdmb Nonspecific degradation rate constant for Bmal1 mRNA 0.02 h
–1
kdmc Nonspecific degradation rate constant for Cry mRNA 0.02 h
–1
kdmp Nonspecific degradation rate constant for Per mRNA 0.02 h
–1
kdmr Nonspecific degradation rate constant for Rev-erbα mRNA 0.02 h
–1
kdn Nonspecific degradation rate constant for other proteins 0.02 h
–1
kdnc Nonspecific degradation rate constant for cytosolic non-phosphorylated CRY 0.02 h
–1
Kd Michaelis constant for protein degradation 0.3 nM
Kdp Michaelis constant for protein dephosphorylation 0.1 nM
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Kp Michaelis constant for protein phosphorylation 1.006 nM
KmB Michaelis constant for degradation of Bmal1 mRNA 0.4 nM
KmC Michaelis constant for degradation of Cry mRNA 0.4 nM
KmP Michaelis constant for degradation of Per mRNA 0.3 nM
KmR Michaelis constant for degradation of Rev-erbα mRNA 0.4 nM
ksB Rate constant for synthesis of BMAL1 protein 0.32 h
–1
ksC Rate constant for synthesis of CRY protein 3.2 h
–1
ksP Rate constant for synthesis of PER protein 1.2 h
–1
ksR Rate constant for synthesis of REV-ERBα protein 1.7 h
–1
n Degree of cooperativity of activation of Per and Cry expression by BMAL1 2
m Degree of cooperativity of repression of Bmal1 expression by REV-ERBα 2
h Degree of cooperativity of activation of Rev-erbα expression by BMAL1 2
V1B Maximum rate of cytosolic BMAL1 phosphorylation 0.07 nM h–1
V1C Maximum rate of cytosolic CRY phosphorylation 1.2 nM h–1
V1P Maximum rate of cytosolic PER phosphorylation 9.6 nM h–1
V1PC Maximum rate of phosphorylation of cytosolic PER-CRY complex 2.4 nM h–1
V2B Maximum rate of cytosolic BMAL1 dephosphorylation 2 nM h–1
V2C Maximum rate of cytosolic CRY dephosphorylation 0.2 nM h–1
V2P Maximum rate of cytosolic PER dephosphorylation 0.6 nM h–1
V2PC Maximum rate of cytosolic PER–CRY complex dephosphorylation 0.2 nM h–1
V3B Maximum rate of nuclear BMAL1 phosphorylation 0.07 nM h–1
V3PC Maximum rate of phosphorylation of nuclear PER/CRY complex 2.4 nM h–1
V4B Maximum rate of nuclear BMAL1 dephosphorylation 4 nM h–1
V4PC Maximum rate of dephosphorylation of nuclear PER/CRY complex 0.2 nM h–1
Vphos Phosphorylation rate 0.4 nM h–1
vdBC Maximum rate of degradation of cytosolic phosphorylated BMAL1 3 nM h–1
vdBN Maximum rate of degradation of nuclear phosphorylated BMAL1 3 nM h–1
vdCC Maximum rate of degradation of cytosolic phosphorylated CRY 1.4 nM h–1
vdIN Maximum rate of degradation of nuclear PER/CRY/CLOCK/BMAL1     complex 1.6 nM h–1
vdPC Maximum rate of degradation of cytosolic phosphorylated PER 3.4 nM h–1
vdPCC Maximum rate of degradation of cytosolic phosphorylated PER/CRY complex 1.4 nM h–1
vdPCN Maximum rate of degradation of nuclear phosphorylated PER/CRY complex 1.4 nM h–1
vdRC Maximum rate of degradation of cytosolic REV-ERBα 4.4 nM h–1
vdRN Maximum rate of degradation of nuclear REV-ERBα 0.8 nM h–1
vmB Maximum rate of Bmal1 mRNA degradation 1.3 nM h–1
vmC Maximum rate of Cry mRNA degradation 2.0 nM h–1
vmR Maximum rate of Rev-erbα mRNA degradation 1.6 nM h–1
vmP Maximum rate of Per mRNA degradation 2.2 nM h–1
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vsB Maximum rate of Bmal1 mRNA synthesis 1.55 nM h–1
vsC Maximum rate of Cry mRNA synthesis 2.2 nM h–1
vsP Maximum rate of Per mRNA synthesis 2.4 nM h–1
vsR Maximum rate of Rev-erbα mRNA synthesis 1.6 nM h–1
Cell cycle
Parameters are (with some modifications) based on those provided in Supporting Table S2 in Gérard and 
Goldbeter (2009; see http://www.pnas.org/content/106/51/21643/suppl/DCSupplemental).
GF Growth factor 1
Kagf Michaelis constant for synthesis of AP1 induced by growth factor 0.1 μM
kdap1 Apparent first-order rate constant for AP1 transcription factor degradation 0.15 h
-1
eps Scaling factor used to modify the time scale of cell cycle 20.45
vsap1 Rate of synthesis of the transcription factor AP1 depending on growth factor GF 1 μM h-1
kde2f Apparent first-order rate constant for non-specific E2F degradation 0.002 h
-1
kde2fp Apparent first-order rate constant for E2Fp degradation 1.1 h
-1
kdprb Apparent first-order rate constant for pRB degradation 0.01 h
-1
kdprbp Apparent first-order rate constant for pRBp degradation 0.06 h
-1
kdprbpp Apparent first-order rate constant for pRBpp degradation 0.04 h
-1
kpc1 Bimolecular rate constant for binding of pRB to E2F 0.05 μM-1 h-1
kpc2 Rate constant for dissociation of complex between pRB and E2F 0.5 h
-1
kpc3 Bimolecular rate constant for binding of pRBp to E2F 0.025 μM-1 h-1
kpc4 Rate constant for dissociation of complex between pRBp and E2F 0.5 h
-1
K1 Michaelis constant for pRB phosphorylation 0.1 μM
K2 Michaelis constant for pRBp dephosphorylation 0.1 μM
K3 Michaelis constant for pRBp phosphorylation 0.1 μM
K4 Michaelis constant for pRBpp dephosphorylation 0.1 μM
V1 Rate constant for phosphorylation of pRB 2.2 h-1
V2 Maximum rate of dephosphorylation of pRBp 2 μM h-1
V3 Rate constant for phosphorylation of pRBp 1 h-1
V4 Maximum rate of dephosphorylation of pRBpp 2 μM h-1
K1e2f Michaelis constant for E2F phosphorylation by Cyclin A/Cdk2 5 μM
K2e2f Michaelis constant for E2F dephosphorylation 5 μM
V1e2f Rate constant for phosphorylation of E2F by Cyclin A/Cdk2 4 h-1
V2e2f Maximum rate of dephosphorylation of E2F 0.75 μM h-1
vse2f Basal rate of synthesis of E2F 0.15 μM h-1
vsprb Basal rate of synthesis of pRB 0.8 μM h-1
Cdk4tot Total concentration of Cdk4-6 kinase 1.5 μM
Ki7 Constant of inhibition by pRB of Cyclin D synthesis 0.1 μM
Ki8 Constant of inhibition by pRBp of Cyclin D synthesis 2 μM
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kcd1 Rate constant for Cyclin D synthesis induced by AP1 0.4 h
-1
kcd2 Rate constant for Cyclin D synthesis induced by E2F 0.005 h
-1
kdecom1 Rate constant for dissociation of complex between Cyclin D and Cdk4-6 0.1 h
-1
kcom1 Bimolecular rate constant for binding of Cyclin D to Cdk4-6 0.175 μM-1 h-1
kc1 Bimolecular rate constant for binding of Cyclin D/Cdk4-6 to p27 0.15 μM-1 h-1
kc2 Rate constant for dissociation of complex between Cyclin D/Cdk4-6 and p27 0.05 h
-1
kddd Apparent first-order rate constant for non-specific Cyclin D protein degradation 0.005 h
-1
Kdd Michaelis constant for Cyclin D degradation 0.1 μM
K1d Michaelis constant for Cyclin D/Cdk4-6 (inactive) activation 0.1 μM
K2d Michaelis constant for Cyclin D/Cdk4-6 (active) inactivation 0.1 μM
Vdd Maximum rate of degradation of Cyclin D 5 μM·h-1
Vm1d Maximum rate of activation of Cyclin D/Cdk4-6 (inactive) 1 μM·h-1
Vm2d Maximum rate of inactivation of Cyclin D/Cdk4-6 (active) 0.2 μM·h-1
ae
Factor measuring the contribution of Polo-like kinase 3 (Plk3) to phosphorylation 
and activation of Cdc25 phosphatase (Pei) 0.25 μM
Cdk2tot Total concentration of Cdk2 kinase 2 μM
ib1
Factor measuring the contribution of kinase Myt1 to phosphorylation and 
inhibition of Cyclin E/Cdk2 0.5 μM
Ki9 Constant of inhibition by pRB of Cyclin E synthesis 0.1 μM
Ki10 Constant of inhibition by pRBp of Cyclin E synthesis 2 μM
kce Rate constant for Cyclin E synthesis induced by E2F 0.29 h
-1
kc3 Bimolecular rate constant for binding of Cyclin E/Cdk2 to p27 0.2 μM-1 h-1
kc4 Rate constant for dissociation of complex between Cyclin E/Cdk2 and p27 0.1 h
-1
kdecom2 Rate constant for dissociation of complex between Cyclin E and Cdk2 0.1 h
-1
kcom2 Bimolecular rate constant for binding of Cyclin E to Cdk2 0.2 μM-1 h-1
kdde Apparent first-order rate constant for non-specific Cyclin E degradation 0.005 h
-1
kddskp2 Apparent first-order rate constant for non-specific Skp2 degradation 0.005 h
-1
kdpe
Apparent first-order rate constant for degradation of active Cdc25 phosphatase 
(Pe) 0.075 h
-1
kdpei
Apparent first-order rate constant for degradation of inactive Cdc25 phosphatase 
(Pei) 0.15 h
-1
Kde Michaelis constant for Cyclin E degradation 0.1 μM
Kdceskp2 Michaelis constant for activation by Skp2 of Cyclin E degradation 2 μM
Kdskp2 Michaelis constant for Skp2 degradation 0.5 μM
Kcdh1 Michaelis constant for activation by Cdh1 of Skp2 degradation 0.4 μM
K1e
Michaelis constant for Cyclin E/Cdk2 (inactive) activation through 
dephosphorylation by phosphatase Cdc25 (Pe) 0.1 μM
K2e
Michaelis constant for Cyclin E/Cdk2 (active) inactivation through 
phosphorylation by kinases WEE1 and Myt1 0.1 μM
K5e
Michaelis constant for Cdc25 (Pei) activation through phosphorylation by Cyclin 
E/Cdk2 and Plk3 0.1 μM
K6e Michaelis constant for Cdc25 (Pe) inactivation 0.1 μM
Vde Maximum rate of Cyclin E degradation 3 μM h-1
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Vdskp2 Maximum rate of Skp2 degradation 1.1 μM h-1
Vm1e
Rate constant for activation of Cyclin E/Cdk2 (inactive) through dephosphorylation 
by phosphatase Cdc25 (Pe) 2 h
-1
Vm2e
Rate constant for inactivation of Cyclin E/Cdk2 (active) through phosphorylation 
by kinases WEE1 and Myt1 1.4 h
-1
Vm5e
Rate constant for activation of phosphatase Cdc25 through phosphorylation by 
Cyclin E/Cdk2 and Polo-like kinase 3 5 h
-1
V6e Maximum rate of inactivation of phosphatase Cdc25 through phosphorylation 0.8 μM h-1
vspei Rate of synthesis of phosphatase Cdc25 acting on Cyclin E/Cdk2 0.13 μM h-1
vsskp2 Maximum rate of synthesis of Skp2 0.15 μM h-1
xe1
Factor measuring basal, Chk1-independent contribution to the rate of inactivation 
through phosphorylation of phosphatase Cdc25 (Pe) 1
aa
Factor measuring the contribution of Polo-like kinase 3 (Plk3) to phosphorylation 
and activation of phosphatase Cdc25 (Pa) 0.2 μM
ib2
Factor measuring the contribution of kinase Myt1 to phosphorylation and 
inhibition of Cyclin A/Cdk2 0.5 μM
Ki11 Constant of inhibition by pRB of Cyclin A synthesis 0.1 μM
Ki12 Constant of inhibition by pRBp of Cyclin A synthesis 2 μM
Ki13 Constant of inhibition by pRB of p27 synthesis 0.1 μM
Ki14 Constant of inhibition by pRBp of p27 synthesis 2 μM
kca Rate constant for Cyclin A synthesis induced by E2F 0.0375 h
-1
kdecom3 Rate constant for dissociation of complex between Cyclin A and Cdk2 0.1 h
-1
kcom3 Bimolecular rate constant for binding of Cyclin A to Cdk2 0.2 μM-1 h-1
kc5 Bimolecular rate constant for binding of active Cyclin A/Cdk2 to p27 0.15 μM-1 h-1
kc6 Rate constant for dissociation of complex between Cyclin A/Cdk2 and p27 0.125 h
-1
kdda Apparent first-order rate constant for non-specific Cyclin A degradation 0.005 h
-1
kddp27 Apparent first-order rate constant for non-specific p27 degradation 0.06 h
-1
kddp27p Apparent first-order rate constant for non-specific p27p degradation 0.01 h
-1
kdcdh1a Apparent first-order rate constant for degradation of active Cdh1 0.1 h
-1
kdcdh1i Apparent first-order rate constant for degradation of inactive Cdh1 0.2 h
-1
kdpa
Apparent first-order rate constant for degradation of active phosphatase Cdc25 
(Pa) 0.075 h
-1
kdpai
Apparent first-order rate constant for degradation of inactive phosphatase Cdc25 
(Pai) 0.15 h
-1
Kda Michaelis constant for Cyclin A degradation 1.1 μM
Kdp27p Michaelis constant for p27p degradation 0.1 μM
Kdp27skp2 Michaelis constant for activation by Skp2 of p27p degradation 0.1 μM
Kacdc20 Michaelis constant for activation by Cdc20 of Cyclin A degradation 2 μM
K1a
Michaelis constant for Cyclin A/Cdk2 (inactive) activation through 
dephosphorylation by Cdc25 (Pa) 0.1 μM
K2a
Michaelis constant for Cyclin A/Cdk2 (active) inactivation through 
phosphorylation by kinases WEE1 and Myt1 0.1 μM
K1cdh1 Michaelis constant for Cdh1 (inactive) activation through dephosphorylation 0.01 μM
K2cdh1
Michaelis constant for Cdh1 (active) inactivation through phosphorylation by 
Cyclin A/Cdk2 and Cyclin B/Cdk1 0.01 μM
K5a
Michaelis constant for Cdc25 (Pai) activation through phosphorylation by Cyclin 
A/Cdk2 and kinase Plk3 0.1 μM
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K6a Michaelis constant for Cdc25 (Pa) inactivation 0.1 μM
K1p27 Michaelis constant for p27 phosphorylation by Cyclin E/Cdk2 0.5 μM
K2p27 Michaelis constant of p27p dephosphorylation 0.5 μM
Vdp27p Maximum rate of p27p degradation 5 μM h-1
Vda Maximum rate of Cyclin A degradation 2.5 μM h-1
Vm1a
Rate constant for activation of Cyclin A/Cdk2 (inactive) through dephosphorylation 
by phosphatase Cdc25 (Pa) 2 h
-1
Vm2a
Rate constant for inactivation of Cyclin A/Cdk2 (active) through phosphorylation 
by kinases WEE1 and Myt1 1.85 h
-1
Vm5a
Rate constant for activation of phosphatase Cdc25 (Pai) through phosphorylation 
by Cyclin A/Cdk2 and kinase Plk3 4 h
-1
V6a Maximum rate of phosphatase Cdc25 (Pa) inactivation 1 μM h-1
vscdh1a Rate of synthesis of active Cdh1 0.11 μM h-1
vspai Rate of synthesis of phosphatase Cdc25 (Pai) acting on Cyclin A/Cdk2 0.105 μM h-1
vs1p27 Basal rate of synthesis of p27 0.8 μM h-1
vs2p27 Rate constant for synthesis of p27 induced by E2F 0.1 h
-1
V1cdh1 Maximum activation rate of Cdh1 (inactive) through dephosphorylation 1.25 μM h-1
V2cdh1
Rate constant for inactivation of Cdh1 (active) through phosphorylation by Cyclin 
A/Cdk2 and Cyclin B/Cdk1 8 h
-1
V1p27 Rate constant for inactivation of p27 through phosphorylation by Cyclin E/Cdk2 100 h-1
V2p27 Maximum rate of activation of p27p through dephosphorylation 0.1 μM h-1
xa1
Factor measuring basal, Chk1-independent contribution to the inactivation rate of 
phosphatase Cdc25 (Pa) 1
ab
Factor measuring the contribution of Polo-like kinase 1 (Plk1) to phosphorylation 
and activation of Cdc25 phosphatase (Pbi) 0.11 μM
Cdk1tot Total concentration of the Cdk1 kinase 0.5 μM
ib
Factor measuring the contribution of kinase(s) other than Cdk1 to phosphorylation 
and inactivation of kinase WEE1 0.75 μM
ib3
Factor measuring the contribution of kinase Myt1 to phosphorylation and 
inhibition of Cyclin B/Cdk1 0.5 μM
kc7 Bimolecular rate constant for binding of Cyclin B/Cdk1 (active) to p27 0.12 μM-1 h-1
kc8 Rate constant for dissociation of complex between Cyclin B/Cdk1 and p27 0.2 h
-1
kdecom4 Rate constant for dissociation of complex between Cyclin B and Cdk1 0.1 h
-1
kcom4 Bimolecular rate constant for binding of Cyclin B to Cdk1 0.25 μM-1 h-1
kdcdc20a Apparent first-order rate constant for degradation of active Cdc20 0.05 h
-1
kdcdc20i Apparent first-order rate constant for degradation of inactive Cdc20 0.14 h
-1
kddb Apparent first-order rate constant for non-specific Cyclin B degradation 0.005 h
-1
kdpb
Apparent first-order rate constant for degradation of active phosphatase Cdc25 
(Pb) 0.1 h
-1
kdpbi
Apparent first-order rate constant for degradation of inactive phosphatase Cdc25 
(Pbi) 0.2 h
-1
kdwee1 Apparent first-order rate constant for degradation of active kinase WEE1 0.1 h
-1
kdwee1p Apparent first-order rate constant for degradation of inactive kinase WEE1 0.2 h
-1
Kdb Michaelis constant for Cyclin B degradation 0.005 μM
Kdbcdc20 Michaelis constant for activation by Cdc20 (active) of Cyclin B degradation 0.2 μM
70
Chapter 2
Kdbcdh1 Michaelis constant for activation by Cdh1 (active) of Cyclin B degradation 0.1 μM
K1b
Michaelis constant for Cyclin B/Cdk1 (inactive) activation through 
dephosphorylation by phosphatase Cdc25 (Pb) 0.1 μM
K2b
Michaelis constant for Cyclin B/Cdk1 (active) inactivation through 
phosphorylation by kinases WEE1 and Myt1 0.1 μM
K3b
Michaelis constant for Cdc20 (inactive) activation through phosphorylation by 
Cyclin B/Cdk1
0.1 μM
K4b Michaelis constant for Cdc20 (active) inactivation through dephosphorylation 0.1 μM
K5b
Michaelis constant for Cdc25 (Pbi) activation through phosphorylation by Cyclin 
B/Cdk1 and kinase Plk1
0.1 μM
K6b Michaelis constant for Cdc25 (Pb) inactivation 0.1 μM
K7b
Michaelis constant for Wee1 inactivation through phosphorylation by Cyclin B/
Cdk1 and kinase Plk1
0.1 μM
K8b Michaelis constant for Wee1 activation through dephosphorylation 0.1 μM
Vdb Maximum rate of Cyclin B degradation 0.06 μM h-1
Vm1b
Rate constant for activation of Cyclin B/Cdk1 (inactive) through dephosphorylation 
by phosphatase Cdc25 (Pb)
3.9 h-1
Vm2b
Rate constant for inactivation of Cyclin B/Cdk1 (active) through phosphorylation 
by kinases WEE1 and Myt1
2.1 h-1
vscdc20i Rate of synthesis of Cdc20 (inactive) 0.1μM h-1
Vm3b
Rate constant for activation of Cdc20 (inactive) through phosphorylation by 
Cyclin B/Cdk1
8 h-1
Vm4b Maximum rate of Cdc20 (active) inactivation through dephosphorylation 0.7μM h-1
Vm5b
Rate constant for activation of phosphatase Cdc25 (Pbi) through phosphorylation 
by Cyclin B/Cdk1 and kinase Plk1 5 h
-1
V6b Maximum inactivation rate of phosphatase Cdc25 (Pb) 1 μM h-1
Vm7b
Rate constant for inactivation of kinase WEE1 through phosphorylation by Cyclin 
B/Cdk1 and kinase Plk1 1.2 h
-1
Vm8b Maximum rate of kinase Wee1 activation through dephosphorylation 1 μM h-1
vspbi Rate of synthesis of phosphatase Cdc25 (Pbi) acting on Cyclin B/Cdk1 0.12 μM h-1
xb1
Factor measuring basal, Chk1-independent contribution to the rate of phosphatase 
Cdc25 (Pb) inactivation 1
Coupling the mammalian cell cycle to the circadian clock through Wee1
Parameters are (with some modifications) based on those given in Supporting Information to Gérard and 
Goldbeter (2009; see http://www.pnas.org/content/106/51/21643/suppl/DCSupplemental) and in Figure 2 in 
Gérard and Goldbeter (2012).
Kdmw Michaelis constant for the degradation of Wee1 mRNA (Mw) 0.5 μM
Kaw
Threshold constant for activation by CLOCK/BMAL1 (Bn) of Wee1 mRNA (Mw) 
synthesis 4 nM
nmw Degree of cooperativity for the activation by CLOCK/BMAL1 (Bn) of Wee1 mRNA (Mw) synthesis 4
Vdmw Maximum rate of degradation of Wee1 mRNA (Mw) 2.445×10-2μMh-1
vswee1
Rate of synthesis of Wee1 mRNA (Mw) independent from coupling to the circadian 
clock 5.721×10
-4μMh-1
vsw Rate of synthesis of Mw depending on CLOCK/BMAL1 (Bn) 6.846×10-3μMh
-1
ksw Rate constant for synthesis of WEE1 protein 5 h
-1
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Kdmcb Michaelis constant for the degradation of Cyclin B mRNA (Mcb) 0.5 μM
Kacb
Threshold constant for activation by CLOCK/BMAL1 (Bn) of Cyclin B mRNA 
(Mcb) synthesis 4 nM
ncb Degree of cooperativity for the activation by CLOCK/BMAL1 (Bn) of Cyclin B mRNA (Mcb) synthesis 4
Vdmcb Maximum rate of degradation of cyclin B mRNA (Mcb) 2.445×102μMh-1
vcb
Rate of synthesis of cyclin B mRNA independent from coupling to the circadian 
clock 5.263×10
4μMh1
vscb Rate of synthesis of cyclin B mRNA depending on CLOCK/BMAL1 (Bn) 9.78×105μMh
1
kcb Rate of synthesis of Cyclin B protein 5 h
-1
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 The circadian clock and the cell cycle are two intracellular oscillators that 
employ cyclic gene expression and protein degradation to impose diurnal 
rhythmicity on behavior, physiology and metabolism, and to drive cell 
division, respectively. Recently, we have used the NIH3T33C mouse cell 
line, carrying fluorescent reporter genes for clock and cell cycle phase, 
to show that the circadian clock and the cell cycle are 1:1 phase coupled 
in proliferating cells. Previously we have shown the impact of positive 
circadian elements (CLOCK/BMAL1) on cell cycle progression. In the 
present study, we have investigated the impact of negative circadian el-
ements on cell cycle progression and on the coupling between these two 
systems. To this end, we knocked out cryptochrome genes in NIH3T33C 
cells and analyzed timing of cell cycle progression at the single cell and 
population levels. Cryptochrome deficiency shortened the total cell cycle 
length. Notably, Cry deficient cells spend less time in G1 before entering 
S phase, which is supported by the elevated levels of Cyclin E in G1/S and 
early S phase cells. In addition, subsequent molecular analysis revealed 
involvement of cryptochromes on mitotic progression by modulating the 
phosphorylation of mitotic substrates. In conclusion, we show that crypto-
chromes modulate cell cycle progression at two different levels, by regu-
lating G1/S transition and mitotic progression. 
| Abstract
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 | Introduction 
 The circadian clock and the cell cycle are two biological oscillators that interact closely 
with each other via intracellular molecular connections. They follow sequential events of 
transcription, translation, protein modification and degradation that drive their timed and 
cyclic events. 
 All living organisms possess an internal timing system called the “circadian clock”, to ad-
just behavior, physiology and metabolism to the environmental changes that are instigated by 
the rotation of the earth around its own axis, i.e. the day and night (Pittendrigh et al., 1996). 
Mammals possess a master circadian clock which is centrally located in the suprachiasmatic 
nucleus of the brain (SCN) (Ralph et al., 1990). SCN neurons receive light input signals 
from photoreceptors located in the inner nuclear layer of the retina, to remain synchronized 
to the day/night cycle (Gooley et al., 2001). Subsequently, the SCN neurons transmit clock 
synchronizing signals via hormonal and neural cues to the peripheral clocks that are located 
in almost every single cell of an organism (Welsh et al., 2004). At the molecular level, both 
central and peripheral cells generate circadian rhythms through the same set of clock genes 
that act in autoregulatory transcriptional-translational feedback loops (TTFL) (Reppert et al., 
2001; Yagita et al., 2002). The positive limb of the molecular oscillator consists of the Brain 
and Muscle Arnt-Like 1 (Bmal1) and Circadian Locomotor Output Cycles Kaput (Clock) 
genes (Bunger et al., 2000). The CLOCK/BMAL1 heterodimer acts as transcriptional ac-
tivator of E-box promoter element containing genes, including the period (Per1 and Per2), 
cryptochrome (Cry1 and Cry2), and nuclear hormone receptor Rev-Erbα clock genes (Taka-
hashi et al., 2008). PER and CRY proteins, which make up the negative limb, accumulate in 
the cytoplasm and translocate to the nucleus, where they repress the activity of the CLOCK/
BMAL1 heterodimer, thereby also inhibiting transcription of their own genes (Takahashi et 
al., 2008; Mohawk et al., 2012). Moreover, the CLOCK/BMAL1 heterodimer induces tran-
scription of E-box containing Clock Controlled Genes (CCG), comprising over 10% of the 
cellular transcriptome (Miller et al., 2007). Thus, circadian transcription couples the circadi-
an oscillator to a wide variety of physiological processes such as hormone secretion, drug and 
xenobiotic metabolism, and cell cycle progression (Takahashi et al., 2008). 
 Like the circadian clock, the cell cycle is a highly regulated oscillatory system, driven by 
cyclic gene expression and protein degradation. During the cell cycle, cells duplicate their 
genome in S-phase (S), followed by the separation of the genome in two daughter cells in 
mitosis (M). These two important phases of the cell cycle are separated by two gap phases, 
G1 and G2, that allow the cells to prepare for DNA replication and cell division, respectively 
(Norbury & Nurse 1992). Progression through the cell cycle relies on the rhythmic activity 
of cyclin-CDK kinase complexes. Cyclins are regulatory subunits that are produced at a 
specific phase of the cell cycle and subsequently associate with their catalytic subunits, the 
Cyclin-Dependent Kinases (CDKs) (Tyson & Novak, 2008). Specific combination of cy-
clin-CDK complexes triggers various cell cycle events such as DNA replication and mitosis. 
In addition, degradation of the cyclins at the end of each cell cycle phase is equally important 
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for cell cycle progression as it attenuates the kinase activity of the CDK partner, thereby 
allowing the cell to move forward and blocking the way back. Thus, cyclic activity of the 
cyclins and their associated CDK partners regulates cell cycle progression in a sequential and 
uni-directional manner. 
 Evidence is increasing that the circadian and cell cycle systems are not independent, but 
rather are coupled. Single cell studies, making use of a mouse fibroblast cell line (NIH3T3) 
expressing a clock reporter (Bieler et al., 2014) or a clock reporter together with two cell 
cycle markers (NIH3T33C) (Feillet et al., 2014,2015), have shown that these two oscillators 
are phase coupled at a 1:1 ratio. Several other studies have shown the existence of molecu-
lar connections between these two cyclic processes. For instance, transcription of Wee1, an 
important kinase for G2/M transition (Matsuo et al., 2003), of tumor suppressor gene P21 
(Gréchez-Cassiau et al., 2008), and of P16-INK4 (Kowalska et al., 2013) is driven by the 
circadian clock. Conversely, the cell cycle gene p53 negatively regulates Per2 expression 
(Miki et al.,2013).
 Although it is clear that the circadian clock and cell cycle are interconnected, little is known 
about how disruption of one of the systems can impact the other. This question can be ad-
dressed by genetically disrupting the circadian clock and investigating how this impacts cell 
cycle progression, and vice versa. It is also important to assess how a dysregulated commu-
nication between the two systems impacts disease and cancer predisposition. Previously we 
have shown that siRNA mediated knock down of Bmal1 or Clock gene expression prolonged 
the total cell cycle length by delaying G2/M transition. At the molecular level, the CLOCK/
BMAL1 heterodimer was shown to induce expression of Cyclin B1, thereby promoting 
G2/M transition and overruling the CLOCK/BMAL1-mediated induction of the G2/M transi-
tion inhibitor gene Wee1 (Farshadi et al., unpublished). Since positive and negative elements 
of the circadian transcription-translation feedback loop act oppositely on the expression of 
clock controlled genes, the question arises if, and how the negative circadian elements (CRY 
and PER) may regulate cell cycle progression. 
 In the current study, we have knocked out the endogenous cryptochrome genes (Cry1 and 
Cry2) in the NIH3T33C mouse fibroblast cell line by CRISPR/Cas9 mediated technology and 
investigated cell cycle progression We show that the absence of cryptochrome proteins af-
fects the cell cycle. Importantly, we shed light on the possible molecular mechanisms of this 
cryptochrome-mediated regulation of cell cycle progression.
 | Material and methods 
Cell culture 
 NIH3T33C cells containing Rev-Erbα-VNP clock reporter and FUCCI hCdt1-mKOrange 
and hGeminin-CFP FUCCI cell cycle reporter genes (Feillet et al., 2014) were cultured in 
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Dulbecco’s Modified Eagle’s Medium (DMEM)/F10 (Lonza) containing 10% Fetal Bovine 
Serum (FBS) (Gibco), 100 U/ml Penicillin and 100 µg/ml Streptomycin in a standard humid-
ified incubator at 37°C and 5% CO2 (pH7.7). 
 In a subset of experiments, the cell cycle of proliferating cells (seeded on 6-well plates at a 
density of 80.000 cells per well) was synchronized by treatment of cell cultures with 2.5 mM 
thymidine (Sigma) treatment for 24 hours, which arrests most of the cells at the G1/S transi-
tion or early S phase. Cells were released from thymidine block by washing 3 times with PBS 
and harvested at the indicated time points.
 To collect cells in mitosis, cell cultures (seeded on 10cm dishes at a density of 280.000 cells 
per dish) were treated with nocodazole (0.25 µg/ml, Sigma) for 12 hour. After incubation 
with nocodazole, cells were harvested with a gentle mitotic shake off. After washing with 
PBS, mitotic cells were reseeded in fresh medium and harvested at the indicated time points. 
Generation of Cry1/Cry2 double knock out NIH3T33C cell line 
 The CRISPR/Cas9 genome editing approach was applied to knock out the Cry1 and Cry2 
genes and obtain cryptochrome deficient NIH3T33C cells. Specific sgRNA sequences, target-
ing exon one of the Cry genes, were cloned into a blasticidine resistance selection marker 
containing back bone plasmid, containing a doxycycline inducible H1 promoter. The guide 
sequences are as follows: Cry1: Oligo 1= 5’ GGT CGA GGA TAT AGA CGC AG 3’; Oligo 
2= 5’ CT GCG TCT ATA TCC TCG ACC; Cry2: Oligo 1= 5’ TTT GCG GAA CCA GTG 
CAC CG 3’; Oligo 2= 5’ CG GTG CAC TGG TTC CGC AAA 3’. 
 NIH3T33C cells were seeded on 6 well plates and were transfected the day after, at 70% 
confluency, simultaneously with the vectors containing the desired gRNAs for Cry1, Cry2, 
and Cas9 plasmid using Polyplus jetPei transfection reagent (Westburg). Transfection was 
carried out according to the manufacturer’s protocol. Transfected cells were selected using 
5ug/ml Blasticidine for several days. Subsequently, single cells were seeded on a 96 wells 
plate to obtain pure clones.
 Isolated clones were screened for Cry gene inactivation by sequencing. To this end, ge-
nomic DNA around the exon 1 of Cry1 and Cry2 genes was PCR amplified using a Phusion 
High-Fidelity DNA Polymerase PCR Master kit (Thermo Fisher) according to manufactur-
er’s protocol, using the following primers: Cry1: forward: 5’ CGA TCG ATT GAT TTC 
CCA AG 3’; Reverse: 5’ CTG GAA GGT ATG CGT GTC CT 3’; Cry2: forward: 5’ GTT 
AGA AAG GGC CCG GTA AC 3’; Reverse: 5’ CAG ATC CTC CCT CAG GTT GA 3’. 
Gel extracted PCR products were sent for Sanger sequencing. The sequencing results were 
analyzed by the TIDE (Tracking of Indels by DEcomposition) algorithm (https://tide.nki.nl) 
(Brinkman et al., 2014).
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Real time bioluminescence monitoring of circadian performance
 To monitor circadian oscillations in real time, cells were seeded in 35mm petri dishes. 
After 24 hours, at 60-70% confluency, the cells were transfected with a Bmal1::Luciferase 
reporter construct (1 µg/dish) using X-tremeGENE HP DNA Transfection Reagent (Roche) 
according to the manufacturer’s protocol. After reaching confluency cell cultures were treat-
ed with forskolin (dissolved in 100% ethanol, added to a final concentration of 10µM) to 
synchronize the circadian clocks and subsequently cultured in medium buffered with 25 mM 
HEPES and containing 0.1 mM luciferin (Caliper Life Science, Hopkinton, MA, USA). The 
bioluminescence signal was monitored for 7 days (60 sec measurements at 10 min intervals) 
in a standard dry incubator using a LumiCycle 32-channel automated luminometer (Actimet-
rics), placed in a dry incubator at 37 °C. Prior to placing dishes in the LumiCycle, the lid was 
replaced by a glass coverslip and sealed with parafilm. The data were extracted and analyzed 
using Microsoft Excel. 
Time-lapse fluorescence microscopy
 For time-lapse recording of circadian clock and cell cycle progression, cells were seeded 
on 4 well poly-L-lysine coated glass bottom dishes (D141410, Matsunami Glass Ind.) at a 
density of 6000 cells per well. After 24 hours, dishes were placed in the temperature (37°C), 
CO2 (5%) and humidity controlled chamber of a live cell imaging Zeiss LSM510/Axiovert 
200M confocal microscope, equipped with a 10x Ph objective. Images were taken every 30 
min for 48 hours or more using a Coolsnap HQ/Andor Neo sCMOS camera. Live cell imag-
ing was conducted using the following parameters (as set up in Zeiss 200 software): Venus 
(green): 1000 ms (filter cube: Ex= 475/40 nm, DM= 500 nm, Em= 530/50 nm); mKO2 (red): 
300 ms (filter cube: Ex= 534/20 nm, DM=552 nm, Em: 572/38 nm); CFP (blue): 300 ms 
(filter cube: Ex= 458/17 nm, DM=450 nm, Em: 479/40 nm). A bright field image for each 
frame was also acquired to ease cell tracking and analysis. The ConvertZeissTLV3 program 
was used to merge the acquired images into a single file to generate a movie, which was used 
for further analysis. Single cell numerical time series for each of the fluorescent markers 
were generated using the LineageTracker plugin for ImageJ. (https://github.com/pkrusche/
lineagetracker.jsonexport). Time series were analyzed for circadian cycle length, cell cycle 
length and G1 and S/G2/M cell cycle phase length. The G1 phase is defined as the interval 
between the peaks of hGeminin-CFP and hCDT1-mKOrange expression. Oppositely, the S/
G2/M phase is defined as the interval between the peaks of hCDT1-mKOrange and hGemi-
nin-CFP expression
Flow cytometry 
 To analyze the cell cycle distribution by quantification of DNA content, cells were seeded 
and harvested at 50% confluency. Next, cells were washed with PBS, and fixed overnight at 
4°C with cold 70% ethanol. Then, the fixed cells were washed with PBS, treated for 15 min 
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at 37°C with PBS containing 100 μg/ml bovine pancreas RNase (Calbiochem), and left over-
night at 4°C in PBS with 40 μg/ml propidium iodide (PI; Life Technologies). To detect mi-
totic cells, fixed cells were stained for the presence of the MPM-2 phospho-epitope on DNA 
topoisomerase IIα, using mouse anti-MPM2 primary antibodies (Merck-Millipore; dilution 
1:200; 1 h, 0°C) and goat-anti mouse FITC secondary antibodies (Abcam; dilution 1:50, 30 
min, 0°C). Cells were analyzed using a Becton Dickinson LSRFortessaTM Cell Analyzer (BD 
Biosiences). PI and FITC fluorescence intensities were measured at 610 nm and 530 nm, 
respectively. For each condition, at least 10,000 cells were counted. Frequency histograms 
were made using BD FACSDivaTM software (BD Biosciences). 
Western blot analysis 
 Protein levels were determined by Western blot analysis. After harvesting cells were lysed 
for 30 min on ice in RIPA lysis buffer, containing 5.15 mM NaCl, 2 mM Tris-HCl pH8.0, 
0.5% NaDOC, 0.1% SDS, 0.1% TX-100, 10 mM EDTA, a PhosSTOP phosphatase inhibitor 
tablet (Roche) and a Pierce Protease inhibitor tablet (Thermofisher). Lysed cells were cleared 
by centrifugation at 13000 rpm for 10 min at 4°C and supernatant was collected. 2x sample 
buffer (130 mM TrisCl pH 8.0, 20% glycerol, 4.6% SDS, 0.02% bromophenol blue, 100 mM 
DTT or 10% 2-mercaptoethanol) was added (1:1). Samples were heated at 95°C for 5 min. 
Proteins were kept on ice for at least 5 min before loading on a Bis-Tris Plus 4-12% poly-
acrylamide gel (Novex®, Life technologies). The proteins were size separated in 10% run-
ning buffer composed of 0.25 M Trizma base, 1.92 M Glycine and 1% SDS. Proteins where 
transferred to a Polyvinylidene fluoride (PVDF) membrane in 20% methanol and 10% trans-
fer buffer (1.2 M Trizma base, 0.4 M Glycine). The membrane was cut into different pieces 
for each protein according to their size, using the Precision Plus Protein Standard (Bio-Rad) 
as a guide for protein size. The membranes were blocked with 4% skim milk and incubat-
ed with the primary antibody of interest (listed below) overnight at 4°C. After 3x washing 
with PBS/0.05%Tween, membranes were incubated with the secondary antibodies (1:2000 
dilution) for 1 hour at 4°C. Protein bands were visualized using a SuperSignal¥ West Femto 
Maximum Sensitivity Substrate Kit (#34094) and autoradiography. Band intensities were 
quantified by Fiji® software and normalized against β-actin protein levels. Next, intensities 
were normalized to the average intensity of the blot to quantitatively compare different blots. 
 Antibodies used: Santa Cruz Actin C-2 (sc8432, dilution 1:750), Cyclin B1 (sc245, dilution 
1:2000), Cyclin A1 (sc751, dilution 1:1000), WEE1 (sc325, dilution 1:500),  and BMAL1 
(sc48790, dilution 1:2000). Abcam Cry1 (ab104736, dilution 1:500), Cry2 (ab38872, dilution 
1:400), Cyclin E (ab7959, dilution 1:300), Cyclin D (ab134175, dilution 1:1000). Secondary 
antibodies: goat anti-rabbit IgG (H+L)-HRP conjugate (P0260, Dako) or rabbit anti-mouse 
IgG (H+L)-HRP conjugate (P0448, Dako).
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Statistical analysis 
 All statistical analyses were carried out with GraphPad software. For single cell studies, af-
ter performing the normality test, the two-tailed Mann-Whitney test was used to analyze the 
duration of the circadian and cell cycle (including G1, S/G2/M phase). For Western blot, flow 
cytometry, and immunofluorescence experiments, the two-tailed Student’s t-test was applied. 
 | Results
Generation and validation of Cry dko NIH3T33C cell lines
 To inactivate the endogenous Cry1 and Cry2 genes in the NIH3T33C cell line, containing 
Rev-Erbα-VNP clock reporter, and hCdt1-mKOrange and hGeminin-CFP FUCCI cell cycle 
reporter genes, we applied the CRISPR/Cas9 gene editing method. NIH3T33C cells were 
simultaneously transfected with the gRNAs targeting Cry1 and Cry2 genes together with a 
Cas9 plasmid. Transfected cells were selected and sequenced to validate the targeting effi-
ciency for both Cry1 and Cry2 loci. Next, we selected single clones, followed by sequencing 
to further validate the clones. Two of the targeted clones, hereafter referred to as Cry dko1 
and Cry dko2, were further analysed. In addition, one of the non-target clones was selected 
as the negative control  (ntCtrl). 
 To quantify the editing efficacy and identify the type and frequency of Indels (Insertions 
and deletions) in the selected clones, a TIDE (Tracking of Indels by DEcomposition) analy-
sis (Brinkman et al., 2014) was performed. As shown in Fig. S1A, the expected Cas9 break 
site for the Cry1 and Cry2 loci is located at the right position in the Cry dko1 and Cry dko2 
clones. In addition, we checked type (inseration or deletion), and size of the mutations in Cry 
dko1 and dko2 clones (Fig. S1B). Fig. 1, represent the position of the aberrant sequences in 
the Cry1 and Cry2 loci for Cry dko1 and Cry dko2 cells. As it is shown for the Cry1 locus 
(Fig. 1A), aberrant sequences and large deletions start in the coding region 87 base pairs 
downstream of the ATG start codon in both targeted clones. Based on these large deletions, 
no functional CRY1 protein is expected. For the Cry2 Locus, Cry dko1 and Cry dko2 cells 
carry a +1 insertion of a thymidine at nucleotide 68 downstream of the ATG start codon (Fig. 
1B; supplementary Fig.1B). This mutation caused a frame shift that generates non-functional 
CRY2 protein (Fig. 1B).  In conclusion, according to the sequencing results, no functional 
CRY1 and CRY2 proteins are expected in the selected clones.
 We next compared the circadian performance of Cry dko clones and the Non-target con-
trol (ntCtrl) to that of the parental cell line (Ctrl) by transiently transfecting the cells with 
a Bmal1::luciferase reporter construct and subsequent time lapse recording of the biolumi-
nescence signal for 6 days. As shown in Fig. 1C, a robust oscillation in bioluminescence is 
observed in the non-target control, with an amplitude and period that compares well to that 
of the parental Ctrl line, indicating that the CRISP/Cas9 procedure did not affect clock pefor-
mance. As expected on the basis of the loss of circadian rhythmicity in Cry1-/-Cry2-/-  double 
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Figure 1.  Characterization of the CRY deficient clones. Sequence alignment of the 
control and test samples for Cry1 (panel A) and Cry2 loci (panel B) in Ctrl (top row) 
Cry1 dko1 (middle row) and dko2 (bottom row) cells. In Cry1 locus, Substitution of a 
single nucleotide is shown by arrow in Cry dko1 clone. Mismatches and deletions between 
the control sequence and the targeted sequences are shown by dashes. In Cry2 locus, the 
position of the inserted nucleotide is shown by an arrow. Change in the reading frame 
is shown in red. (C) Representative example of bioluminescence rhythms in confluent 
cultures of Ctrl and ntCtrl (top panel), Ctrl and Cry dko1 (middle panel), Ctrl and Cry 
dko2 (bottom panel). Cells are transfected with a Bmal1::Luciferase reporter construct 
and synchronized with Forskolin (clock synchronizer). Y- axis represents the base line 
subtracted bioluminescence value. 
knockout mice and fibroblasts (van der Horst et al., 1999; Yagita et al., 2001), no oscillations 
could be detected in the Cry dko1 and Cry dko2 cells. From these data we conclude that we 
have successfully inactivated the Cry1 and Cry2 alleles in Cry dko1 and Cry dko2 cells. 
Absence of Cryptochromes shortens the cell cycle 
 We next analyzed clock performance and cell cycle progression in proliferating Cry dko1 
cells at the single cell level by time lapse confocal microscopy. Fig. 2A shows a representa-
tive example of an individual proliferating Ctrl cell (upper panel), and a Cry dko1 cell (lower 
panel) spanning the circadian cycles and G1/S/G2/M cycles over the period of 68 hours. In 
line with earlier observations (Feillet et al., 2014; Farshadi et al, un published) proliferating 
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Ctrl cells show clock phase-coupled cell proliferation patterns with a clock and cell cycle 
period (as calculated from the time interval between two peaks of REV-ERBα-VNP and 
hCdt1-mKOrange fluorescence respectively) of 17.5 ± 0.4 h and 17.6 ± 0.4 h respectively 
(n=40 cells). Surprisingly, as confluent Cry dko1 cells are completely arrhythmic, a mark-
edly attenuated oscillation of the REV-ERB-VNP clock marker could still be observed with 
a periodicity of 15.5 ± 0.3 h (n=40 cells). Moreover, the circadian clock of Cry1 dko1 cells 
appears still 1:1 phase coupled to the cell cycle, having a comparable period of 15.5 ± 0.3 
h. These data suggest that proliferating Cry dko1 cells may still have a partially functional 
clock. Further comparison of the total cell cycle length of Ctrl and Cry dko1 cells revealed 
that inactivation of the Cryptochrome genes significantly (p<0.001) shortened the total cell 
cycle length from 17.6 ± 0.4 h to 15.7± 0.2 h (mean ± SEM Fig. 2B). 
 Next, we quantified the length of the G1 and combined S, G2 and M (hereafter referred to 
as S/G2/M) phases in Ctrl and Cry dko cells. The G1 phase is defined as the interval between 
the peaks of hGeminin-CFP and hCDT1-mKOrange expression, and the S/G2/M phase as the 
interval between the peaks of hCDT1-mKOrange and hGeminin-CFP expression. As shown 
in Fig. 2B, the mean length of the G1 phase decreased significantly from 7.9 ± 0.2 h in Ctrl 
cells to 5.9 ± 0.1 h in Cry dko cells (mean ± SEM p <0.0001). The average length of S/G2/M 
was comparable in both conditions (9.6 ± 0.2 h in Ctrl cells and 9.8 ± 0.1 h in Cry dko1 cells, 
p= 0.4) (Fig. 2B). Similar results were obtained with Cry dko2 cells (supplementary Fig. 2A). 
Taken together, the single cell data show a modulating role of cryptochrome proteins on the 
G1 phase of the cell cycle. 
Altered cell cycle distribution in the absence of cryptochromes  
 The single cell experiments showed that knocking out Cry genes shortens the G1 phase of 
the cell cycle, without affecting the overall S/G2/M phase length. To uncover potential alter-
ations in S, G2 and M phase, we analyzed the cell cycle phase distribution of proliferating 
Cry dko1 cell cultures by flow cytometry. Fig. 2C shows a representative example of the cell 
cycle distribution of Propidium Iodide (PI) stained Ctrl and Cry dko1 cells. In line with the 
single cell experiments, quantification of the cell cycle phase distribution (Fig. 2D) revealed 
a significant decrease in the percentage of G1 dko1 cells, as compared to Ctrl cells (48.4 ± 
0.9 % and 44.3 ± 0.4 % for Ctrl and Cry dko1 cells; n=3, p=0.02). Interestingly, whereas the 
overall length of the combined S, G2 and M phase of dko cells was not altered, the distribu-
tion of S and G2/M phase cells was dramatically shifted in Cry1/Cry2 knockout cells. The 
percentage of S phase cells significantly decreased from 20.7 ± 0.9 % in Ctrl cells to 13.5 
± 0.2 % in Cry dko cells (p=0.01) (Fig. 2D). In contrast, the percentage of cells in G2 and 
M phase increased significantly (p<0.0001) from 28.0 ± 0.4 % in controls to 38.3 ± 0.3 % 
(mean ± SEM; n=3) in Cry dko cells. To discriminate between G2 and M phase cells, we also 
stained the cells with an antibody against the mitosis-specific MPM-2 phospho-epitope on 
DNA topoisomerase IIα. 
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Figure 2. Cell cycle dynamics in the absence of cryptochromes. (A)  Representative 
examples of time-lapse confocal imaging of a Ctrl (NIH3T33C) (upper panel) and a Cry dko 
cell (lower panel). Plotted are fluorescence intensities of circadian clock (Rev-Erbα-VNP; 
yellow), and of G1 (hCdt1-mKOrange; red) and S/G2/M (hGeminin-CFP; blue) cell cycle 
markers over a 68-hour period. The G1 phase is defined as the interval between the peaks 
of hGeminin-CFP and hCDT1-mKOrange expression. S/G2/M is defined as the interval 
between the peaks of hCDT1-mKOrange and hGeminin-CFP expression. (B) Box-whisker 
plot showing the length of the total cell cycle (grey), G1 (red) and S/G2/M (blue) in Ctrl 
and Cry dko cells (n= 40 cells per condition). The range between the highest and lowest 
values is shown. The solid line and cross within the box represent the median and mean 
value, respectively. The lowest and highest boundaries of the box indicate the 25 and 75 
percentiles, respectively. *** p<0.001 and **** p<0.0001 (Mann Whitney test). C) Flow 
cytometric analysis of cell cycle phase distribution in Ctrl and Cry dko cells. Shown are 
representative examples of propidium iodide (PI) stained Ctrl and Cry dko cells, analyzed 
for DNA content (n=3 experiments). The vertical axis indicates the relative number of 
cells and the horizontal axis indicates the relative PI fluorescence intensity. The 2N and 
4N peaks and intermediate region correspond to G1, G2/M and S phase, respectively. 
(D) Quantification of cell cycle phase distribution of proliferating Ctrl and Cry dko cells. 
Shown is the average of 3 biological replicates (20000 cell counts/per sample). The data 
were analyzed using the two-tailed paired Student’s t-test. Error bars indicate the SEM. (C) 
Representative example of flow cytometry analysis to determine of the number of mitotic 
cells. The bivariate dot plots show DNA content (PI) and mitotic phosphoproteins content 
(MPM2 stain) on the X and Y axis, respectively. The box marks cells stained positive for 
MPM2.
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As shown in Fig. 2E, we observed a highly significant increase (p<0.001) in the percentage 
of MPM2-positive cells from 1.7 ± 0.2 % in controls to 3.4 ± 0.2 % (mean ± SEM; n=3) in 
Cry dko cells. Similar data were obtained for the Cry dko2 clone (supplementary Fig. 2B). In 
conclusion, cell cycle profile analysis shows relatively less cells in G1 and S, but more cells 
in G2 and mitosis in the CRY deficient clones.
Cryptochromes regulate two cell cycle check points 
 Phase specific and timed expression and degradation of different Cyclins is important for 
regulated cell cycle progression. We therefore next studied the kinetics of different cell cycle 
regulators in proliferating CRY deficient cells. To this end, we used a thymidine block (which 
arrests the cells at G1/S), followed by a release protocol. Cells were harvested 0, 2, 4, 6, 8, 
and 10 hours after release from the thymidine block and expression levels of the various 
cyclins in exponentially proliferating Ctrl and Cry dko cells were examined by western blot 
analysis. Cyclin E peaks at late G1 and is an important molecule for the G1/S transition (Koff 
et al., 1992; Jackson et al., 1995). As shown in Figs. 3A and B, at the G1/S transition and the 
beginning of S phase (time points 0 and 2 hours after thymidine release), an elevated level of 
Cyclin E is observed (p=0.01 and p=0.04 respectively). Therefore, higher Cyclin E protein 
levels explain the shortening of the G1 phase. 
 Next, we analyzed Cyclin A2 protein levels in Ctrl and Cry dko1 cells upon release from 
a thymidine block (Fig. 3A and C). Calculations of the time spent in each of the cell cycle 
phases based on the flow cytometry data and single cell analysis (Table 1) showed that the 
approximate total time spent in S and G2 is about 8 hours in both Ctrl and Cry dko1 cells (S 
and G2-phase cells in total 48% and 51%, at a cell cycle length of 17.6 and 15.7 hours in Ctrl 
and Cry dko1 cells, respectively). Thereby, mitosis should start approximately 8 hours after 
thymidine release. Progression through mitosis requires degradation of Cyclin A2 right after 
break down of the nuclear envelope (Den Elzen et al., 2001). Between the 6 hour and 10 hour 
time points, Cyclin A2 is degraded by 75% in the Ctrl cells, indicating that the cells reached 
late G2 or early mitosis. In contrast, Cry dko1 cells only show a 30% reduction in Cyclin A2 
protein levels (p=0.02 at 10 hours) (Fig. 3C). 
 Furthermore, Cyclin B1 protein level gradually increased with the same kinetics in Ctrl and 
Cry dko1 cells during the S and G2 phase, reaching a maximal level 6 hours after thymidine 
release (Fig. 3A and D). Interestingly, a significant higher level of Cyclin B1 was detected 
in Cry dko1 cells 8 and 10 hour after thymidine release (p<0.01 at 10 hours; Fig. D). It is 
well known that exit from mitosis requires degradation of Cyclin B1 (Holloway et al., 1993; 
Pines et al.,2006). Therefore, failure to degrade Cyclin B1 at the end of mitosis could cause 
unsuccessful or delayed mitosis. To examine the degradation kinetics of Cyclin B1 at the end 
of mitosis, we arrested the cells at metaphase with Nocodazol, followed by a release protocol. 
Cells were harvested 0, 1, 2, 3, 4, 5, and 6 hours after Nocodazol release and analyzed for 
Cyclin B1 levels. As shown in Fig. 3E and F, although Cyclin B1 appears to be up-regulated 
in metaphase cells, no clear difference could be observed in the degradation of Cyclin B1 at 
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the end of mitosis in Ctrl and Cry dko cells. Therefore, we speculate that the aberrant mitotic 
profile could be due to a delay in early mitosis. 
 
Table 1. Estimated duration of individual cell cycle phases: Percentages were obtained from 
flow cytometry analysis. The percentage of cells in G2 was calculated as the percentage 
of cells in G2/M (PI staining) minus the percentage of cells in M (MPM2 staining). The 
values of total cell cycle length are derived from the single cell analysis. 
Figure 3. Cell cycle protein expression in Ctrl and Cry dko cells. (A) Western blot 
analysis of Cyclin E, Cyclin A2 and Cyclin B1 protein levels in Ctrl and Cry dko cells after 
release from a thymidine block. Shown are representative examples of n=3 independent 
experiments. Actin was used as a loading control. (B-D) Kinetics of Cyclin E (B), Cyclin 
A2 (C) and Cyclin B1 (D) expression after release from a thymidine block. Expression 
levels were normalized against actin and are relative to the Ctrl at t=0.  Error bars indicate 
SEM (n=3 experiments). (E) Western blot analysis of Cyclin B1 and MPM2, in Ctrl and 
Cry dko cells, after release from a Nocodazol block. Shown are representative examples of 
n=3 independent experiments. Actin was used as a loading control. (F) Kinetics of Cyclin 
B1 expression after release from a Nocodazol block. Cyclin B1 expression levels were 
normalized against actin and are relative to the Ctrl at t=0. Error bars indicate SE (n=3 
experiments).
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Phosphorylation of mitotic proteins is highly regulated and is a central mechanism for mi-
totic progression. These post-translational modifications define stability and activity of mi-
totic proteins (Olsen et al., 2010). To determine whether this process is affected in the CRY 
deficient clones, we performed Western blot analysis of the Nocodazol released cells using 
an antibody against the MPM2 mitotic marker (recognizes a phosphorylated epitope (S/T) 
found in mitotic phosphoproteins). As shown in Fig. 3E, we observed elevated levels of phos-
phorylation of mitotic proteins in the Cry dko1 cells. Taken together, these findings indicated 
that CRY proteins are required for proper progression through early stages of mitosis. 
 | Discussion
 In the present study, we have investigated the impact of the negative elements of the cir-
cadian oscillator on cell cycle progression by genetic disruption of the cryptochrome genes. 
First, we analyzed the clock performance in the Cry double knock out cell line compared to 
control cells. Surprisingly, as based on the population time lapse experiment and according 
to previous literature (van der Horst et al., 1999; Yagita et al., 2001) we did not expect any 
circadian oscillation in Cry deficient cells, we observed a dampened  REV-ERB-VNP in the 
proliferating Cry dko cell lines. This can be explained by assuming that in the absence of 
the CRY proteins (but with the BMAL1 and CLOCK proteins still functional), the circadian 
clock may act as an hour glass clock. We hypothesize that during mitosis the clock is reset 
and CLOCK/BMAL1 heterodimers start to activate E-box genes. However, in the absence of 
the CRY proteins (representing the negative limb of the TTFL) the oscillation fails to contin-
ue and gain amplitude. 
 Previously, we showed that knocking down the positive circadian elements (Bmal1 or 
Clock) extended the cell cycle length of proliferating NIH3T33C cells by about 4 hours. The 
progression from G2 to M was delayed as a consequence of impaired expression of Cyclin 
B1.  In this study, using NIH3T33C cells lacking cryptochromes (Cry dko1 and dko2), we 
show that disruption of the negative circadian elements shortened the total cell cycle by about 
2 hours. Our data indicate a shortening of the G1 phase by 2 hours in Cry double knock out 
cells, while no significant changes could be detected in the total S/G2/M length at the single 
cell level. Interestingly, flow cytometric analysis revealed reduced numbers of cells in both 
G1 and S, and a significant increase in the percentage of G2/M cells. We have observed a 
two-fold higher percentage of mitotic cells, which can partially explain the increased 4N 
population. 
 Subsequent analysis of important cell cycle regulators in  cell cycle synchronized cell cul-
tures revealed involvement of cryptochromes in the regulation of G1/S and M phase. Pro-
liferating Cry dko cells are characterized by a shortened G1 phase and express high level of 
Cyclin E at G1/S. This finding is in good agreement with the observation that overexpression 
of Cyclin E decreases the time of G1 to S phase transition, which leads to a shortening of G1 
(Ohtsubu et al., 1995; Resnitzky et al., 1995). It is known that transcription of Cyclin E is 
induced by the Myc oncogene. On the other hand, Myc transcription is directly controlled by 
circadian clock genes (Fu et al., 2002). Therefore, regulation of Cyclin E by cryptochromes 
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could occur via Myc transcriptional regulation. 
 Whereas the kinetics of the Cyclin A2 and Cyclin B1 cell cycle regulators during S and G2 
was in the normal range, Cry dko cells showed an attenuatted degradation of Cyclin A2 and 
Cyclin B1. It is known that accumulation of Cyclin A2 at late G2 and early M cells will in-
terfere with chromosome alignment and cause a mitotic delay (Den Elzen et al., 2001; Pines 
et al., 2006). Therefore, in the absence of CRY proteins accumulation of Cyclin A2 at the 
beginning of mitosis may interfere with mitotic progression, which also could explain the 
higher mitotic index in Cry dko cells, as determined by flow cytometry. 
 Active Cyclin A2-CDK2 and Cyclin B1-CDK1 phosphorylate key mitotic substrates (Pines 
et al., 2006), and these post-translational modifications define activity and stability of the 
mitotic proteins (Ptacek et al., 2006; Oslen et al., 2010). Timed degradation of Cyclin A2 and 
Cyclin B1 allows phosphatases to reverse the phosphorylation of mitotic substrates, allowing 
the cell to progress through mitosis (Domingo-Sananes et al., 2011). Therefore, the observed 
delayed degradation of these cyclins in the CRY deficient cells may interfere with mitot-
ic progression, by affecting the phosphorylation pattern of mitotic substrates. Interestingly, 
when we analyzed the level of phosphorylation of mitotic substrates, determined by western 
blot analysis of nocodazole released cells, we observed elevated levels of phosphorylated 
MPM2 epitope (mitotic marker). This confirms that phosphorylation of mitotic proteins is 
de-regulated in the CRY deficient cells. 
 Circadian oscillation in transcription has been extensively studied, and it is known that at 
least 10% of the genome is under circadian control (Panda et al., 2002; Zhang et al., 2014). 
However, recent proteome studies revealed that 40% of the phosphoproteins are significant-
ly oscillating in mouse liver (Robles et al., 2017). This study indicates a prominent role of 
circadian regulation at the post translational level, such as protein phosphorylation. Taking 
into account that we have observed a significant increase in the phosphorylation of several 
mitotic proteins (Figure 3E), and knowing that phosphorylation is a central mechanism of 
control for both mitosis (Olsen et al., 2010) and circadian rhythms, we speculate that in 
the absence of CRY proteins the circadian control of the cell cycle is lost in these cells as a 
consequence of a de-regulated phosphoproteome. To test this hypothesis, a comparative time 
course phosphoproteomics experiment in the WT and Cry dko cell lines using the HighPhos 
workflow could be performed.
 So far, several studies have linked circadian disruption to tumorigenesis. Impaired crypto-
chrome gene expression has been reported in colorectal (Mazzoccoli et al., 2016) and breast 
cancer (Hoffman et al., 2010). Our results support the link between cryptochrome deficiency 
and tumorogenesis by showing a shortened G1/S transition together with elevated levels of 
Cyclin E in Cry double knock out cells.  It is known that Cyclin E activity is tightly regulated 
in normal cells and is frequently de-regulated and overexpressed in cancer cells (Mazum-
der et al., 2004; Hwang et al., 2005). Therefore, overexpression of Cyclin E is considered 
as an oncogenic factor. Moreover, impaired mitotic progression may cause chromosomal 
instability, which is a hallmark of cancer.  Therefore, in this study we un-covered the effect 
of cryptochrome deficiency on cell cycle progression and, to some extent, we shed light on 
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the underlying mechanism. Improvement of the FUCCi system in NIH3T33C cell line will 
allows us to discriminate between each of the S, G2, and M phases and may further help us 
to un-cover the effect of circadian elements on each specific cell cycle phases. 
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Fig.S1. Evaluation of genome editing using the TIDE algorithm. (A) Aberrant sequence 
signal in Control (black bars), and targeted cells (green bars). Expected cut site is shown by 
the vertical blue line. The right panels correspond to the Cry1 locus and the left panels to 
the Cry2 locus (shown are three different clones for each locus). B) Occurrence frequency 
of Insertions and deletions (Indels) is shown for the Cry1 locus (left panel) and Cry2 locus 
(right panel). p-value (statistical significance for each Indel) is calculated using the Tide 
algorithm.
 | Supplementary information
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Fig.S2. Cell cycle dynamics in the absence of cryptochromes. (A) Box-whisker plot 
showing the length of the total cell cycle (grey), G1 (red) and S/G2/M (blue) in Ctrl and 
Cry dko2 cells (n= 20 cells per condition). The range between the highest and lowest 
values is shown. The solid line and cross within the box represent the median and 
mean value, respectively. The lowest and highest boundaries of the box indicate the 25 
and 75 percentiles, respectively. ** p<0.01 and ****p<0.0001(Mann Whitney test). B) 
Quantification of cell cycle phase distribution of proliferating Ctrl and Cry dko2 cells. 
Shown is the average of 3 biological replicates (20000 cell counts/per sample). The data 
were analyzed using the two-tailed paired Student’s t-test. Error bars indicate the SEM. 
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|  Abstract
Circadian control of cell division is well established in diverse organisms. 
Recent single cell studies on mouse fibroblast cells have shown that the 
circadian clock and cell cycle systems are robustly phase-coupled (Feil-
let et al., 2014; Bieler et al., 2014).  The importance of clock-cell cycle 
coupling in timed mitosis and rhythmic DNA replication in healthy cells 
is evident (Scheving., 1983; Lévi et al., 2007). However, little is known 
about the interplay between these two oscillators in cancer cells, which 
often display de-regulated cell proliferation and circadian gene expres-
sion. In this study, we have investigated the reciprocal interaction between 
the circadian clock and the cell cycle in cancer cells. We introduced a 
fluorescent clock reporter into a p53 mutant mouse breast cancer cell line 
and studied the clock-cell cycle coupling using live single cell imaging. 
We found that in the mouse breast cancer cell (MBC) line MBC399 the 
circadian clock is free running and that mitosis occurs independent of the 
circadian phase. We report here for the first time uncoupling between the 
circadian and cell cycle systems. Our observation illustrates the principle 
of chronotherapy that benefits from asynchrony in timed mitosis between 
the host and the malignant cells in order to predict the optimal time of 
treatment. Moreover, our study opens possibilities to further investigate 
the role of uncoupling in malignant cell growth. 
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 | Introduction 
 The circadian clock and cell cycle systems are two biological oscillators that are tightly con-
nected to each other in different species, from unicellular organisms to mammals (Iwasaka et 
al., 2000; Mori et al., 2000., Reppert et al., 2001). 
 The circadian system is responsible to adjust the physiology and behaviour of an organism 
to the environmental changes such as the day/night cycle (Mohawk et al., 2012). The circa-
dian clock is orchestrated in a hierarchy manner with the SCN at the top of hierarchy and 
peripheral clocks all over the body (Ko et al., 2006). The SCN clocks are entrained by the 
light signals that they receive from the photoreceptors located in the retinal ganglion (Meijer 
et al.,2007). Subsequently, the SCN transfers these entraining signals to the peripheral clocks 
via hormonal or neural cues (Welsh et al., 2004). 
 Circadian oscillations are generated by a circadian clock based on a network of transcrip-
tional-translational feedback loops, which are governed by a set of clock genes including 
Clock, Bmal1, Per (Per1, Per2), and Cry (Cry1, Cry2) (Lowery et al., 2004). The CLOCK/
BMAL1 heterodimer induces transcription of the Per and Cry genes via an E-Box enhancer 
element in their promoter. PER and CRY proteins heterodimerize and translocate to the nu-
cleus where they inhibit CLOCL/BMAL1-mediated transcription, including their own tran-
scription (Takahashi et al., 2008; Mohawk et al., 2012). Rev-erbα is another E-box clock gene 
that is under direct control of the CLOCK/BMAL1 complex, and plays an additional role in 
the circadian system to reinforce the strength of the primary negative feedback loop-driven 
oscillation (Preitner et al., 2002; Lowery et al., 2004). CLOCK/BMAL1 also drives transcrip-
tion of so the called Clock Controlled Genes (CCGs), comprising at least 10% of the genome 
(Miller et al., 2007). Rhythmic expression of the CCGs brings rhythmicity to many metabolic 
and physiological events, including cell proliferation (Fu et al., 2013). Dividing cells copy 
their genome during S phase, and divide the genome into two daughter cells during mitosis 
(M phase). These two phases are separated by two gap phases (G1, and G2). During the G1 
and G2 phases cells are prepared for the next step by cell growth, protein synthesis, and DNA 
repair (Norbury et al.,1992). Different cell cycle stages are triggered by a timed oscillation in 
the abundance of the important cell cycle regulatory molecules (Tyson et al., 2008).
 Circadian control of cell proliferation has been shown in different studies. For instance, 
studies in human oral mucosa and skin have shown circadian rhythmicity in M and G1 phases 
of the cell cycle (Bjarnason et al., 2001). Bjarnason and co-workers analysed the correlation 
between rhythmic expression of clock genes and cell cycle markers in human oral mucosa 
and skin biopsies over the period of 24 hours. The highest level of Per1 mRNA was in the 
morning, and coincided with the peak expression of P53 as a G1 marker. In contrast, Bmal1 
transcript reached its highest expression at night, showing synchrony with the peak expres-
sion of CyclinB1, a marker of G2 and M phase. Rhythmicity in DNA synthesis and mitosis 
has been also demonstrated in epidermis, spleen, gastro-intestinal tract, and skin of rodent 
(Scheving., et al 1959; Burns et al., 1976; Scheving et al., 1983; Lévi et al., 2007). Moreover, 
in unicellular organisms, the circadian clock acts as an extra check point for mitosis, that only 
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allows the cells to divide at a specific time of the day (Mori et al., 2000). 
 Recent single cell studies on mouse fibroblast cell lines addressed the influence of the clock 
on the dynamics of the cell cycle (and vice versa) (Feillet et al., 2015; Bieler et al., 2014). By 
using the NIH3T3 cell line expressing a fluorescent clock reporter alone (Bieler et al., 2014) 
or in combination with two cell cycle markers (Feillet et al., 2014), dynamic interactions 
between the circadian clock and the cell cycle have been addressed. Both studies showed a 
robust coupling between the circadian clock and cell cycle with a ratio of 1:1 between their 
respective periods and mitosis always occurring at the same circadian clock phase. Feillet 
and co-workers proposed a bidirectional coupling between these two oscillators. Altering 
the cell cycle length, by changing the FBS concentration, impacted on the circadian period 
accordingly. Similarly, resetting the circadian clock, by the use of the clock synchronizer 
dexamethasone, clustered mitosis (Feillet et al., 2015). Considering the bi-directional inter-
actions between the circadian oscillator and the cell cycle machinery in healthy cells, it may 
well be that this link is disrupted in the cancer cells. 
 Chemotherapy is often making use of cytotoxic drugs in conjugation with radiation therapy 
targeting dividing cells (Fu et al., 2013). These anti-cancer drugs do not discriminate between 
active growing host cells and tumor cells. Therefore, chemotherapy is always associated with 
some toxicity and side effects for the healthy cells. Thus, one of the challenges is to protect 
the host tissue and specifically target the malignant cells. Biological processes such as drug 
metabolism and cell proliferation follow a circadian rhythm (Philip et al., 2011; Levi et al., 
2007). As a result, efficiency and toxicity of several anticancer drugs differs based on the 
time of drug administration during the day (Dallmann et al., 2016). On the other hand, dedif-
ferentiated cells or fast growing cells often show different circadian rhythmicity, dampened 
amplitude, phase shifts and altered clock gene expression (Mormont et al., 1997; Fu et al., 
2013).  Chronotherapy is benefiting from the differences in circadian physiology between the 
host and cancer tissues in order to optimize the anti-cancer treatment, by reducing the toxic-
ity of the treatment for the host cells and increasing the efficiency for the cancer cells (Levi 
et al., 2007).  Gaining knowledge about the circadian clock and cell cycle coupling state in 
metastatic and fast growing cancer cells compared to host tissues may help us to strengthen 
the effect of chronotherapy.
 In this study, we introduced a fluorescent clock reporter (Rev-Erbα-VNP) into a p53 mutant 
mouse breast carcinoma cell line and studied the circadian clock and cell cycle progression 
using live single cell imaging. Our data for the first time show un-coupling between the cir-
cadian clock and cell cycle in a cell line. 
 | Materials and Methods
Cell culture 
 NIH3T33C cells, containing the Rev-Erbα-VNP clock reporter and FUCCI hCdt1-mKOrange 
and hGeminin-CFP FUCCI cell cycle reporter genes (Feillet et al., 2015), were cultured in 
101
4
Dulbecco’s Modified Eagle’s Medium (DMEM)/F10 (Lonza), containing 10% Fetal Bovine 
Serum (FBS) (Gibco), 100 U/ml Penicillin and 100 µg/ml Streptomycin (pH7.7) in a stan-
dard humidified incubator at 37°C and 5% CO2). MBC-399 cells were cultured in DMEM/
F12 GlutaMAX™ (Gibco), containing 10% FBS (Gibco), 100 U/ml Penicillin and 100 
µg/ml Streptomycin, 5 μg/ml insulin (Sigma), 5 ng/ml EGF (Invitrogen), 5 ng/ml cholera 
toxin (Sigma) (pH 7.7), in a standard humidified incubator at 37°C and 5% CO2. 
 To stably introduce a fluorescent circadian clock reporter, MBC-399 cells were seeded at 
70% confluency and transfected with the Rev-Erbα-VNP construct (Nagoshi et al., 2004; 
kindly provided by Dr. Ueli Schibler; 1 µg per 6 well plate) and pcDNA3-neomycin (Invitro-
gen 200 ng per 6 well plate) using fuGENE transfection reagent (Roche) according to user’s 
manual. Neomycin resistant clones were selected and kept for 2 weeks on 200 µg/ml G418. 
Time-lapse Fluorescence Microscopy 
 For time-lapse imaging of circadian clock performance, cells were grown on glass bottom 
dishes and placed in the temperature (37°C), CO2 (5%) and humidity controlled chamber of 
a live cell imaging Zeiss LSM510/Axiovert 200M confocal microscope, equipped with a 
10x Ph objective. Images were recorded every 30 min for at least 72 hours using a Coolsnap 
HQ/Andor Neo sCMOS camera. Live cell imaging was conducted using the following pa-
rameters (as set up in Zeiss 200 software): Venus (yellow): 1000 ms (filter cube: Ex= 475/40 
nm, DM= 500 nm, Em= 530/50 nm). Acquired images were concatenated and merged into a 
single file to generate a movie which was used for further analysis. Single cell numerical time 
series for the VNP fluorescent marker were generated using the LineageTracker plugin for 
ImageJ (https://github.com/pkrusche/lineagetracker.jsonexport). Time series were analyzed 
for circadian clock period. The clock period is defined as the mean intervals between the two 
peaks of Rev-Erbα-VNP.  
Real time bioluminescence monitoring 
 In order to monitor the circadian clock rhythm, 2x105 MBC399 cells were plated in ø35mm 
CELLSTAR® Tissue Culture dishes (Greiner Bio-One). Cells were transiently transfected 
with 1 µg Bmal1::luciferase reporter and 4 µl of X-tremeGene HP DNA Transfection Re-
agent (Roche Life Sciences) per dish, and grown to confluency at 37˚C and 5% CO2. Conflu-
ent cells were circadian clock synchronized for one hour with 100 nM dexamethasone (Sig-
ma). After one hour, the medium was replaced with medium buffered with 25mM HEPES 
(Lonza) and containing 0.1 mM luciferine (Caliper Life Sciences). The bioluminescence 
signal was monitored for 7 days (60 sec measurements at 10 min intervals) in a standard dry 
incubator using a LumiCycle 32-channel automated luminometer (Actimetrics), placed in a 
dry incubator at 37 °C. Prior to placing dishes in the LumiCycle, the lid was replaced by a 
glass coverslip and sealed with parafilm. The data were extracted using Actimetrics software 
and analyzed using Microsoft Excel. 
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Quantitative real time PCR 
 To analyze circadian clock gene expression, MBC 399 cells were seeded in triplicate in 
6 well plates and grown to confluency, after which cellular clock were synchronized with 
a 1-hour pulse of 100 nM dexamethasone (Sigma). Cells were harvested at 24, 28, 32, 36, 
40, and 44 hours after synchronization. Total RNA was isolated using TRIzol reagent (Life 
Technologies, Carlsbad, CA, USA) following manufacturer’s protocol and first strand cDNA 
was synthesized using iScript cDNA Synthesis Kit (Bio-Rad) according to the manufactur-
er’s protocol.
 qPCR was performed in 384-well plates using iQ SYBR® Green Supermix (Bio-Rad) ac-
cording to the manufacturer’s protocol, using the following forward and reverse primers: 
Rev-erbα: Fwd 5’-ACC TTA CTG CTC AGT GCC TGG AAT-3’ and Rev 5’-TGG ACC TTG 
ACA CAA ACT GGA GGT-3’. Bmal1: Fwd 5’-GAC ATA GGA CAC CTC GCA GA-3’ and 
Rev 5’-GCC TTC CAG GAC ATT GGC TAA-3’. Cry1: Fwd 5’-CTC CAG CGG AAA CGA 
GAA CTG-3’ and Rev 5’-GCT GTC CCC GAA TCA CAA ACA -3’. Per2: Fwd 5’-AGG 
ATC TTG ATG CCA ATC TAC GA-3’ and Rev 5’-TTG GCA GAC TGC TCA CTA CTG-3’. 
B2M: Fwd 5’-ACC GGC CTG TAT GCT ATC CAG AAA-3’ and Rev 5’- ATT TCA ATG 
TGA GGC GGG TGG AAC-3’.
 All samples were analyzed in quadruplicate. Expression levels were normalized to the 
housekeeping gene beta-2-microglobulin (B2M) and plotted relative to the first time point. 
Relative gene expression was calculated using the comparative C(t) method described by 
Livak et al 2001. 
Statistical analysis
 For single cell studies, after performing the normality test, the two-tailed Mann-Whitney 
test was used to analyze the period of the circadian clock and of the cell cycle. Statistical 
analysis of circadian gene expression was performed using CircWave (R. Hut, University of 
Groningen).
 | Results 
Clock performance in MBC399 cells
 To study interactions between the circadian clock and the cell cycle in cancer cells, we used 
a mouse breast carcinoma cell line (MBC399) derived from a tumor obtained from a mamma-
ry epithelial cell specific p53R270H/+ mouse (Wijnhoven et al., 2005; Van Dycke et al., 2015). 
First, we examined the circadian properties of the MBC399 cell line. To this end, MBC399 
cells were transiently transfected with a Bmal1 promoter-driven luciferase reporter construct 
(Bmal1::Luc), and bioluminescence was monitored in real time in clock synchronized cell 
cultures. As shown in Fig. 1A, MBC399 cells show robust bioluminescence rhythms with a 
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circadian period of 23.08 ± 0.11 hours, which well matches with that of established normal 
mouse cell lines such as NIH3T3.  
Figure 1. Circadian clock performance of MBC399 breast carcinoma cells. (A)
Representative example of bioluminescence rhythms in clock synchronized confluent 
cultures of Bmal1::Luc transfected MBC399 cells. The Y-axis represents the baseline 
corrected oscillations in bioluminescence. The X-axis represents the time after 
synchronization. т = 23.08 ± 0.11 hours (period of the oscillation; n=4). (B) Relative gene 
expression of the clock genes Cry1, Rev-erbα and Per2 over a period of 20 hours, starting 
24 hour after clock synchronization. The line represents the fitted curve generated by 
CircWave, the dots represent the individual samples (n=3 per time point).
To analyze endogenous circadian clock gene expression, confluent MBC399 cell cultures 
were clock synchronized with dexamethasone, and total RNA was isolated 24, 28, 32, 36, 40, 
and 44 hours after synchronization. As shown in Fig. 1B, a significant circadian oscillation in 
gene expression of core clock genes has been observed (Cry1 p=0.022, Rev-erbα p=0.0043, 
and Per2 p=0.0045). Taken together, these data demonstrate that MBC399 cells contain a 
functional circadian oscillator that responds normally to clock synchronizing chemical cues. 
The circadian clock-cell cycle coupling is lost in the MBC399 breast can-
cer cells
 To follow the kinetics of the circadian clock in individual cells by live cell imaging, we 
stably introduced the fluorescent REV-Erbα-VNP reporter (previously described by Nagoshi 
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et al., 2004) in MBC399 cells and compared clock performance with that of NIH3T33C nor-
mal mouse fibroblasts previously generated in our lab (Feillet et al., 2014). Likewise, we 
followed cell division by phase contrast microscopy (as described by Nagoshi et al., 2004).
 Fig. 2A shows time lapse fluorescence and phase contrast images of a representative single 
NIH3T33C cell, spanning one complete circadian cycle. In line with our previous observa-
tions, REV-ERBα-VNP fluorescence shows a robust oscillation, with mitosis (indicated by a 
red arrow) occurring consistently at the trough level of REV-ERBα-VNP expression, indic-
ative for 1:1 phase coupling of the circadian clock and cell cycle (Fig. 2B). Consistent with 
circadian clock-cell cycle phase coupling, subsequent analysis of the circadian clock period 
(calculated from the interval between two peaks of Rev-ERBα-VNP) and cell cycle period 
(as calculated from the interval between two mitotic events) revealed statistically similar 
(p=0.4) cycle lengths of 17.6 ± 2.2 h (mean ± SD; Fig. 1C Lower panel) for the circadian 
clock and 17.1 ± 1.9 h (mean ± SD; Fig. 2C upper panel) for the cell cycle.
 Next, we repeated this analysis for proliferating MBC399 cells. Fig. 2D shows a represen-
tative example of time lapse images of a single MBC399 cell, spanning a complete circadian 
cycle. Interestingly, and in marked contrast to NIH3T33C cells, mitosis in MBC399 cells 
occurs randomly and independent of the circadian phase (Fig. 2E). Moreover, whereas the 
mean cell cycle period of proliferating MBC399 cells is 15.9 ± 2.1 h (mean ± SD; Fig. 1F 
upper panel), we observed a significantly longer (p<0.0001) clock period spanning 25.8 ± 
3.1 h (mean ± SD; Fig. 2F lower panel). The circadian period of proliferating MBC399 cells 
is similar to that of confluent MBC399 cells (23.08 ± 0.11). These findings suggest that the 
circadian clock in proliferating MBC399 cancer cells is free-running and that the circadian 
clock and cell cycle are no longer phase coupled.
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Figure 2. Circadian clock and cell cycle dynamics of MBC399 carcinoma cells. (A) 
Representative example of time series images of the nucleus of a proliferating NIH3T33C 
cell, stably expressing the circadian clock reporter (Rev-Erbα-VNP; yellow). Shown are 
images at 1.5 hour time intervals over a 18 h period, spanning one circadian cycle. The 
white arrows represent cytokinesis. (B) Representative example of fluorescence rhythms 
of Rev-Erba-VNP expression (NIH3T33C) during a period of 96 hours. Cell division is 
marked by the red arrows. (C) Frequency graph, showing cell cycle period (upper panel) 
and clock period (lower panel) of individual NIH3T3 cells (n=40). Mean and standard 
deviation are shown. (D) Representative example of time series images of the nucleus of 
a proliferating MBC399 cell, stably expressing the fluorescent circadian clock reporter 
Rev-Erbα-VNP (yellow). Shown are images at 2 hour time intervals over a 30 h period, 
spanning one circadian cycle. The white arrows represent cell division. (E) Representative 
examples (3 different cells) of fluorescence intensities of the Rev-Erbα-VNP signal 
(MBC399) during a period of 96 hours. Cell division is marked by the red arrows. (F) 
Frequency graph, showing cell cycle period (upper panel) and clock period (lower panel) 
of individual MBC399 cells (n=25). 
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 | Discussion 
 In this study, we have analyzed the relation between the circadian clock and cell cycle in 
the p53R270H/+ mutant mouse breast carcinoma cell line MBC399 and observed that whereas 
the cell cycle period of MBC399 cancer is in the same range as that of proliferating normal 
NIH3T33C fibroblasts, the circadian period is significantly higher. In proliferating NIH3T33C 
cells, the circadian clock and the cell cycle are phase coupled at a 1:1 ratio, and accordingly 
synchronously oscillate with a period of approximately 17 hours. We have recently obtained 
first evidence that upon reaching confluency, the period of circadian oscillations in NIH3T33C 
cells shifts to a free-running period close to 24 hours. This finding strongly suggests that the 
cell cycle can synchronize the circadian clock of cells in proliferating state. The circadian 
period of proliferating MBC399 cells, however, does not follow the cell cycle period and 
in fact resembles that of confluent cells. Moreover, mitosis in proliferating MBC399 cells 
occurs independent of the circadian phase. To our knowledge, this is the first example of a 
cell line in which clock and cell cycle systems are uncoupled and free-running. Importantly, 
further research involving other cell lines of the MBC mouse breast cancer cell panel, as well 
as other rodent and human tumor cell lines, should provide insight in whether the circadian 
clock - cell cycle uncoupling occurred incidentally, or is a common feature of cancer cells.
 The obvious question arising is which key molecules mediate the coupling of these two 
intracellular oscillators. So far, the P53 tumor suppressor protein is the only identified cell 
cycle molecule that has mutual influences on both clock and cell cycle systems (Miki et al., 
2013). As tumorigenesis in the p53R270H/+ mouse model likely requires loss of the wild type 
p53 allele (Olive et al., 2004; Wijnhoven et al., 2005) it would be interesting to correct the 
MBC399 cell line with a wild type p53 allele and investigate whether this would restore the 
coupling between the clock and cell cycle. We found that the cellular clock-cell cycle cou-
pling is intact in a P53 mutant human lung carcinoma cell line (H1299) (data is not shown). 
This indicates that P53 deficiency alone does not lead to loss of coupling. Genome and tran-
scriptome analysis of proliferating MBC399 cells could be an effective way to identify key 
candidate coupling proteins and for uncovering the underlying mechanism behind the clock 
- cell cycle coupling. 
 Drugs used in cancer therapy often target specific cell cycle phases (Lévi et al.,2007). For 
instance, chemotherapeutic drugs such as 5-fluorouracil act on S-phase cells, whereas other 
drugs such as taxanes exert their highest toxicity on M-phase cells. The 24-hour rhythmicity 
in cell proliferation allowed the development of new cancer chemotherapeutic approaches 
which focus on the determination of the best treatment time (Levi et al.,2007). Extending the 
current knowledge of the circadian clock-cell cycle coupling mechanism in cancer cells will 
enable the development of new chronotherapuetic approaches in which the clock-cell cycle 
coupling in the normal tissue is used to predict the optimal time of treatment. For example, 
by choosing a time window in which normal cells are less sensitive to the treatment, while 
malignant cells undergo random cell division independent of the circadian phase. Our finding 
that in cancer cells the circadian clock and cell cycle can be uncoupled has shed new light on 
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the interplay between these two systems in cancer cells and may facilitate further improve-
ment of cancer treatment.
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The circadian clock is an internal time-keeping system that generates near 
24-hour rhythms in the physiology, metabolism and behavior of most or-
ganisms. At the cellular level, circadian rhythms are generated by a molec-
ular oscillator, composed of clock genes and proteins, that act in transcrip-
tion/translation based feedback loops. Several epidemiological and animal 
studies have demonstrated that disruption of the circadian system increas-
es cancer risk and accelerates tumor progression. Furthermore, we have 
recently shown in a murine cell line that the positive (Bmal1 and Clock) 
and negative (Cry1 and Cry2) limb of the circadian oscillator differentially 
affect cell cycle length, and could therefore have opposite influence on 
cancer development. In the present study we have used the human small 
lung carcinoma cell line H1299 to investigate the impact of the circadian 
clock on cancer cell properties. To this end, we generated stable knock-
down cell lines for the BMAL1 and CRY genes and performed transcrip-
tomics analysis. We subsequently measured cancer cell hallmarks such as 
proliferation rate, migration, invasion and tumor growth, all of which were 
altered according to the transcriptomics data. Our results demonstrate that 
clock genes BMAL1 and CRY are involved in determining the proliferative 
capacity, cell migration and invasiveness of H1299 cells, and differentially 
regulate their tumor forming ability. A comparison with literature reveals 
that the impact of clock gene function on cancer properties could well be 
tumor cell specific and may vary with the spectrum of mutations in cell 
cycle and DNA damage response genes. Importantly, our data show that 
comparative transcriptome profiling is a good measure of the in vivo tum-
origenic properties of cancer cell lines. 
|  Abstract
115
5
 | Introduction
As a consequence of the earth’s rotation around its own axis, most forms of life are exposed 
to recurring light/dark and temperature changes (Dunlap et al., 1999). To anticipate to these 
daily environmental cycles, most organisms have developed an internal circadian clock with 
a near (circa) 24-hour (dies) periodicity that adjusts behavior, physiology and metabolism 
(e.g. body temperature, sleep-wake cycle, blood pressure, hormone secretion) to the needs 
across the day (Albrecht et al., 2003; Pittendrigh et al., 2003). In mammals, the circadian 
system is composed of a master clock in the neurons of the suprachiasmatic nuclei (SCN) 
in the anterior hypothalamus, and peripheral clocks in virtually all other cells and tissues. 
To keep synchrony with the light-dark cycle, the SCN clock is daily reset by light. In turn, 
the SCN synchronizes the peripheral clocks through neuronal connections and through the 
release of humoral factors (Reppert et al., 2002, Weaver et al., 1998, Welsh et al., 2010). 
Besides peripheral tissues, cells in culture also exhibit circadian rhythms (Yoo et al., 2004, 
Balsalobre et al., 1998). 
 At the molecular level, circadian rhythms are generated by a self-sustained oscillator com-
posed of clock genes and proteins. The circadian oscillator consists of positive and neg-
ative transcription translation feedback loops (TTFL) that are rhythmically activated and 
repressed to maintain a 24-hour periodicity. The heterodimeric bHLH-PAS transcription fac-
tors CLOCK and BMAL1 drive the transcription of E-box promoter containing target genes 
such as the Period (PER) 1 and 2 and Cryptochrome (CRY) 1 and 2 genes and the REV-ER-
Bα gene. In the negative loop, the PER and CRY proteins form a heterodimeric complex 
that translocates to the nucleus and represses CLOCK/BMAL1-driven transcription, thereby 
inhibiting their own expression (Reppert et al., 2001; Ko et al., 2006). In the positive feed-
back loop, the REV-ERBα protein rhythmically inhibits RORα-mediated transcription of the 
BMAL1 gene, thereby conferring robustness to the molecular oscillator (Preitner et al., 2002; 
Sato et al., 2004). Central and peripheral oscillators are composed of the same set of clock 
genes and proteins (Yagita et al., 2001).
 Several studies have shown that approximately 10% of all genes are under circadian regu-
lation (Panda et al., 2002, Storch et al., 2002). Such clock controlled genes (CCGs) are tis-
sue-specific and couple circadian output processes to defined stages of the day. Interestingly, 
among the CCGs are genes involved in cell-cycle regulation and cell growth. Moreover, it 
has been proposed that the circadian system can act as a gatekeeper of cell cycle progression, 
as illustrated by the synchronization of cell divisions in epithelial tissues (Matsuo et al., 2003; 
Miller et al., 2007; Bjarnason et al., 2000; Feillet et al., 2014; Bieler et al., 2014).
 Since loss of cell cycle control is the hallmark of a cancer cell, and given the intimate link 
between the circadian clock and the cell cycle, it is not surprising that genetic or environmen-
tal disturbance of the circadian system promotes carcinogenic events. Several epidemiolog-
ical studies have shown that chronic disruption of the human circadian clock by shift work 
increases cancer incidence and negatively affects the prognosis of cancer patients (Hansen 
et al., 2006). Moreover, mutations in the core circadian clock genes PER1 and PER2 have 
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been identified in human breast and colon cancer (Sjöblam et al., 2006., Winter et al., 2007). 
Furthermore, several animal studies have demonstrated a link between disturbed circadian 
rhythmicity and enhanced tumor proliferation. Mice with a complete ablation of the SCN 
demonstrated not only a loss of rhythmic locomotor activity in constant darkness, but under 
these conditions also exhibit accelerated growth of implanted tumors (Filipski et al., 2002, 
2003). Likewise, when chronically exposed to jet lag conditions, wild type mice exhibit ac-
celerated tumor growth compared to mice kept in regular LD cycles (Filipski et al., 2004; Van 
Dycke et al., 2015). At the genetic level, mice lacking the Per1, Per2, Cry1/Cry2 or Bmal1, 
demonstrated to be cancer prone after exposure to a single sub lethal dose of γ-radiation 
(Lee te al., 2010., Fu et al., 2002). The PER1 and PER2 proteins are also known to possess a 
tumor suppressor function by regulating cell-cycle genes that activate DNA damage check-
points (Fu et al., 2002., Yang et al., 2009., Hua et al., 2006). A recent study contradicts this 
finding (Antoch et al., 2013), suggesting that the role of clock genes in cancer properties is 
not straightforward.
 The involvement of the core clock genes in tumor progression is still poorly understood. 
In the present study, we investigated the impact of RNAi mediated clock gene knockdown 
in the well characterized human lung carcinoma cell line H1299. We focused on BMAL1 
and CRY which are the dominant elements of the positive and negative limb of the circadi-
an oscillator, respectively, and which we have shown to have opposite effects on cell cycle 
length (Farshadi et al., submitted for publication; Farshadi et al., manuscript in preparation). 
The initial step was to compare transcriptomics profiles by RNA sequencing. Significantly 
affected processes were further analyzed in vitro, notably proliferation rate, cell migration 
and invasiveness. Capacity of the knockdown cell lines to form tumors in vivo was analyzed 
using a xenograft model. Our data demonstrate that the core circadian clock genes BMAL1 
and CRY1/2 have a significant effect on cancer progression. These findings may ultimately 
contribute to improving treatment of this type of lung cancer.
 | Materials and Methods
Cell culture
 The human non-small-lung adenocarcinoma cell line H1299 was obtained from the Amer-
ican Type Culture Cell Collection (ATCC). The H1299 cell line was cultured in RPMI 1640 
(Gibco) containing 10% fetal bovine serum (FBS) (Gibco) and 100 U/ml penicillin/strepto-
mycin (Gibco) under the condition of 5% C02 at 37°C. 
shRNA transfection
 Initially, the H1299 cell line was transduced with a lentiviral construct expressing the firefly 
luciferase from the mouse Per2 promoter (Oklejewicz et al., 2008) to obtain a stable cell line. 
that allows real time recording of circadian oscillations.
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In order to obtain a stable knock-down of clock genes, the Per2::Luc H1299 cell line 
was plated in a 24-well plate and grown to 50% confluency. Subsequently, the cells were 
transfected with pLKO.1-pura vectors (Sigma) expressing shRNA targeting BMAL1 
(TRCN0000095054), CRY1 (TRCN0000011304), CRY2 (TRCN0000078302), or a control 
non-targeting hairpin (SHC002). Cells were kept under puromycin selection for 2 weeks in 
order to obtain stable cell lines with inactivated core clock genes.
Real-time bioluminescence monitoring
 In order to monitor circadian core clock performance, H1299 cells were cultured in RPMI 
1640 medium buffered with 25 mM HEPES (Gibco) containing 0.1 mM luciferin (Sigma). 
After synchronization of intracellular clocks by treatment of confluent cultures with forskolin 
(Sigma) (dissolved in 100% ethanol, added to the culture medium at a final concentration 
of 10 µM, bioluminescence was recorded for 6 days (75 sec measurements at 10 min inter-
vals) with a LumiCycle 32-channel automated luminometer (Actimetrics) placed in a dry, 
temperature-controlled incubator at 37°C. Data was analyzed with the Actimetrics software. 
RNA isolation and quantitative PCR
 Total RNA was isolated from cultured cells in triplicate using TRIzol (Invitrogen) following 
manufacturer’s instructions. First-strand cDNA was synthesized from 1 mg of total RNA 
using oligo (dT) primers and SuperScript reverse transcriptase (Invitrogen) according to the 
manufacturer’s protocol. Quantitative PCR amplification was performed using the iCycler 
iQ™ Real-Time PCR Detection System (BioRad), with SYBR-green and primer sets gen-
erating intron-spanning products of 150-300 bp. The following forward and reverse primers 
were used: CRY1: 5’-AGC TTT CAC GAT ATA GAG GAC-3’ and 5’-CTT GAG AGC AAC 
TTC CAC TG-3’; CRY2: 5’-GGA CTA CAT CAG GCG ATA CC-3’ and 5’-CTG GTA AAT 
CTG CTT CAT TCG T-3’; BMAL1: 5’-TCT TCT ATT CTT GGT GAG AAC CC-3’ and 5’-
TCC TTA TCC AGT AAG CTT CAC AG-3’; CLOCK: 5’-TTC CCT CAG TCA CAT CAC 
CAG CAA-3’ and 5’-TGC TGG AAC TTT CCC TCC TTT CCT-3’; PER1: 5’-ATG ACC 
TCT GTG CTG AAG CAG GAT-3’ and 5’-TCC ACA CAG GCC ATC ACA TCA AGA-
3’; PER2: 5’-TGA GAA GAA AGC TGT CCC TGC CAT-3’ and 5’-GAC GTT TGC TGG 
GAA CTC GCA TTT-3’; β2M: 5’-CTC TTG TAC TAC ACT GAA TTC A-3’ and 5’-CCT 
CCA TGA TGC TGC TTA CA-3’; HPRT: 5’-TGG AGT CCT ATT GAC ATC GCC AGT-
3’ and 5’-AAC AAC AAT CCG CCC AAA GGG AAC-3’; GAPDH: 5’-AAG GTG AAG 
GTC GGA GTC AA-3’ and 5’- ACC ATG TAG TTG AGG TCA ATG-3’. The generation 
of specific products was confirmed by melting curve analysis, and primer pairs were tested 
with a logarithmic dilution of a cDNA mix to generate a linear standard curve, which was 
used to calculate primer pair efficiencies. Expression levels were normalized to hypoxan-
thine guanine phosphoribosyl transferase (HPRT), β2 microglobulin (β2M) and Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) mRNA levels. 
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Western Blot analysis
 Whole cell extracts from H1299 core clock gene knockdown and control lines were ob-
tained by lysing the cells with NP40 lysis buffer (1% Triton, 50 mM Tris-HCl pH8, 150 
mM NaCl). Protein content was determined with the BCA Protein Assay Reagent (Thermo 
Scientific). Proteins were separated on a 4-12 gradient polyacryl amide gel (Invitrogen) and 
transferred to a nitrocellulose membrane (Schleicher and Schuell). Following incubation 
with blocking buffer (3% non-fat milk and 1% BSA) at RT for 2 hours, the membranes were 
incubated overnight with primary antibodies (1:1000 dilution) against core clock proteins 
at 4°C. After incubation with the secondary antibody (1:1000 dilution), bands were visual-
ized using the ECL detection kit (Amersham) following the manufacturer’s instructions. The 
bands were analyzed by Image Quant analysis software, using actin as a loading control. Pri-
mary antibodies against actin (sc10231), BMAL1 (sc48790), CRY1 (sc101006), and CRY2 
(sc130731) were purchased from Santa Cruz Biotechnology Inc.
Transcriptomics analysis
 To analyze circadian gene expression in the H1299 cell lines, cells were seeded in 35 mm 
dishes at a density of 2 x 105 cells and were harvested in log phase. RNA was isolated and 
purified with the NucleoSpin kit (Machery-Nagel) according to the manufacturer’s protocol. 
Prior to processing samples for RNA Seq analysis, the quality of the experiment (i.e. syn-
chronization) was confirmed by qPCR analysis of clock and clock-controlled gene expres-
sion as described above. For RNA sequencing, quality control and sequencing was performed 
at ServiceXS (Leiden, The Netherlands). FPKM values (FPKM + value1: a value of “1” was 
added to each value) were imported into OmniViz version 6.1.13.0 (Instem Scientific, Inc., 
UK). For each gene, the geometric mean of the value for all samples was calculated. The 
level of expression of a gene was determined relative to this geometric mean and log2-trans-
formed. The geometric mean of the counts of all samples was used to ascribe equal weight to 
gene expression levels with similar relative distances to the geometric mean. Unsupervised 
cluster analyses was performed in Omniviz using Pearson’s correlation in the Correlation 
View. Supervised analysis was done using statistical analysis of microarrays (SAM) to iden-
tify differentially expressed genes (DEG). Cutoff values for significantly expressed genes 
were a false discovery rate (FDR) of 0.05 or less and absolute fold change of 1.5. Functional 
annotation of the DEG was done using Ingenuity Pathway Analysis (Ingenuity, Mountain 
View, CA)
Proliferation, cell migration and cell invasion assays
 To determine the proliferation rate of the H1299 core clock gene knockdown and control 
lines, 1x103 cells were seeded in a 96-well plate. The cell growth was measured daily using 
the WST-1 assay (Roche) following the manufacturer’s instructions. Assays were performed 
in triplicate.
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 In addition, we determined the cell cycle phase distribution over a 48 hour period after seed-
ing 2x105 cells. Cells were harvested at indicated time-points, washed with PBS and fixed 
with 70% ethanol. The fixed cells were washed with PBS and incubated with PBS containing 
100 μg/ml RNase and 50 μg/mg propidium iodide (Sigma) for 30 min at 37°C. The cells were 
analyzed by a Becton Dickinson FACScan Flow Cytometer. The flow cytometry data were 
analyzed in FlowJo.
 Cell migration and invasion were assayed in real time mode using the xCELLigence DP 
system (Roche diagnostics), in a 37°C incubator at 5% C02. For the migration assay, 5x104 
cells were seeded in the upper chamber containing RPMI 1640 medium without FBS. The 
lower chamber was filled with 160 µl RPMI 1640 medium containing 10% FBS as attractant. 
Cell migration of was monitored in real time for 30-hours. For the invasion assay, the upper 
chamber was coated with 0.2 μg/ml matrix gel prior to seeding 5x104 cells. The upper cham-
ber was filled with 160 µl RPMI1640 medium without FBS and the lower chamber was filled 
with 160 µl RPMI1640 medium supplemented with 10% FBS. The invasion was followed in 
real time for 48 hours. 
Tumor xenograft studies
 Male NMRI nude mice (age weeks) were obtained from Harlan and kept under a 12:12 hour 
light-dark cycle with ad libitum access to water and food. Mice were kept at the Animal Re-
source Center (Erasmus University Medical Center), which operates in compliance with the 
European guidelines (European Community 1986) and The Netherlands legislation for the 
protection of animals used for research, including ethical review. Animal studies at Erasmus 
University Medical Center were approved by DEC Consult, an independent Animal Ethical 
Committee (Dutch equivalent of the IACUC) under permit number 139-11-03 (EMC2360).
 At the age of 6 weeks, mice were injected subcutaneously on the flank with 106 cells, sus-
pended in a volume of approximately 200 µl RPMI 1640 medium supplemented with 50% 
FBS (6 animals per knockdown cell line). Tumor growth was monitored weekly and mea-
sured in two dimensions. The tumor size was calculated using the formula V=a2 b/2, were a is 
the shortest and b the longest diameter. As all H1299 knockdown cell lines contained the for 
Per2::Luc reporter, development of metastasis was monitored three times during the experi-
ment with an IVIS Spectrum in vivo imaging device (Caliper Life Sciences).
 Formalin-fixed tumor samples were embedded in paraffin and stained with hematoxylin and 
eosin for general histopathological analysis. Immunohistochemical analysis was performed 
using antiphosphohistone (mitosis marker) and caspase-3 (apoptotic marker) antibodies as 
described (de Bruin et al., 2003; Jiang et al., 2005). 
Statistical analysis
 Data are presented as the mean SEM and the Student’s t-test was used to compare between 
the groups. P-values < 0.05 were considered statistically significant.
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 | Results
Stable shRNA-mediated downregulation of core clock genes in H1299 
lung cancer cells
 Prior to knocking down circadian clock genes, we transduced H1299 cells with a lentiviral 
mouse Per2 promoter-driven luciferase reporter construct and selected a stable clone. This 
allows real time monitoring of clock performance in forskolin synchronized cell cultures. 
 To achieve stable down regulation of core clock genes, the parental Per2::Luc H1299 was 
transduced with shRNA constructs targeting BMAL1, CRY1, CRY2, or CRY1/CRY2. As a con-
trol, we also transduced H1299 cells with a non-targeting shRNA construct. For each shR-
NA construct, independent stable clones were selected for determining the relative mRNA 
expression levels after down regulation of clock genes by quantitative RT-PCR (Suppl. Fig 
S1A-C). Consistent with the reduction of mRNA levels, Western blot analysis of the shRNA 
expressing H1299 clones revealed reduced protein levels for the corresponding knockdown 
(Suppl. Fig. S1D-F). Based on the mRNA and protein levels we selected the two best shRNA 
responsive clones for further analysis. In the remainder of the paper, we show the data for 
clone 1, (similar data were obtained with clone 2 of all clock knockdown H1299 cell lines 
(data not shown)).
 Given the molecular constitution of the circadian oscillator (i.e. interconnected positive 
and negative transcription-translation feedback loops), we also tested the relative expression 
levels of other clock genes in the various H1299 knockdown cell lines. As expected, down 
regulation of the transcription activator gene BMAL1 resulted in a significant reduction of 
PER gene expression levels. However, the relative expression levels of CRY were not sig-
nificantly reduced in the BMAL1 H1299 knockdown cell lines (Suppl. Fig. S2). The relative 
expression level of CLOCK was reduced after shRNA mediated knockdown of either CRY1 
or CRY2 (Suppl. Fig. S2), while relative BMAL1 mRNA levels were slightly increased after 
down regulation of CRY1 or CRY2 (Supp. Fig. S2). In contrast, whereas knockdown of both 
CRY genes resulted in a small increase in the relative expression level of CLOCK, BMAL1 
mRNA levels were markedly elevated. The increased BMAL1 expression levels after knock-
down of the negative components TTFL contradicts previous studies (Shearman et al., 2000; 
Zhang et al., 2009), suggesting that this might depend on the cell type.
 Next, we investigated the circadian performance of the panel of H1299 clock knockdown 
cell lines after treatment of the cell cultures with the clock synchronizing compound forsko-
lin. Whereas the H1299 control cell line (stably expressing a non-targeting control shRNA) 
displayed a robust rhythm with a period of approximately 24.3 hour (Fig. 1A), knockdown 
of BMAL1 attenuated the bioluminescence rhythm (Fig.1B). As expected, down regulation 
of CRY1 or both CRY1 and CRY2 also blunted circadian oscillations (Fig. 1C and E) while, 
somewhat unexpectedly, knockdown of CRY2 had a similar effect (Fig. 1D). In conclusion, 
knockdown of the core clock genes in H1299 lung cancer cells largely recapitulates the cir-
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cadian phenotype of human U2OS osteosarcoma cells after knockdown of the corresponding 
gene(s) (Baggs et al., 2009).
Transcriptomics analysis of clock knock down cell lines 
 To investigate the effect of clock gene knock down on the properties of H1299 cells, gene 
expression analysis was performed on CRY1, CRY2, CRY1/CRY2, and BMAL1 knockdown 
cells. Cells were harvested at log phase, and RNA isolation was performed for next gener-
ation sequencing. This experiment was performed in triplicate for each group of samples. 
Correlation analysis, based on expression of all the genes, shows the highest similarity in 
gene expression patterns between triplicate clusters (Fig. 2A). The high correlation between 
each of the triplicate samples within a group indicates the high quality of the data. CRY2 and 
CRY1/CRY2 knock down cells show the most similarities in the gene expression pattern, 
while the least correlation is seen in the gene expression profiles between these two cell lines 
compared to the rest of the groups (controls, BMAL1 and CRY1 knock down cells). 
 Gene expression levels were determined relative to the geometric mean, and non-significant 
values were excluded from further analysis. The threshold chosen was absolute fold-change 
Figure 1. Clock performance of the H1299 cells after stable knockdown of core clock 
genes. Representative examples of real-time bioluminescence recordings of confluent 
cultures of forskolin synchronized H1299 mPer2::Luc cells, expressing a non-targeting 
shRNA (A), or shRNAs targeting BMAL1 (B), CRY1 (C), CRY2 (D), CRY1/CRY2 (E). The 
Y-axis represents the luminescence value, the X-axis represent time after synchronization 
(days).
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>1.5 and FDR < 0.05, and in total 7081 genes were detected as differentially expressed genes 
(DEGs) in all the groups. Among those, the highest number of DEGs are in CRY1/CRY2 
double knock down group, consisting of 2792 down-regulated genes and 2005 up-regulated 
genes (Fig.2B). OmniViz treescape represents a hierarchical clustering of the DEGs, where 
each row and column corresponds to one individual gene and one individual sample, respec-
tively (Fig.2C). The most different gene expression pattern is observed in the CRY1/CRY2 
cluster versus control, and this difference is mostly coming from CRY2 knock down, indicat-
ing a dominant effect of CRY2 knock down in the CRY1/CRY2 double knock down cell line.
Identification of differentially regulated biological functions and diseas-
es
 Ingenuity pathway analysis (IPA) on differentially expressed genes revealed biological 
functions and diseases that are mostly related to each of the cell lines (Fig. S1-S4). Cancer 
is one of the top diseases and disorders which is significantly affected in all the knock down 
cell lines, indicating the strong involvement of the BMAL1 and CRY in the regulation of the 
Figure 2. Transcriptomics analysis of 
clock knock down cells lines. (A) Plot 
view of the correlation matrix based on 
all genes. Red indicates high correlation 
and blue ndicates low correlation. (B) 
The number of differentially expressed 
genes in each of the cell lines. Red 
represents up-regulated genes and blue 
represents down-regulated genes. (C) 
Heat-map representation of hierarchical 
clustering of differentially expressed 
genes, compared to the geometric mean.
     C
     A  
  B     
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cancer properties of the cells. We have selected the top 10 altered biological functions in each 
of the groups, sorted by the smallest p-value (p<0.05) (Fig. 3A). 
Figure 3. Differentially regulated biological functions and diseases. (A) Top 10 affected 
bio-functions in each of the knockdown cell lines, sorted by the smallest p-value (the most 
significantly altered functions are on top of the list). Commonly affected bio-functions 
are in boldface. The p-value and number of molecules affected in each bio-function are 
indicated. (B) Scatter plot of commonly affected bio-functions in each knock down cell 
line, relative to non-targeting control. The Y-axis represents the activation Z-score for each 
single disorder within a bio-function. Positive Z-scores indicate up-regulation, negative 
Z-scores indicate down-regulation. 
124
Chapter 5
 Among these top 10 pathways, commonly affected functions between all the groups are 
cancer, cellular movement, cellular growth and proliferation, cellular function and mainte-
nance, and cellular assembly, which are high-lighted in Fig. 3A. There are various types of 
disorders that are connected and relevant to each of the above biological functions. Fig. 3B, 
shows the normal distributions from the mean value (z-score) for all these relevant disorders 
in each category of biological function. Positive and negative expression values indicate up- 
and down-regulation of these disorders, respectively. In the category of cancer, the average 
grade for all the Z-scores is negative in the case of BMAL1 knockdown, while the mean 
Z-score values for the other cell lines are positive, with the highest value in the CRY1/CRY2 
double knockdown cells.  These data show that, in general, the trend for cancer development 
in BMAL1 knockdown cells is decreased, while cancer development is increased in CRY1, 
CRY2, and CRY1/CRY2 knockdown cells (Fig. 3B).  Cellular movement is down regulated in 
BMAL1 and CRY2 knock down cells, and unaffected in the case of the CRY1/CRY2 double 
knockdown. However, CRY1 knockdown cells show up regulation of this function. Finally, 
cellular growth and proliferation for all knockdown cell lines show a slight down regulation 
or are unaffected (Fig. 3B).
 Since cellular movement, proliferation, and cancer development are important characteris-
tics of a cancer cell line, we took a closer look at the properties related to these categories of 
biological function (supplementary tables S1-S4). For a better comparison analysis we have 
selected common diseases and disorders in each of the categories of bio-functions, allowing 
to study the trend of change in gene expression profile for a specific disorder which is com-
mon among all the knockdown cell lines (Fig. 4). Interestingly, growth of malignant tumors 
was one of the cancer properties which was commonly and significantly (Zscore >2) affected 
in both CRY1/CRY2 and BMAL1 knockdown cells.  Growth of malignant tumors was mark-
edly increased in CRY double knockdown cells, whereas it was significantly reduced in the 
BMAL1 knockdown condition (Fig. 4). Therefore, tumor growth as well as other properties 
such as cellular movement and proliferation were chosen to further be validated in vitro and 
in vivo studies. 
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Figure 4.  Comparison of affected diseases and disorders. Comparison analysis for 
common relevant diseases and disorders for each category of a bio-function (Cancer, 
Cellular movement, Cellular growth and proliferation). A Z-score of 0 means that the genes 
expression is comparable to the non-targeting control. The higher the absolute Z-score, the 
higher the significance of the genes expression change. Absolute Z-scores above 2 are 
considered significant. 
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Downregulation of core clock genes affects the in vitro tumorigenic 
properties of H1299 cells 
 Genetic defects in, as well as down regulation of core clock genes, have been shown to 
affect the cell proliferation rate in vitro (Antoch et al., 2008; Yang et al., 2008; Sun et al., 
2009; Farshadi et al., submitted for publication; Farshadi et al., manuscript in preparation). 
Furthermore, our transcriptomics data suggest that cellular cancer related properties could 
be affected in the knockdown cell lines. We next examined the proliferation of the H1299 
knockdown cell lines using the colorimetric WST-1 assay. Down regulation of either CRY1, 
CRY2 or both resulted in a significant reduction (p < 0.005) of the proliferative capacity of 
H1299 cells by 28 to 75%, while knockdown of BMAL1 did not have any effect (Fig. 5A). 
In addition, we analyzed the cell cycle distribution of proliferating control and knockdown 
H1299 cells. Within the time window analyzed, non-targeting shRNA expressing control 
H1299 cells accumulate in G2 phase while the percentage of S phase cells is reduced, which 
suggests that cells slowdown proliferation and reach confluency. However, the cell cycle 
phase distribution of all knockdown cell lines remained unaltered (Fig. 5B).
 An important characteristic of a cancer cell is its ability to migrate to and invade surround-
ing tissues. These features should be affected in the knockdown cell lines, as suggested by 
the transcriptomics analysis. We therefore determined the cell migration as well as the inva-
sive properties (Fig. 5C-D) of our H1299 knockdown cell lines in vitro in real time mode, 
using the xCELLigence system. After down-regulation of BMAL1, both cell migration and 
invasion were severely decreased by 80% (p < 0.005). The cell migration capacity was also 
significantly reduced after down regulation of CRY1 or CRY2, and knockdown of both CRY 
genes further slowed down migration and repressed invasion capacity. 
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Figure 5.  In vitro characterization of H1299 cells after knockdown of core clock genes.
(A) Proliferation rate of H1299 cells stably expressing a shRNA targeting BMAL1 , CRY1, 
CRY2, and CRY1/CRY2. Cells (1x103/well) were seeded in quadruplicate in 96-well plates 
on day 0 and cell density was assayed on subsequent days using the colorimetric WST-
1 assay. Blue bars represent the control H1299 cells stably expressing a non-targeting 
shRNA. Data are presented as mean ± SEM (NS = not significant, *** p<0.001; Student’s 
t test). (B) Cell cycle phase distribution of proliferating of H1299 cells stably expressing 
a non-targeting shRNA or shRNAs targeting BMAL1, CRY1, CRY2 or CRY1/CRY2. At 
indicated times cells were collected, stained with propidium iodide, and analyzed by flow 
cytometry. Data (n=3 experiments) are shown as mean ± SEM. (C and D) Cell migration 
and invasion properties of H1299 cells after stable knockdown of core clock genes. 
Representative examples of real-time recordings of cell migration (C) and invasion (D) of 
H1299 cells, stably expressing shRNAs targeting BMAL1, CRY1, CRY2 or CRY1/CRY2. 
Migration and invasion were monitored for 30-hours using the xCELLigence DP system. 
Blue lines represent the control H1299 cells stably expressing a non-targeting shRNA. 
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Down regulation of BMAL1 and CRY differentially affects H1299 tumor 
formation in vivo
 The transcriptomics data of the knockdown cells lines suggests that knocking down BMAL1 
decreases the cancer properties of the H1299 cells, while knocking down CRY appears to 
have the opposite effect. However, the in vitro analysis of the different cell lines suggests 
that knocking down CRY or BMAL1 should have a similar impact on the cancer properties 
of H1299 cells. We next set out to analyze the in vivo tumor formation properties of the 
knock down lines. To determine whether knockdown of core clock genes affects the tumor 
growth in vivo, we inoculated the non-targeting shRNA expressing control H1299 cells and 
core clock gene knockdown H1299 cells in NMRI-nude mice and followed tumor growth. 
Whereas control H1299 cell derived tumors became apparent 7 weeks after inoculation (Fig. 
6), knockdown of BMAL1 suppressed tumor formation, as evident from the absence of pal-
pable tumors 16 weeks after inoculation (Fig. 8, right panel). Knockdown of CRY1, CRY2, or 
both CRY1 and CRY2 did not abolish tumor formation, and tumor growth appeared unaltered 
as compared to the control (non-shRNA expressing) H1299 xenografts (Fig. 6). Importantly, 
down regulation of CRY2 or both CRY1 and CRY2 accelerated tumor appearance by two 
weeks (Fig. 6). As the H1299 cell lines contain the Per2::Luc reporter gene, we also subject-
ed tumor bearing animals to in vivo bioluminescence imaging. Within the time span of the 
experiment, neither of the animals developed detectable metastasis (Suppl. Fig. S3). Tumors 
were analyzed for possible differences in morphology (HE staining), as well as in the ex-
pression of apoptosis and proliferation markers (caspase 3 and phospho-histone H3 staining, 
respectively).  For all parameters tested, CRY1, CRY2 and CRY1/CRY2 knockdown H1299 
cell derived tumors were indistinguishable from control (data not shown). 
 From these data, we conclude that BMAL1, and consequently high expression of E-box 
containing clock controlled genes, is required to maintain in vivo tumor formation properties 
of H1299 cells. Knocking down CRY did not affect the ability of the H1299 cells to form tu-
mors, nor did it affect the growth rate of the tumor. Importantly, knockdown of CRY2 (alone 
or in combination with CRY1) reduced the tumor latency time by 2 weeks. 
Figure  6.  In vivo tumor formation and growth rate of 
H1299 xenograft after knockdown of core clock genes.
Nude mice were inoculated with 106 H1299 cell, 
stably expressing a non-coding shRNA or clock gene 
shRNAs. Animals were screened for the formation 
of tumors (bottom panel) and tumor volume (top 
panel). Data are presented as mean ± SEM (n=4).
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 | Discussion
 The circadian clock and the cell cycle are two fundamental mechanisms that are known to 
interact with each other and influence many biological processes (Feillet et al., 2014, Bieler 
et al., 2014). Disruption of the circadian clock has been shown to deregulate the cell cycle, 
leading to serious consequences such as cancer (Borgs et al., 2009; Lee et al., 2010). Several 
studies performed with circadian clock mutant mouse models and cell lines revealed a link 
between the circadian clock and cancer progression (Fu et al., 2002; Lee et al., 2010; Zheng 
et al., 2010; Van Dycke et al., 2015). However, the underlying mechanism is not fully un-
derstood.
 In this study, we analyzed the transcriptome and systematically investigated the cancer 
properties of H1299 human non-small lung carcinoma cells after stable downregulation of 
the circadian core clock genes BMAL1, CRY1 and CRY2. As expected, downregulation of the 
transcriptional activator BMAL1 abolishes circadian rhythmicity in H1299 cells. In contrast 
to normal cells, where loss of negative limb genes may change period rather than abolish 
rhythms (e.g. Cry2) (Liu et al., 2007), but similar to U2OS osteosarcoma cells (Baggs et 
al., 2009), circadian rhythmicity of H1299 cells is heavily blunted after knockdown of any 
of the CRY. This finding strongly suggests that paralog compensation, a network feature 
that confers robustness to the molecular oscillator (Baggs et al., 2009) is altered in H1299 
cells and that inactivation of a single transcriptional repressor gene is sufficient to demolish 
rhythmicity. 
 We have observed that inactivation of the CRY genes resulted in a reduction of the pro-
liferation rate of H1299 cells, while inactivation of BMAL1 had no effect. Furthermore, 
while in control cells the cell cycle profile changed in time after seeding, no changes were 
observed in the knockdown cell lines. This observation contrasts the transcriptomics data, 
which suggested that cell growth and proliferation was only slightly affected. This could 
mean that, although the knockdown cell lines have a normal proliferation rate, they may have 
an extended lag phase. 
 Studies addressing the effect of clock gene inactivation on proliferation rate have yield-
ed conflicting results. As an example, primary Cry1-/-/Cry2-/- mouse embryonic fibroblasts 
(MEFs) display an increased growth rate (Destici et al., 2011), similar to the effect we ob-
served in CRY deficient NIH3T3 cells (Farshdi et al., manuscript in preparation), while im-
mortalized Cry1-/-/Cry2-/- MEFs fibroblasts proliferate at wild type rate (Gauger and Sancar 
2005). Likewise, primary Bmal1 knockout mouse hepatocytes were reported to grow slower 
(Gréchez-Cassiau et al., 2008), an effect that we recapitulated by knocking down Bmal1 
or Clock in mouse NIH3T3 fibroblasts (Farshadi et al., submitted for publication). How-
ever, downregulation of Bmal1 in murine fibroblasts increases the proliferation rate (Zeng 
et al.,2010). Apparently, the effect of down regulation of the core clock genes on cell pro-
liferation may depend on cell type (e.g. cancer vs normal cells, hepatocytes vs fibroblasts, 
etc.), specific cell characteristics (e.g. status of cell cycle related genes), as well as on gene 
inactivation procedure (e.g. gene knockout, stable shRNA knockdown or transient shRNA or 
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siRNA transfection). 
 The malignancy of tumors not only depends the on growth rate of cancer cells, but also on 
their ability to migrate and invade surrounding tissue to form metastasis. We have shown that 
the cell migration and invasion capacity of H1299 cells was inhibited after down regulation 
of BMAL1, as well as by down regulation of the CRY genes. From the transcriptomics data we 
would expect CRY1 down regulation to increase the migration and invasion capacity, which 
is in contrast with the in vitro data. The ability of the H1299 cell lines to form tumors was 
tested in vivo, but, as no metastasis were observed, we cannot conclude what the effect is of 
BMAL1 or CRY down regulation on the capacity of a tumor to metastasize.
 As described above, changes in the in vitro cell proliferation, migration and invasion proper-
ties of H1299 cells after knockdown of core clock genes did not show a clear correlation with 
the transcriptomics data. In contrast, such correlation was largely observed in in vivo studies 
addressing tumor formation and growth of H1299 core clock gene knockdown cells. While 
knockdown of BMAL1 abolished tumor formation, inhibition of the CRY genes did not affect 
the ability of H1299 cells to form tumors in xenograft studies. Importantly, down regulation 
of CRY2 decreased the latency time of the tumors. We can conclude that, using the H1299 
tumor cell line, high level expression of E-box genes is required for tumor development. This 
is the predicted outcome based on the analysis of the RNA sequencing results, indicating 
that omics-based approaches are valuable tools in determining the tumorigenic potential of 
cancer cell lines and appear more predictive than in vitro phenotyping. 
Concluding remarks
 At least to our knowledge, this is the first study that addresses the relation between circa-
dian core clock genes and cancer properties of a tumor cell line in a systematical manner 
by stable shRNA-mediated gene inactivation and subsequent phenotypical characterization. 
,Transcriptome analysis of a panel of H1299 cell lines revealed how clock genes impact on 
cancer related pathways. We have shown that clock genes BMAL1 and CRY are involved in 
determining the tumor forming ability of the H1299 cells, and that the positive and negative 
circadian elements exert opposite effects . To what extent these findings are applicable to 
other tumor cell lines remains to be investigated, as tumor cell line specific mutations in cell 
cycle and DNA damage response genes may modulate the impact of clock genes. To obtain 
mechanistic insight in how these clock proteins link to the oncogenic properties of cancer 
cells more research is required.
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 | Supplementary information
Figure  S1.  mRNA and protein levels after stable shRNA mediated knockdown of 
core clock genes in H1299 cells. Quantitative RT-PCR (A-C) and western blot analysis 
(D-F) of whole cell lysates of H1299 cells for the presence of BMAL1 (A,D), CRY1 
(B,E), CRY2 (C,F) after stable knockdown of the corresponding mRNA. mRNA levels 
were normalized to GAPDH and expressed relative to the mRNA levels in control (non-
targeting shRNA expressing) H1299 cells. In the western blot analysis, Actin was used as 
a loading control.
Figure S2.  Relative core clock gene mRNA 
levels in H1299 clock gene knockdown cells. 
Quantitative RT-PCR analysis of CRY1, CRY2, 
PER1, PER2, CLOCK, or BMAL1 mRNA 
levels in H1299 cells after stable knockdown 
of circadian core clock genes. mRNA levels 
were normalized to GAPDH and expressed 
relative to the mRNA levels in control (non-
targeting shRNA expressing) H1299 cells. 
Data are presented as mean ± SEM (*p < 
0.05, **p < 0.01, ***p < 0.001; Student’s t test). 
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Figure S3. Visualization of tumors derived from xenografted circadian core 
clock gene knockdown H1299 cells. Nude NMRI mice were inoculated with 106 
H1299 cell, stably expressing a non-coding shRNA or clock gene shRNA. Tumor 
developing mice were non-invasively monitored under isoflurane anesthesia for 
Per2::Luc derived bioluminescence using an IVIS® Spectrum imaging device 
(Caliper/Xenogen). Colors indicate signal intensity. Note the absence of metastasis.
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Cry1 relevant disease and disorders  p-value Molecules
Cellular Movement 4.44E-16-6.1E-04 193
Cancer 1.16E-14-5.95E-04 602
Cellular Development 1.17E-14-5.95E-04 268
Cell Death and Survival 4.25E-14-6.14E-04 275
Tissue Development 5.16E-13-6.1E-04 241
Cellular Growth and Proliferation 6.07E-13-5.95E-04 266
Tumor Morphology 6.07E-13-5.95E-04 104
Cellular Assembly and Organization 2.44E-12-5.9E-04 131
Cellular Function and Maintenance 2.44E-12-5.9E-04 229
Organismal Survival 3.48E-12-1.15E-05 193
Cell Morphology 8.63E-12-5.87E-04 222
Cardiovascular System Development and Function 1.67E-10-6.14E-04 132
Gene Expression 2.49E-10-4.96E-04 167
Organismal Development 4.8E-10-5.95E-04 259
Tissue Morphology 1.07E-09-5.48E-04 219
Cardiovascular Disease 1.37E-09-1.81E-04 148
Neurological Disease 1.97E-09-3.7E-04 174
Gastrointestinal Disease 3.19E-09-1.46E-04 272
Skeletal and Muscular Disorders 3.39E-09-2.79E-04 184
Hereditary Disorder 4.18E-09-4.18E-09 63
Psychological Disorders 4.18E-09-1.85E-08 75
Embryonic Development 5.62E-09-5.95E-04 191
Cell-To-Cell Signaling and Interaction 2.26E-08-6.29E-04 141
Connective Tissue Development and Function 2.73E-08-5.95E-04 115
Organ Development 2.73E-08-5.95E-04 150
Organ Morphology 2.73E-08-6.14E-04 136
Skeletal and Muscular System Development and Function 2.73E-08-6.14E-04 162
Connective Tissue Disorders 3.33E-08-2.26E-04 93
Inflammatory Disease 3.33E-08-3.7E-04 116
Hematological System Development and Function 4.72E-08-5.67E-04 165
Immunological Disease 1.46E-07-3.11E-04 118
Nervous System Development and Function 1.78E-07-5.95E-04 131
Behavior 2.33E-07-5.84E-04 86
Table S1
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Organismal Injury and Abnormalities 4.47E-07-5.95E-04 312
Reproductive System Disease 4.47E-07-3.26E-04 285
Inflammatory Response 9E-07-6.29E-04 138
Immune Cell Trafficking 9.99E-07-5.67E-04 79
Respiratory System Development and Function 2.72E-06-4.75E-04 42
Cell Cycle 5.43E-06-2.1E-04 57
Developmental Disorder 7.5E-06-3.31E-04 130
Organismal Functions 7.59E-06-7.59E-06 21
Endocrine System Development and Function 9.27E-06-5.48E-04 23
Lipid Metabolism 9.27E-06-5.48E-04 66
Small Molecule Biochemistry 9.27E-06-5.48E-04 75
Vitamin and Mineral Metabolism 9.27E-06-1.22E-04 36
Infectious Disease 2.86E-05-2.46E-04 121
Digestive System Development and Function 3.65E-05-1.91E-04 39
Reproductive System Development and Function 3.66E-05-5.95E-04 22
Visual System Development and Function 3.74E-05-4E-04 45
Hematopoiesis 3.9E-05-5.29E-04 85
Hepatic System Disease 4.09E-05-1.46E-04 20
Lymphoid Tissue Structure and Development 5.15E-05-5.09E-04 78
Dermatological Diseases and Conditions 5.17E-05-5.81E-05 17
Renal and Urological Disease 5.29E-05-4.74E-04 64
Hematological Disease 5.81E-05-5.34E-04 15
Respiratory Disease 9.66E-05-4.83E-04 43
Drug Metabolism 1.04E-04-1.04E-04 12
Cellular Compromise 1.46E-04-1.46E-04 6
Renal and Urological System Development and Function 1.46E-04-5.48E-04 33
Carbohydrate Metabolism 2.26E-04-2.26E-04 3
Nutritional Disease 2.31E-04-2.31E-04 38
Cell Signaling 3.65E-04-5.61E-04 54
Amino Acid Metabolism 4E-04-4E-04 7
Molecular Transport 4E-04-4E-04 7
Post-Translational Modification 4.22E-04-4.22E-04 53
Cell-mediated Immune Response 5.09E-04-5.09E-04 40
DNA Replication, Recombination, and Repair 5.62E-04-5.62E-04 34
Ophthalmic Disease 6.24E-04-6.24E-04 8
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Table S2
Cry2 relevant disease and function  p-value Molecules
Cancer 3.22E-22-2.87E-04 1516
Cellular Movement 6.89E-19-3.18E-04 418
Cellular Growth and Proliferation 7.54E-15-2.45E-04 609
Embryonic Development 8.27E-14-3.18E-04 417
Organismal Development 8.27E-14-3.11E-04 556
Cellular Development 1.24E-13-3.12E-04 604
Cardiovascular System Development and Function 3.02E-13-2.65E-04 263
Gastrointestinal Disease 3.37E-13-2.87E-04 673
Cellular Assembly and Organization 3.99E-13-3.02E-04 293
Cellular Function and Maintenance 3.99E-13-3.02E-04 400
Organismal Survival 9.34E-13-1.03E-04 432
Cell Death and Survival 9.38E-13-3.04E-04 596
Tissue Development 1.99E-12-3.11E-04 524
Organismal Injury and Abnormalities 2.68E-12-2.53E-04 805
Reproductive System Disease 2.68E-12-2.53E-04 699
Gene Expression 2.68E-12-3.74E-06 378
Cell Morphology 2.78E-12-3.02E-04 461
Tumor Morphology 5.73E-11-3.73E-05 149
Skeletal and Muscular System Development and Function 7.12E-10-2.79E-04 204
Organ Development 8.12E-10-3.11E-04 348
Neurological Disease 1.09E-09-2.68E-04 435
Respiratory System Development and Function 2.59E-09-1.09E-05 95
Hereditary Disorder 3.19E-09-3.23E-04 272
Psychological Disorders 3.19E-09-9.9E-05 217
Skeletal and Muscular Disorders 3.19E-09-4.64E-05 288
Tissue Morphology 3.34E-09-3.18E-04 414
Connective Tissue Development and Function 3.81E-09-2.79E-04 247
Organ Morphology 3.81E-09-3.11E-04 345
Cell-To-Cell Signaling and Interaction 7.29E-09-2.18E-04 91
Cell Cycle 7.83E-09-1.8E-04 261
Cardiovascular Disease 9.26E-09-3.23E-04 251
Developmental Disorder 1.22E-08-3.23E-04 291
Nervous System Development and Function 1.22E-08-3.02E-04 301
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Reproductive System Development and Function 1.23E-08-1.95E-04 122
Digestive System Development and Function 1.42E-08-2.56E-04 145
Connective Tissue Disorders 6.69E-07-4.64E-05 101
Visual System Development and Function 1.47E-06-1.88E-04 98
Auditory and Vestibular System Development and Function 1.55E-06-3.11E-04 48
Post-Translational Modification 1.87E-06-1.87E-06 124
Endocrine System Development and Function 3.72E-06-3.27E-05 33
Hair and Skin Development and Function 4.39E-06-1.75E-05 86
Carbohydrate Metabolism 6.73E-06-2.97E-04 125
Behavior 6.9E-06-2.05E-05 160
Hepatic System Disease 8.54E-06-2.49E-04 41
Renal and Urological System Development and Function 8.58E-06-2.93E-04 82
Infectious Disease 8.85E-06-2.79E-04 266
Cellular Compromise 1.26E-05-2.15E-04 81
Hepatic System Development and Function 1.96E-05-2.56E-04 12
Organismal Functions 1.96E-05-2.47E-04 69
Ophthalmic Disease 2.53E-05-3.19E-04 35
Lipid Metabolism 3.06E-05-3.06E-05 22
Small Molecule Biochemistry 3.06E-05-3.27E-04 69
Immune Cell Trafficking 3.74E-05-2.15E-04 146
Protein Synthesis 3.87E-05-3.87E-05 139
Hematological System Development and Function 5.44E-05-2.47E-04 256
Inflammatory Response 5.44E-05-2.15E-04 180
DNA Replication, Recombination, and Repair 8.13E-05-3.27E-04 82
Hematological Disease 8.33E-05-2.84E-04 229
Immunological Disease 8.33E-05-2.84E-04 96
Cell Signaling 8.62E-05-8.62E-05 75
Dermatological Diseases and Conditions 1.12E-04-1.12E-04 28
Respiratory Disease 1.34E-04-3.23E-04 53
Molecular Transport 1.87E-04-1.87E-04 41
Hypersensitivity Response 2.15E-04-2.15E-04 27
Hematopoiesis 2.45E-04-2.45E-04 45
Nucleic Acid Metabolism 3.27E-04-3.27E-04 20
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Table S3
Cry1/Cry2 relevant diseases and functions  p-value Molecules 
Cancer 2.39E-26-2.82E-04 2377
Cellular Assembly and Organization 2.83E-24-2.86E-04 518
Cellular Function and Maintenance 2.83E-24-2.7E-04 741
Cell Death and Survival 3.23E-21-2.31E-04 949
Cellular Movement 3.69E-21-2.3E-04 640
Cellular Growth and Proliferation 4.9E-21-2.89E-04 945
Organismal Survival 4.21E-18-5.17E-09 647
Cell Morphology 9.66E-18-2.8E-04 737
Organismal Injury and Abnormalities 3.9E-15-1.87E-04 1317
Reproductive System Disease 3.9E-15-1.28E-04 1243
Cardiovascular System Development and Function 9.25E-15-2.8E-04 443
Gastrointestinal Disease 2.01E-14-1.02E-04 1000
Neurological Disease 1.25E-13-1.41E-04 612
Cellular Development 2.1E-13-2.89E-04 878
Organismal Development 1.3E-12-2.8E-04 851
Embryonic Development 1.4E-12-2.58E-04 663
Gene Expression 5.8E-12-7.08E-06 559
Nervous System Development and Function 9.15E-12-2.57E-04 528
Tissue Morphology 2.27E-11-2.8E-04 684
Hereditary Disorder 4.46E-11-5.7E-05 234
Psychological Disorders 4.46E-11-1.61E-04 252
Skeletal and Muscular Disorders 4.46E-11-2.17E-04 417
Tissue Development 6.07E-11-2.89E-04 814
Cell-To-Cell Signaling and Interaction 1.39E-10-2.7E-04 243
Cell Cycle 5.86E-10-1.96E-04 392
Organ Morphology 1.26E-09-2.8E-04 406
Developmental Disorder 1.82E-09-2.75E-04 436
Organ Development 2.99E-09-2.58E-04 480
Connective Tissue Development and Function 3.03E-09-2.58E-04 367
Skeletal and Muscular System Development and Function 3.03E-09-2.89E-04 410
Cardiovascular Disease 5.62E-09-2.75E-04 508
Tumor Morphology 8.3E-09-1.02E-04 248
Infectious Disease 1.72E-07-1.28E-04 419
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Digestive System Development and Function 6.67E-07-8.53E-06 208
Respiratory System Development and Function 7.82E-07-2.42E-04 92
Cell Signaling 9.85E-07-2.69E-04 305
Behavior 1.49E-06-1.96E-04 269
Renal and Urological Disease 3.28E-06-1.7E-04 166
Renal and Urological System Development and Function 4.06E-06-9.7E-05 87
Protein Synthesis 4.11E-06-2.09E-04 283
Connective Tissue Disorders 5.31E-06-2.17E-04 122
Dermatological Diseases and Conditions 5.93E-06-5.93E-06 42
Hematological Disease 5.93E-06-5.93E-06 42
Cellular Compromise 1.52E-05-2.86E-04 105
Post-Translational Modification 1.8E-05-1.57E-04 216
Inflammatory Response 2E-05-2.7E-04 96
Reproductive System Development and Function 2.49E-05-1.51E-04 179
Visual System Development and Function 2.5E-05-1.22E-04 128
Lymphoid Tissue Structure and Development 3.63E-05-2.88E-04 163
Hematological System Development and Function 7.78E-05-2.88E-04 245
Lipid Metabolism 1.09E-04-1.22E-04 86
Small Molecule Biochemistry 1.09E-04-1.57E-04 148
Auditory and Vestibular System Development and Function 1.16E-04-2.58E-04 45
Molecular Transport 1.22E-04-2.09E-04 124
Endocrine System Disorders 1.28E-04-1.28E-04 120
Hematopoiesis 1.47E-04-2.88E-04 210
Organismal Functions 1.52E-04-1.85E-04 69
Protein Degradation 1.68E-04-1.68E-04 117
Ophthalmic Disease 2.06E-04-2.69E-04 58
Protein Trafficking 2.09E-04-2.09E-04 45
Immune Cell Trafficking 2.3E-04-2.3E-04 212
142
Chapter 5
Table S4
Bmal1 relevant diseases and functions  p-value Molecules
Cell Death and Survival 1.33E-20-4.71E-04 547
Cancer 5.72E-19-4.84E-04 1282
Cellular Assembly and Organization 7.25E-18-5.19E-04 302
Cellular Function and Maintenance 7.25E-18-5.19E-04 455
Organismal Survival 7.9E-18-1.15E-11 380
Cellular Growth and Proliferation 4.27E-17-5.19E-04 537
Cellular Development 2.08E-16-4.32E-04 249
Cellular Movement 2.2E-15-4.44E-04 343
Cell Morphology 9.98E-15-5.29E-04 413
Tissue Morphology 1.7E-12-3.55E-04 404
Gene Expression 6.96E-12-1.7E-05 344
Organismal Development 3.24E-11-5.23E-04 494
Cardiovascular System Development and Function 2.27E-10-3.55E-04 236
Tumor Morphology 2.38E-10-2.08E-04 142
Tissue Development 1.01E-09-5.23E-04 481
Connective Tissue Development and Function 1.26E-09-4.18E-04 239
Neurological Disease 1.27E-09-4.87E-04 414
Nervous System Development and Function 1.48E-09-5.23E-04 272
Gastrointestinal Disease 2.19E-09-3.52E-04 560
Developmental Disorder 3.03E-09-4.16E-04 284
Organismal Injury and Abnormalities 6.88E-09-4.16E-04 704
Reproductive System Disease 6.88E-09-1.54E-04 631
Embryonic Development 7.96E-09-5.23E-04 386
Organ Development 7.96E-09-5.23E-04 297
Skeletal and Muscular System Development and Function 7.96E-09-4.77E-04 249
Cell-To-Cell Signaling and Interaction 1.01E-08-4.44E-04 244
Infectious Disease 1.03E-08-3.06E-04 246
Connective Tissue Disorders 2.4E-08-4.16E-04 214
Inflammatory Disease 2.4E-08-3.46E-04 232
Skeletal and Muscular Disorders 2.4E-08-4.16E-04 346
Cardiovascular Disease 3.73E-08-2.59E-04 307
Hematological System Development and Function 4.48E-08-3.62E-04 259
Hematopoiesis 8.54E-08-3.62E-04 136
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Behavior 1.67E-07-4.82E-04 152
Cell Signaling 1.79E-07-1.82E-04 137
Digestive System Development and Function 4.31E-07-3.45E-04 121
Organ Morphology 7.52E-07-4.88E-04 316
Psychological Disorders 1.38E-06-4.87E-04 178
Hereditary Disorder 2.22E-06-1.5E-05 119
Respiratory System Development and Function 2.22E-06-4.63E-05 72
Cell Cycle 2.28E-06-3.87E-04 170
Lymphoid Tissue Structure and Development 4.44E-06-3.55E-04 156
Inflammatory Response 1.05E-05-4.25E-04 259
DNA Replication, Recombination, and Repair 1.06E-05-1.06E-05 67
Immune Cell Trafficking 1.16E-05-3.44E-04 171
Metabolic Disease 1.19E-05-5.22E-04 140
Post-Translational Modification 1.83E-05-4.14E-04 128
Protein Synthesis 1.83E-05-2.03E-05 35
Dermatological Diseases and Conditions 1.85E-05-4.55E-04 140
Antigen Presentation 2.03E-05-2.03E-05 5
Cell-mediated Immune Response 2.52E-05-3.25E-05 79
Hematological Disease 2.64E-05-4.84E-04 189
Reproductive System Development and Function 3.34E-05-4.77E-04 111
Carbohydrate Metabolism 4.6E-05-1.9E-04 46
Molecular Transport 4.6E-05-4.6E-05 38
Small Molecule Biochemistry 4.6E-05-1.82E-04 84
Immunological Disease 4.69E-05-4.84E-04 209
Endocrine System Disorders 4.82E-05-5.22E-04 71
Free Radical Scavenging 5.12E-05-5.29E-04 73
Hair and Skin Development and Function 5.15E-05-2.06E-04 52
Lipid Metabolism 8.59E-05-8.59E-05 19
Protein Folding 9.51E-05-9.51E-05 6
Ophthalmic Disease 1.42E-04-3.11E-04 37
Cellular Compromise 2.08E-04-2.08E-04 4
Nutritional Disease 2.21E-04-2.21E-04 39
Renal and Urological Disease 3.24E-04-3.24E-04 24
Auditory and Vestibular System Development and Function 3.41E-04-3.41E-04 7
Visual System Development and Function 3.45E-04-3.45E-04 5
Cellular Response to Therapeutics 4.55E-04-4.55E-04 10
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 | General discussion
  Dividing cells are characterized by the presence of two clock systems: a circadian clock and 
a cell cycle clock. In mammalian cells, these two oscillatory systems are strongly coupled 
(Bieler et al., 2014; Feillet et al., 2014) and influence each other in a bi-directional way (Feil-
let et al., 2015). Synchronization of the circadian clock by the use of clock synchronizers, 
such as dexamethasone, clustered mitotic events. On the other hand, the circadian period in 
proliferating cells is adjusted to the cell cycle period. Although it is clear that these two os-
cillatory systems are robustly coupled and interact with each other, the details of these inter-
actions remain to be fully determined. In the context of this bi-directional link, it is important 
to know how alteration in one of the oscillators impacts the other one. It is also important 
to verify how these two systems interact in cells displaying aberrant cell proliferation and a 
disrupted circadian system such as cancer cells.
 In Chapter two of this thesis we studied the importance of the circadian clock in the reg-
ulation of cell cycle progression by genetic knockdown of the positive circadian elements 
of the molecular circadian oscillator. To this end, we have used a mouse fibroblast cell line 
(NIH3T33C) that expresses fluorescent reporters for the clock (Rev-Erb-VNP), and for the G1 
phase (Cdt1:mKO2) and combined S, G2 and M phases (Geminin: E2crimson) of the cell cy-
cle (Feillet et al., 2014). Using this system, we were able to quantify the kinetics of circadian 
oscillation and cell cycle progression in individual cells by live cell imaging. First, we ana-
lyzed the circadian oscillation in dividing versus non-dividing NIH3T33C cells. In line with 
our previous observation (Feillet et al., 2014), we observed circadian and cell cycle periods 
of approximately 17 hour in proliferating cells. Notably, after cells reached confluency, the 
circadian period was close to 23 hours. This suggests that the circadian clock in proliferating 
cells is no longer free running, but rather is entrained or reset by the cell cycle, likely each 
mitotic event.
 Next, we analyzed the cell cycle progression in the absence of the positive circadian el-
ements by silencing either the Clock or Bmal1 gene, the gene products of which form the 
heterodimeric transcription activator CLOCK/BMAL1. Knockdown of these positive cir-
cadian regulators completely suppressed the circadian oscillation and induced an increase 
of 4 hours in the total cell cycle length, as determined by single cell imaging. Our results 
in particular demonstrate the importance of circadian regulation on the dynamics of cell 
division. Subsequent FACS analysis revealed that the increased cell cycle length was due 
to a lengthening of the G2 phase, which is suggestive for a role of the CLOCK/BMAL het-
erodimer in G2/M transition. Further, we have elucidated the molecular mechanism under-
lying CLOCK/BMAL1 mediated regulation of G2/M transition. Knockdown of Bmal1 or 
Clock genes dampened Cyclin B1 protein levels in late G2 cells. High Cyclin B1 protein 
levels, as well as high Cyclin B1-Cdk1 kinase activity in late G2 cells, are essential for G2/M 
transition (Gavet & Pines, 2010). However, to avoid premature mitosis Cyclin B1-CDK1 
complexes are initially kept in an inactive state by the inhibitory effect of WEE1 and MYT1 
kinases (Mueller et al., 1995; Parker & Piwnica-Worms, 1992; Fung et al., 2005). It has been 
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well established that expression of WEE1 kinase is also under direct circadian control of the 
CLOCK/BMAL1 transcription factor (Matsuo et al., 2003). Thus, it appears that CLOCK/
BMAL1 complex has a dual role in controlling G2/M check point by simultaneously reg-
ulating an activator (Cyclin B1) and an inhibitor (WEE1) of mitotic entry. However, the 
increased cell cycle length in siClock and siBmal1 cells suggests that the regulatory effect 
of CLOCK/BMAL1 complex on the activator (Cyclin B1) of G2/M check point is dominant 
over the effect on the repressor (WEE1) of G2/M transition (See Fig. 1 for a schematic model 
of CLOCK/BMAL1 regulation on the G2/M cell cycle transition). This finding is supported 
by earlier reports showing a decreased cell proliferation in Clock or Bmal1 knock out condi-
tion. For instance, after partial hepatectomy hepatocytes from Clock knock out mice showed 
delayed liver regeneration, which can be attributed to a delayed entry into mitosis (Matsuo et 
al., 2003). Moreover, primary hepatocytes from Bmal1 knock out mice showed a decreased 
proliferation rate (Grechez-Cassaiu et al.,2008). Thus, our results suggest a novel regulatory 
mechanism of BMAL1/CLOCK on G2/M transition by modulating the G2 specific expres-
sion of Cyclin B1, explaining the observed slower cell cycle progression.
 In Chapter three we continued to investigate the role of the circadian clock in cell cycle 
regulation by studying the impact of CRISPR/Cas9 mediated inactivation of the negative 
circadian elements (Cry1 and Cry2) in NIH3T33C cells. Using live cell imaging of cell cycle 
progression in individual cells and FACS analysis of proliferating cell cultures, we have 
shown that inactivation of both Cry genes shortened the G1 phase of proliferating cells by 2 
hours, along with a significant increase in G2 and M phases. 
CDC25
P
BMAL1
CLOCK
CDK1Cyclin B1 ActiveInactive
-CDK1 levels
-Cyclin B1-CDK1activity
-Cyclin B1 levels
Late S and G2     Mitotic entry and exit
WEE1, MYT1
P
CDK1Cyclin B1
Cyclin B1
Figure 1. Schematic model. Activation of CyclinB1-CDK1 complex and role 
of CLOCK/BMAL1 in G2/M cell cycle transition (as it is described in the text).
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 To shed light on the underlying molecular mechanism, we also investigated Cyclin expres-
sion in the CRY deficient cells. We observed elevated levels of Cyclin E protein at G1/S tran-
sition in CRY deficient cells, which well explains the shortened G1 phase. In line with this 
finding, it has been shown that overexpression of Cyclin E decreases the time that cells spend 
to finish G1 phase and enter S phase (Ohtsubu et al., 1995; Resnitzky et al., 1995). Moreover, 
Cyclin A2 and Cyclin B1 protein levels remain high in early mitotic Cry double knock out 
cells, while these two cyclins are gradually degraded in the control cells. This observation is 
an indication of delayed degradation of these mitotic Cyclins. In line with this observation, 
there was higher phosphorylation of mitotic substrates (as detected by western blot analysis) 
and a larger mitotic cell population (flow cyctometry data). It has been reported that active 
Cyclin A2-CDK2 and Cyclin B1-CDK1 phosphorylate key mitotic substrates (Pines et al., 
2006) and thereby regulate the stability and activity of mitotic proteins (Ptacek et al., 2006; 
Oslen et al., 2010). Subsequently, timed degradation of Cyclin A2 and Cyclin B1 allows 
phosphatases to reverse the phosphorylation of mitotic substrates and end mitosis (Domin-
go-Sananes et al., 2011). Therefore, our results suggest a prominent role of the negative 
circadian elements on phosphorylation of mitotic proteins, by modulating the degradation 
of important mitotic kinases. This in turn can have a high impact on mitotic progression. A 
comparative time course phosphoproteomics experiment in the Ctrl and Cry dko cell lines 
is needed to reveal the underlying mechanism involved in CRY-mediated post translational 
regulation and its effect on cell cycle progression.
 Therefore, we have shown that the positive circadian elements (CLOCL/BMAL1) are in-
volved in the regulation of G2/M transition, and that the negative circadian factors (CRY1 
and CRY2) regulate G1/S, as well as mitotic progression. The positive and negative circadian 
elements increased and decreased the total period of the cell cycle respectively. The observed 
difference in phenotypes could be expected, considering the opposite regulatory effect of the 
positive and negative circadian elements on E-box transcription of clock controlled genes 
(CCG) participating in the regulation of cell cycle events.
 The importance of the circadian clock-cell cycle coupling in healthy cells is well under-
stood.
 For instance, the cellular clock-cell cycle coupling has a major impact on timed mitosis at 
the tissue level (Scheving et al., 1959; Geyfman et al., 2012). Importance of the coupling was 
also shown to be necessary in tissue integrity (Janich et al., 2011). Regarding the significance 
of coupling in healthy cells, the interplay between the circadian clock and the cell cycle in 
cancer cells, that normally display de-regulated cell proliferation and disrupted clock gene 
expression, is of great interest. This raises the question whether the circadian clock/cell cycle 
coupling exists in the tumor cells. If not, what are the consequences of un-coupling between 
these two systems in the cancer cells. 
 In Chapter four, we have started to investigate the circadian clock - cell cycle coupling in a 
panel of p53R270H/+ mutant mouse breast carcinoma (MBC) cell lines. To this end, we have sta-
bly introduced the fluorescent clock reporter Rev-Erbα-VNP to study the interaction between 
the circadian clock and cell cycle at the single cell level. Interestingly, whereas in proliferat-
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ing NIH3T33C cells the circadian clock and cell cycle have comparable periods and are phase 
coupled in a 1:1 ratio, we observed that in proliferating MBC399 cells the circadian clock is 
free-running while mitosis occurs independent of the circadian phase. To our knowledge, this 
is the first example of a cell line in which the circadian clock and the cell cycle are uncoupled. 
The obvious question arising is which molecules are mediating the coupling between these 
two systems. One possible candidate could be P53 protein, which is the only identified cell 
cycle molecule that has mutual influences on both the circadian and cell cycle systems (Miki 
et al., 2013). Correcting the p53R270H/+ mutant mouse breast carcinoma cell line could be an at-
tractive strategy to study the role of P53 gene in the coupling between the circadian clock and 
cell cycle. Nonetheless, considering the complexity of circadian clock and cell cycle systems, 
P53 most likely is not the only mediating molecule. Therefore, transcriptome analysis of the 
MBC-399 cells in the proliferating state would provide us more details on probable coupling 
candidates. These molecules will be attractive targets for therapeutic purposes.
 Chronotherapy benefits from desynchrony between cancer and normal cells in various pro-
cesses that are under circadian control, such as drug metabolism and proliferation (Lévi et al., 
2007). New cancer chronotherapeutic approaches for optimization of treatment time were de-
veloped based on the 24-hour rhythmicity in cell proliferation (Levi et al., 2007). Obtaining 
more knowledge about the circadian clock-cell cycle coupling in cancer cells will facilitate 
the improvement of chronotherapuetic approaches in which asynchrony in timed mitosis be-
tween the host and malignant tissues is used to predict the optimal time of treatment. For in-
stance, by choosing a time window in which normal cells are least sensitive to the treatment, 
while malignant cells undergo random cell proliferation independent of the circadian phase.
 In Chapter five, we aimed to understand how manipulation of core clock gene expression 
can affect the cancer properties of a cancer cell. To this end, we used the human lung carcino-
ma cell line H1299 and generated a panel of clock knockdown H1299 cell lines with attenuat-
ed expression of CRY1, CRY2, CRY1/CRY2, or BMALl1. We first analyzed the transcriptome 
of these cells. Ingenuity Pathway Analysis (IPA) on differential expressed genes revealed that 
cancer is one of the top significantly affected diseases and bio-functions in all the knockdown 
cell lines. Interestingly, categories related to the cancer properties of the cells, such as growth 
of malignant tumors and proliferation of tumor cells, were oppositely affected with a signif-
icant up regulation in CRY1/CRY2 knockdown H1299 cells, and down regulation in BMAL1 
knockdown H1299 cells. Next, we validated our transcriptome profile using in vitro (cell 
culture) and in vivo (xenograft) studies. Our in vitro experiments showed that inactivation 
of the CRY genes resulted in a reduction of the proliferation rate of H1299 cells, while inac-
tivation of BMAL1 had no effect. Therefore, this observation contrasts the transcriptomics 
data, which showed up regulation and down regulation of cell proliferation in BMAL1 and 
CRY knock down cells.  However, in line with the transcriptomics data, in vivo experiments 
showed accelerated tumor formation by about 2 weeks in CRY/CRY2 knockdown cells. In 
contrast, tumor formation was entirely suppressed in BMAL1 knock down cells. Therefore, 
a good correlation was observed between in vivo studies, addressing tumor formation and 
growth of H1299 core clock gene knockdown cells, and transcriptome data.
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 To understand the mechanisms involved, a detailed pathway enrichment analysis is required.
 In conclusion, we have dissected the circadian clock/cell cycle coupling in healthy cells 
by genetically disrupting core circadian clock genes. By the use of Fuuci cell cycle system 
with the two cell cycle reporters (G1, and S/G2/M) we were able to study the cell cycle 
progression at the single cell level. Considering the broad impact of clock genes on differ-
ent cell cycle phases further improvements of the Fucci system is required to discriminate 
between each of the S, G2, and M phases. Moreover, one of the questions that has not been 
firmly addressed is the bi-directionality in the interaction between the circadian and cell cycle 
systems. Previous reports in which the circadian clock and cell cycle are pharmaceutically 
manipulated are subject to debate since many of these drugs act on both systems. Therefore, 
an approach to manipulate only one of the oscillators without a direct influence on the other 
one is required. For instance, an optogenetic approach is an effective way to synchronize 
the circadian clock by light while cell cycle is not directly affected, and vice-versa. Such an 
approach, combined with a genome wide RNAi screen, will be a powerful means to identify 
molecules involved in the coupling between the circadian clock and the cell cycle. It will be 
important to determine the status of the coupling in various cancers in future studies, and to 
apply this knowledge to develop new therapeutic approaches. Gaining insight into the mole-
cules mediating the coupling will help to design novel anti-cancer therapy targets.
151
6
 | References
Antoch MP, Gorbacheva VY, Vykhovanets O, Toshkov IA, Kondratov RV, Kondratova AA, Lee C, 
Nikitin AY (2008) Disruption of the circadian clock due to the Clock mutation has discrete effects on 
aging and carcinogenesis. Cell Cycle 7:1197–1204.
Bieler J, Cannavo R, Gustafson K, Gobet C, Gatfield D, Naef F (2014) Robust synchronization of cou-
pled circadian and cell cycle oscillators in single mammalian cells. Mol Syst Biol 10:739.
Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U (2000) Restricted feeding 
uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic 
nucleus. Genes Dev 14: 2950-2961.
Destici E, Oklejewicz M, Saito S, van der Horst GT (2011) Mammalian cryptochromes im-
pinge on cell cycle progression in a circadian clock-independent manner. Cell Cycle 10:3788-3797.
Domingo-Sananes MR, Kapuy O, Hunt T, Novak B (2011) Switches and latches: a biochemical tug-
of-war between the kinases and phosphatases that control mitosis. Philos Trans R Soc Lond B Biol Sci 
366:3584-3594.
Feillet C, Krusche P, Tamanini F, Janssens RC, Downey MJ, Martin P, Teboul M, Saito S, Lévi FA, 
Bretschneider T, van der Horst GTJ, Delaunay F, Rand DA (2014) Phase locking and multiple oscillat-
ing attractors for the coupled mammalian clock and cell cycle. Proc Natl Acad Sci USA 111:9828-9833.
Feillet C, van der Horst GT, Levi F, Rand DA, Delaunay F (2015) Coupling between the Circadi-
an Clock and Cell Cycle Oscillators: Implication for Healthy Cells and Malignant Growth. Front Neu-
rol 6:96.
Fu L, Kettner NM (2013) The circadian clock in cancer development and therapy. Prog Mol Biol Transl 
Sci 119:221-282.
Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G (2005) The molecular clock mediates leptin- regu-
lated bone formation. Cell 122:803-815.
Fung TK, Poon RYC (2005) A roller coaster ride with the mitotic cyclins. Sem Cell Dev Biol 16:335-
342.
Gavet O, Pines J (2010) Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev 
Cell 18:533-543.
Geyfman M, Kumar V, Liu Q, Ruiz R, Gordon W, Espitia F, Cam E Millar SE, Smyth P, Ihler A,  Taka-
hashi JS, Andersen B (2012) Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell 
proliferation and susceptibility to UVB-induced DNA damage in the epidermis. Proc Natl Acad Sci U 
S A 109:11758-11763.
Gréchez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F (2008) The circadian clock com-
ponent BMAL1 is a critical regulator of p21WAF1/CIP1 expressionand hepatocyte proliferation. J Biol 
Chem 283:4535-4542.
Hoffman AE, Zheng T, Yi CH, Stevens RG, Ba Y, Zhang Y, Leaderer D, Holford T, Hansen J, Zhu Y 
(2010) The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating 
152
Chapter 6
hormone signaling. Cancer Prev Res 3:539:548.
Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control Mechanism of the Circadian 
Clock for Timing of Cell Division in Vivo. Science, 2003, 302 (5643): 255-259.
Mazzoccoli G, Colangelo T, Panza A, Rubino R, De Cata A, Tiberio C, Valvano MR, Pazienza V, Merla 
G, Augello B, Trombetta D, Storlazzi CT, Macchia G, Gentile A, Tavano F, Vinciguerra M, Bisceglia G, 
Rosato V, Colantuoni V, Sabatino L, Piepoli A (2016) Deregulated expression of cryptochrome genes in 
human colorectal cancer. Mol Cancer 15:16.
Miki T, Matsumoto T, Zhao Z, Lee CC (2013) p53 regulates Period2 expression and the circadian clock. 
Nat Commun 4:24444.
Mueller PR, Coleman TR, Kumagai A, Dunphy WG (1995) Myt1: a membrane-associated inhibitory 
kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 270:86-90.
Lévi F, Filipski E, Iurisci I, Li XM, Innominato P (2007) Cross-talks between circadian timing system 
and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol 
72:465-475.
Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human Cyclin E, a nuclear 
protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612-2624.
Oslen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, 
Nigg EA, Brunak S, Mann M (2010) Quantitative phosphoproteomics reveals widespread full phos-
phorylation site occupancy during mitosis. Sci Signal 3: ra3.
Parker LL, Piwnica-Worms H (1992) Inactivation of the p34cdc2-cyclin B complex by the human 
WEE1 tyrosine kinase. Science 257:1955-1957.
Pines J (2006) Mitosis: a matter of getting rid of the right protein at the right time. Trends Cell Biol 
16:55-63.
Ptacek J, Snyder M (2006) Charging it up: global analysis of protein phosphorylation. Trends Genet 
22:545-554.
Resnitzky D, Reed SI (1995) Different roles for Cyclins D1 and E in regulation of G1-to-S transition. 
Mol Cell Biol 15:3463-3469.
Rue P, Martinez Arias A (2015) Cell dynamics and gene expression control in tissue homeostasis and 
development. Mol Syst Biol 11:729.
Scheving LE (1959) Mitotic activity in the human epidermis. Anat Rec 135:7-19
Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M (2001) Entrainment of the circadian clock in the 
liver by feeding. Sience 291:490-493.
Janich P, Pascual G, Merlos-Suarez A, Batlle E, Ripperger J, Albrecht U, Cheng HY, Obrietan K, Di 
Croce L, Benitah SA (2011) The circadian molecular clock creates epidermal stem cell heterogeneity. 
Nature 480:209-214.

           
    APPENDIX    
Summary
Samenvatting ( Dutch summary )
PhD Portfolio
List of puplications 
Curriculum vitae
Acknowledgments
156
Chapter 7
 | Summary
   Life on earth is exposed to a 24-hour light/dark cycle generated by the earth rotation around 
its own axis. Almost all living organisms have developed an internal timing system, called 
“the circadian clock”, to adapt to the daily environmental changes. The circadian clock sys-
tem gives a 24-hour rhythmicity to various physiological processes (such as behavior, metab-
olism, sleep wake cycle, and hormone secretion) to optimize them to an exact time of the day.
  Mammalian circadian system is organized in a hierarchical manner with the superchiasmat-
ic nucleus (SCN) as the master clock at the top of hierarchy, and peripheral clocks in almost 
all the single cells over the body. The SCN is located in the hypothalamus of brain and is 
composed of approximately 20,000 neurons. Light information is received by the photore-
ceptors located in the ganglion cells in the inner nuclear layer of the retina and transmitted 
to the SCN neurons. Subsequently, synchronizing signals coming from the SCN are trans-
mitted to the peripheral clocks via hormonal and neural cues. Therefore, the whole organism 
is synchronized internally and synchronized to the external environment. At the molecular 
level, the circadian oscillator is based on autonomous and auto-regulatory feedback loops. 
The CLOCK/BMAL1 heterodimer induces E-box transcription of Per (Per1, Per2) and Cry 
(Cry1, Cry2) genes. PER and CRY proteins accumulate in the cytoplasm and after a delay 
of several hours translocate to the nucleus where they inhibit CLOCK/BMAL1-mediated 
transcription. The whole process follows a circadian periodicity close to 24-hours. CLOCK/
BMAL1 heterodimer also induces E-box transcription of the so-called Clock Controlled 
Genes (CCG), composing 10% of the whole genome. Clock controlled genes are involved 
in the regulation of a variety of physiological events such as the cell cycle process. The cell 
cycle is another independent oscillatory system, governed by sequential events of transcrip-
tion, and protein degradation. The circadian clock and cell cycle systems are tightly coupled 
and interact in a bi-directional way, meaning that synchronization of the circadian system 
using clock synchronizers, such as dexamethasone, will entrain mitosis. On the other hand, 
the circadian oscillator is reset by each mitotic event.
  In chapter 2 we investigated the importance of these reciprocal interactions by knocking 
down the positive circadian elements (Bmal1 and Clock genes). Using the NIH3T33C mouse 
fibroblast cell line (carrying fluorescent reporter genes for clock and cell cycle phase), we 
have shown an increased cell cycle length by about 4 hours in Bmal1 knock down cells. 
We found that the slower cell cycle progression originated from a delayed G2/M transition 
caused by an impaired G2 specific expression of Cyclin B1. 
  In chapter 3, we knocked out the cryptochromes (Cry1-/-, Cry2-/-) in the NIH3T33C cells 
and investigated cell cycle progression in the absence of negative circadian elements. We 
have shown a decrease of 2 hours in the total cell cycle length, arising from a short G1 phase. 
Further molecular analysis revealed involvement of the cryptochromes on G1/S transition by 
regulating Cyclin E expression. Moreover, a high phosphorylation pattern of mitotic proteins 
in Cry1-/-, Cry2-/- cells, together with a high percentage of mitotic cells, indicated impaired 
mitotic progression in cryptochrome deficient cells. Our data demonstrate that post-transla-
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tional regulation of mitotic proteins is affected in the absence of cryptochromes.
 In chapter 4, we studied the importance of coupling between the circadian clock and cell 
cycle machineries in cancer cells.  We have stably introduced a circadian clock reporter 
(REV-ERBα promotor) into a mouse breast carcinoma cell line derived from heterozy-
gous p53-R270H/+ WAPCre mice (MBC399). Using this system, we have followed the ki-
netics of circadian clock and cell cycle progression in real time and at the single cell level. We 
observed that the cellular clock/cell cycle coupling is lost in MBC399 cells. In contrast to the 
NIH3T33C cells, cell division occurred independent of the circadian time in MBC399 cells. 
Our results highlight the importance of the cellular clock/cell cycle coupling in controlling 
the proliferation rate, which is lost in MBC399 cells.
 In chapter 5, the effect of circadian clock gene knock-down on the cellular properties of 
human lung carcinoma cell lines (H1299 cell) was investigated. We have performed a tran-
scriptome analysis on a panel of clock knock down H1299 cell lines. It appears that cancer 
and cellular growth are two of the top affected processes in all the clock knock down cell 
lines. Processes related to cancer, such as tumor formation and proliferation of malignant 
cells, were down regulated in Bmal1 knock down cells and up-regulated in cryptochrome 
deficient cells. In line with the transcriptome analysis, our in vivo study shows suppressed 
and accelerated tumor formation in Bmal1 knock down and cryptochrome deficient cells, 
respectively. Overall, our transcriptome analysis, together with the in vivo studies, showed a 
prominent involvement of core circadian clock genes on the proliferation capacity of tumor 
cells, as well as tumor forming ability. The effect observed makes the circadian clock genes 
attractive targets in cancer therapy. 
158
Chapter 7
 | Samenvatting 
Het leven op aarde wordt blootgesteld aan een 24-uurs licht/donker cyclus die wordt gege-
nereerd door de rotatie van de aarde om zijn eigen as. Bijna alle levende organismen hebben 
een intern timingsysteem ontwikkeld, “de circadiane klok” genoemd, om zich aan te passen 
aan deze 24-uurscyclus. Het circadiane kloksysteem geeft een 24-uursritme aan verschil-
lende fysiologische processen (zoals gedrag, metabolisme, slaap-waakritme en hormoonaf-
gifte), zodat ze optimaal zijn op een bepaald tijdstip van de dag.
Het circadiaans systeem van zoogdieren is georganiseerd op een hiërarchische manier. De 
superchiasmatische kern (SCN) als de hoofdklok aan de top van de hiërarchie en perifere 
klokken in bijna alle afzonderlijke cellen van het lichaam. De SCN bevindt zich in de hypo-
thalamus van de hersenen en bestaat uit ongeveer 20.000 neuronen. Lichtinformatie wordt 
ontvangen door de fotoreceptoren die zich in de ganglioncellen in de binnenste laag van 
het netvlies bevinden en worden doorgegeven aan de SCN-neuronen. Vervolgens worden 
synchronisatiesignalen afkomstig van de SCN via hormonale en neurale signalen naar de 
perifere klokken verzonden. Hierdoor wordt het hele organisme intern gesynchroniseerd en 
tevens gesynchroniseerd met de externe omgeving. Op moleculair niveau is de circadiaanse 
oscillator gebaseerd op autonome en zelfregulerende feedbacklussen. Het KLOK/ BMAL1 
heterodimeer induceert E-box-transcriptie van Per (Per1, Per2) en Cry (Cry1, Cry2) genen. 
PER en CRY eiwitten hopen zich op in het cytoplasma en verplaatsen zich na enkele uren 
naar de kern waar ze de KLOK/BMAL1 gemedieerde transcriptie remmen. Het hele proces 
volgt een circadiane periodiciteit, die bijna 24 uur duurt. KLOK/ BMAL1 heterodimeer in-
duceert ook E-box-transcriptie van de zogenaamde Clock Controlled Genes (CCG), die 10% 
van het gehele genoom vormen. Klokgestuurde genen zijn betrokken bij de regulatie van een 
verscheidenheid aan fysiologische gebeurtenissen zoals het celcyclus proces. De celcyclus is 
een ander onafhankelijk oscillatiesysteem, die wordt beheerst door opeenvolgende gebeurt-
enissen van transcriptie en eiwitafbraak. De circadiane klok en celcyclus systemen zijn nauw 
gekoppeld en interageren op een bi-directionele manier met elkaar. Dit betekent dat synchro-
nisatie van het circadiane systeem door middel van klok synchronizers, zoals dexamethason, 
de timing van de mitose meevoert. Aan de andere kant wordt de circadiane oscillator gereset 
bij elke mitose. 
In hoofdstuk 2, onderzochten we het belang van deze reciproke interacties door de pos-
itieve circadiaanse elementen (Bmal1 en Klok genen) te verlagen. Met behulp van de NI-
H3T33C-fibroblastcellijn van muizen (die fluorescerende reportergenen draagt voor de klok 
en celcyclus fase) hebben we een toegenomen lengte van de celcyclus met ongeveer 4 uur in 
Bmal1 knockdown cellen aangetoond. We lieten zien dat de tragere voortgang van de celcy-
clus, als gevolg van een vertraagde G2/M overgang, werd veroorzaakt door een verminderde 
G2-specifieke expressie van Cyclin B1. 
In hoofdstuk 3, hebben we de cryptochromen (Cry1 -/ -, Cry2 -/ -) in de NIH3T33C-cellen 
uitgeschakeld (knock out) en de voortgang van de celcyclus onderzocht in afwezigheid van 
negatieve circadiaanse elementen. We laten een afname van 2 uur in de totale lengte van de 
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celcyclus zien, voortkomend uit een korte G1-fase. Verdere moleculaire analyse onthulde 
de betrokkenheid van de cryptochromen op G1/S-transitie door de expressie van Cyclin E 
te reguleren. Bovendien duidde een hoog fosforyleringspatroon van mitotische eiwitten in 
Cry1 -/ -, Cry2 -/ - cellen, tezamen met een hoog percentage mitotische cellen, op vermin-
derde mitotische progressie in cryptochroom-deficiënte cellen. Onze gegevens tonen aan 
dat post-translationele regulatie van mitotische eiwitten wordt beïnvloed in afwezigheid van 
cryptochromen.
 In hoofdstuk 4, hebben we het belang van de koppeling tussen de circadiane klok en de cel-
cyclus in kankercellen bestudeerd. We hebben op stabiele wijze een circadiane klokreporter 
(REV-ERB-promotor) geïntroduceerd in een muizenborstcarcinoom cellijn afgeleid van het-
erozygote p53-R270H/+WAPCre muizen (MBC399). Met dit systeem hebben we de kinetiek 
van de circadiane klok en celcyclusprogressie in real time en op het niveau van een enkele cel 
gevolgd. We hebben vastgesteld dat de koppeling van de cellulaire klok/ celcyclus verloren 
gaat in MBC399 cellen. In tegenstelling tot de NIH3T33C cellen vond celdeling plaats onaf-
hankelijk van de circadiane tijd in MBC399 cellen. Onze resultaten benadrukken het belang 
van de koppeling van de cellulaire klok/celcyclus, die verloren gaat in MBC399-cellen, bij 
het beheersen van de proliferatiesnelheid.
 In hoofdstuk 5, onderzochten we het effect van de knockdown van circadiane klokgen op 
de cellulaire eigenschappen van menselijke long carcinoomcellijnen (H1299-cel). We heb-
ben een transcriptoom analyse uitgevoerd op een panel van H1299 cellen met knock down 
klokgenen. Het blijkt dat kanker en cellulaire groei twee van de belangrijkst beïnvloede pro-
cessen zijn in alle knock down cellijnen. Processen gerelateerd aan kanker, zoals tumor-
vorming en proliferatie van kwaadaardige cellen, werden neerwaarts gereguleerd in Bmal1 
knockdown cellen en opwaarts gereguleerd in cryptochroom-deficiënte cellen. In lijn met de 
transcriptoom analyse, toont in vivo onderzoek ons vertraagde en versnelde tumorvorming 
in respectievelijk Bmal1 knockdown en cryptochroom-deficiënte cellen. Overall toonde onze 
transcriptoom analyse, in combinatie met de in vivo onderzoeken, een prominente betrok-
kenheid van de belangrijkste circadiane klokgenen op de proliferatiecapaciteit van tumor-
cellen, evenals het tumorvormende vermogen. Dit waargenomen effect maakt de circadiane 
klokgenen aantrekkelijke doelen in kankertherapie. 
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